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Abstract 
 
Mitochondrial Permeability Transition Pore as a Therapeutic Target for 
Acute Pancreatitis 
 
Muhammad Ahsan Javed 
Introduction: Acute pancreatitis (AP) is frequently complicated by pancreatic 
necrosis, multiple organ failure, prolonged hospitalisation and death. There is 
no specific, licensed drug therapy for this disease to date. Opening of the 
mitochondrial permeability transition pore (MPTP) is a key event in the 
pathophysiology of AP and is therefore a valid drug target for its treatment. 
Cylophilin D (CypD, a mitochondrial matrix protein), is a key regulator of MPTP 
formation and opening of the latter is also modulated by a new drug 
TRO40303. The aim of this investigation is to explore the effects of newly 
identified CypD inhibitors and TRO4303 in both murine and human pancreatic 
acinar cells (PAC) in response to established pancreatic toxins as well as the 
severity of experimental acute pancreatitis (EAP). The study also provides a 
qualitative assessment of all published literature evaluating agents tested for 
treatment of EAP using a newly devised scoring system. 
 
Methods: Confocal fluorescence microscopy of isolated PACs was used to 
evaluate the effects of MPTP inhibitors on mitochondrial function, calcium 
handling and cell fate in response to TLCS (taurolithocholate sulphate) and 
other pancreatic toxins - CCK (cholecystokinin) and POAEE (palmitoleic acid 
ethyl ester). In order to identify novel CypD inhibitors, computational modelling 
was undertaken. Compounds predicted to bind with CypD were screened using 
biophysical assay - surface plasmon resonance (SPR) - to evaluate binding 
affinity. Candidates with high affinity for CypD were subsequently evaluated in 
the aforementioned biological assays. Efficacy of TRO40303 in ameliorating 
the severity of EAP was tested in three different models.  
 
Results: TRO40303 prevented loss of mitochondrial membrane potential (m) 
induced by TLCS, CCK and POAEE and improved Ca2+ clearance in PACs. 
TRO40303 reduced necrotic cell death pathway activation in response to TLCS 
in murine (p<0.05) as well as human PACs (p<0.01). Therapeutic 
administration of TRO40303 significantly reduced serum amylase, pancreatic 
trypsin, pancreatic and lung myeloperoxidase and histopathology scores in 
hyperstimulation, biliary and alcoholic EAP. Screening strategy of CypD 
inhibitors identified a novel small molecular inhibitor, AP-1A02, with a KD and 
Ki of 0.8  µM and 1.7 µM respectively. AP-1A02 protected m and also 
significantly reduced necrotic cell death pathway activation in human as well as 
murine PACs in response to TLCS. 
 
Conclusion: This work demonstrates that MPTP is a valid target for the 
treatment of AP. TRO40303 protects mitochondria, reduces necrotic cell death 
pathway activation and ameliorates the severity of EAP and is therefore a 
candidate drug for human AP. Further work needs to be undertaken to optimize 
AP-1A02 and develop other small molecule CypD inhibitors with the aim to 
develop it as a potential drug for AP.  
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1.1 The Pancreas 
1.1.1 Anatomy (acinar unit, ductal system, acinar cell) 
 
The word pancreas is derived from the Greek word pan-kreas meaning ‘all 
flesh’, with regards to its fleshy appearance. The discovery of pancreas has 
been attributed to the Greek anatomist, Herophilos (335-280 BC), who 
performed the first systematic dissections of human cadavers (Busnardo, DiDio 
et al. 1983). The pancreas, embryologically derived from the foregut 
(endoderm), is a glandular organ located in the posterior aspect of the upper 
abdominal cavity in humans. It is anatomically divided into three parts; the 
head, body and tail (figure 1.1). The head of the pancreas abuts the duodenum 
and the tail extends towards the spleen. It has both endocrine and exocrine 
functions. The functional enzyme-secreting unit of the exocrine pancreas is the 
acinus, a Latin name relating to its ‘grape like’ appearance (Bockman, 
Boydston et al. 1983). The acini are formed by the closely packed, terminal 
secretory units of zymogen secreting acinar cells grouped around a central 
common lumen, as well as a few centro-acinar cells located around the 
beginning of the ductal system. The intercalated ducts, which secrete HCO3
- 
and water in response to secretin, along with the acinus form the acinar ductal 
units (figure 1.1). The enzymes produced by the pancreas include; trypsinogen, 
pepsinogen, amylase, lipase and deoxyribonuclease which are secreted as 
inactive pro-enzymes and activated in the duodenum by enterokinase to 
prevent pancreatic autodigestion. 
The pancreatic acinar cell (PAC) is the classical, polarised, secretory 
cell, with intracellular Ca2+ playing a key role in the control of its activities 
(Petersen and Sutton 2006). These non-excitable exocrine cells have a high 
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secretory turnover heavily dependent on mitochondrial production of adenosine 
triphosphate (ATP) (Petersen and Tepikin 2008). The organellar arrangement 
of the PAC is such that the endoplasmic reticulum (ER) is densely packed 
around the nucleus in the basolateral region extending into the apical region, 
where the Golgi extends into the zymogen granules (ZG) (Tinel, Cancela et al. 
1999). Mitochondria surround the apical pole, nucleus and the basolateral 
plasma membrane, providing the energy required for the essential functions of 
these regions (Park, Ashby et al. 2001). 
The endocrine function of the pancreas is regulated by clusters of cells 
referred to as Islet of Langerhans, which comprise approximately 2% of the 
pancreatic tissue. There are approximately three million pancreatic islets in the 
human pancreas (Ionescu-Tirgoviste, Gagniuc et al. 2015), primarily 
responsible for glucose metabolism. There are four different types of cells in 
the pancreas islets, each secreting a different hormone. α alpha cells secrete 
glucagon (increase glucose in blood), β beta cells secrete insulin (decrease 
glucose in blood), δ delta cells secrete somatostatin (regulates/stops α and β 
cells) and PP cells, or γ (gamma) cells, secrete pancreatic polypeptide 
(Constanzo 2006). Histologically, the capillaries of the islets are lined by layers 
of islet cells and most endocrine cells are in direct contact with the blood 
vessels. The function of islets is independent from the digestive role of the 
majority of PACs. 
Since the exocrine pancreas forms the bulk of the gland and is the 
primary site of insult in acute pancreatitis (AP), it will be the main focus of this 
thesis.  
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Figure 1.1 - Anatomy of the Pancreas 
Gross anatomy of the pancreas (A). Acinar ductal unit (B) and structure of 
pancreatic acini, composed of acinar cells grouped around a central lumen (C). 
Transmitted light image of an isolated acinar triplet (D). Modified from Gray’s 
Anatomy for students, 2012.  
A 
B C D 
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1.1.2 Physiological signaling and secretory function 
 
Intracellular Ca2+ signals control normal secretion in PACs. During 
physiological stimulation, binding of the hormone CCK or neurotransmitter 
acetylcholine (ACh) to their respective G-protein linked receptors activates ADP 
ribose cyclase and phospholipase C to form the second messengers; nicotinic 
acid adenine dinucleotide phosphate (NAADP), cyclic ADP ribose (cADPr) and 
inositol trisphosphate (IP3). These second messengers in turn rapidly diffuse 
and bind to their receptors (IP3R, ryanodine receptors, RyR, and NAADPR), 
which are Ca2+ channels on the ER, ZGs and endolysosomes (ELs) (Ashby 
and Tepikin 2002, Petersen and Sutton 2006). Consequently, repetitive local 
rises (spikes) in the free cytosolic Ca2+ concentration are produced which are 
buffered by the peri-apical mitochondria that respond by increasing ATP 
production to drive secretion, and terminate the signal (Tinel, Cancela et al. 
1999, Park, Ashby et al. 2001, Voronina, Sukhomlin et al. 2002) . Ca2+- induced 
Ca2+ release (CICR), notably via RyR prevents the spread of  Ca2+ signals 
beyond the peri-apical buffer zone into the basolateral region of the cell, again 
driving mitochondrial ATP production for transcription, translation and ATPase 
pump activity (Ashby and Tepikin 2002). The sarcoplasmic reticulum Ca2+-
ATPase (SERCA) pump refills the ER Ca2+ store while the plasma membrane 
Ca2+ - ATPase (PMCA) pump assists to restore the normal basal Ca2+ 
(Burdakov, Petersen et al. 2005) and these two pumps also clear a continuous 
ER Ca2+ leak. Ca2+ entry into the cell is regulated at the plasma membrane by 
store-operated Ca2+ channels (Parekh and Putney 2005). Since PAC is a non 
excitatory cell, extracellular Ca2+ entry does not typically initiate signaling, 
however sustains continued signaling, and is required to replace PMCA-
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mediated extrusion and after secretion, to replenish stores that will contribute to 
new ZGs (Petersen 2005). Since the discovery of the Ca2+ entry channel 
ORAI1, it has been shown to be the principal store operated calcium entry 
(SOCE) channel in the PAC (Lur, Haynes et al. 2009). Opening of the ORAI1 
channel is in turn regulated by the stromal interaction molecules (STIM1 and 
STIM2), following decreases in ER Ca2+ store concentrations (Lur, Haynes et 
al. 2009, Muik, Schindl et al. 2012, Derler, Schindl et al. 2013, Gerasimenko, 
Gryshchenko et al. 2013).  
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1.2  Clinical acute pancreatitis 
 
Acute pancreatitis is a disease characterized by acute inflammation of the 
pancreas (Pandol, Saluja et al. 2007). It was first described in 1889 by 
Reginald Fitz, a pathologist at Harvard, when he reported the pathologic 
findings distinguishing; haemorrhagic, suppurative, and gangrenous forms of 
the disease (FITZ 1889) and (Busnardo, DiDio et al. 1983). Acute pancreatitis 
has also been described as the ‘most terrible of all calamities that occur in 
connection with the abdominal viscera’(Moynihan 1925). 
 
1.2.1 Aetiology 
 
Gallstones and excessive alcohol intake are the two most common causes of 
AP, accounting for 40% and 30% of the cases respectively (Forsmark, Vege et 
al. 2016). The prevalence of gallstone disease can exceed 20% in the adult 
population according to population-based studies (Volzke, Baumeister et al. 
2005). It has been established that gallstones within the gallbladder do not 
cause pancreatitis and that the initiation of pancreatitis requires the passage of 
a gallstone from the gallbladder through the biliary tract (Acosta and Ledesma 
1974). There are two hypotheses relating to gallstone-induced pancreatitis 
pathogenesis, both proposed by Eugene Opie in 1901(Pandol, Saluja et al. 
2007). According to the ‘duct obstruction-impaired secretion hypothesis’, a 
gallstone passing through the biliary tract obstructs the pancreatic duct and the 
subsequent flow from the exocrine pancreas triggers acinar or duct cell 
damage . Opie’s ‘common channel - bile reflux hypothesis’ on the other hand 
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postulates that a gallstone impacted at the duodenal papilla creates a 
communication between the pancreatic and common bile ducts. This allows 
flow of bile through this “common channel” into the pancreatic duct and triggers 
pancreatitis. It is now understood that migrating gallstones cause transient 
obstruction of the pancreatic duct, a mechanism shared by other recognized 
causes of AP such as; endoscopic retrograde cholangiopancreatography 
(ERCP), pancreas divisum and sphincter of Oddi dysfunction (Forsmark, Vege 
et al. 2016). 
The overall lifetime risk of pancreatitis among heavy drinkers is 2 to 5% 
where prolonged alcohol use is characterised by four to five drinks daily over a 
period of more than five years (Cote, Yadav et al. 2011). The risk is higher for 
men than for women, perhaps reflecting differences in alcohol intake or genetic 
background (Whitcomb, LaRusch et al. 2012). The type of alcohol ingested 
does not affect risk, and objective analysis during the Oktoberfest in Germany 
has revealed that binge drinking in the absence of long-term, heavy alcohol use 
does not precipitate AP (Phillip, Huber et al. 2011). 
The World Health Organization database includes 525 different drugs 
suspected to cause pancreatitis and drug induced AP accounts for less than 
5% of all cases of pancreatitis. The most strongly associated drugs with AP 
are; azathioprine, 6-mercaptopurine, didanosine, valproic acid, angiotensin-
converting-enzyme inhibitors and mesalamine (Nitsche, Maertin et al. 2012). 
Population based studies have also shown a dose-dependent association 
between increasing polypharmacy and risk of AP (Razavi, Lindblad et al. 2016). 
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A number of genetic mutations and polymorphisms have been 
associated with acute (and chronic) pancreatitis. These include mutations in the 
genes encoding; cationic trypsinogen (PRSS1), serine protease inhibitor Kazal 
type 1 (SPINK1), cystic fibrosis transmembrane conductance regulator (CFTR), 
chymotrypsin C, calcium-sensing receptor and claudin-2 (Whitcomb 2013). 
Hyperlipidaemia is a rare cause of AP in the Western population; 
however it is ranked second as the aetiology of pancreatitis in China, 
accounting for up to 14.3% of the cases (Zhu, Pan et al. 2017). Other causes of 
AP include; autoimmune pancreatitis, ERCP (5-10%), trauma, surgical 
complications of coronary artery bypass grafting (5-10%), malignancy and 
infections secondary to viruses (CMV, EBV and mumps being the most 
common) or parasites (ascaris and clonorchis) (Forsmark, Vege et al. 2016). 
Other conditions that have been associated with AP include obesity, diabetes 
and smoking (Hong, Qiwen et al. 2011, Yadav and Lowenfels 2013).  
 
1.2.2 Epidemiology 
 
The epidemiology of AP has been objectively evaluated by a designated 
taskforce established by United European Gastroenterology, who reported that 
the incidence of AP ranges from 4.6 to 100 per 100 000 population (Roberts, 
Morrison-Rees et al. 2017). The incidence is highest in eastern and northern 
Europe with a consistent trend showing an increase in incidence over time. 
Analysis of aetiology amongst different geographical regions revealed 
cholelithiasis as the commonest aetiology in southern Europe, alcohol in 
eastern Europe and intermediate ratios in northern and western Europe 
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(Roberts, Morrison-Rees et al. 2017). In the United States, AP accounts for 
275,000 hospital admissions each year, with a rise in admissions by 20% over 
the last 10 years, costing the healthcare service approximately $2.5 billion per 
annum  (Peery, Crockett et al. 2015). In the UK, AP accounts for approximately 
26,000 hospital admissions per year (van Dijk, Hallensleben et al. 2017). 
The incidence and outcome of pancreatitis can be influenced by social 
status. Ellis et al, in an epidemiological study across all patients admitted with 
AP in North East England showed that compared to the affluent, individuals 
from the most deprived sections of society were almost 2.5 times more likely to 
develop AP. People belonging to low socio-economic status were also 6.5 
times more likely to have alcohol related disease. The increase in incidence 
was not only confined to alcoholic AP but also in biliary AP, to a lesser degree 
(Ellis, French et al. 2009).  
 
1.2.3 Clinical course 
 
Acute pancreatitis is diagnosed in the presence of at least two of the following 
three diagnostic features (Banks, Bollen et al. 2013): 
(i) upper abdominal pain consistent with AP, 
(ii)  serum lipase or amylase levels that are at least 3 times the upper 
limit of the normal range,  
(iii)  findings consistent with features of AP on cross-sectional imaging 
(computed tomography or magnetic resonance imaging).  
The majority of patients with AP, up to 80%, have a mild, self-limited episode. 
Approximately 20% of the patients have a severe episode defined by the 
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presence of complications that are systemic, local, or both. Systemic 
complications of AP include failure of an organ system or exacerbation of a pre-
existing disorder and early organ failure is responsible for the majority of deaths 
in AP (figure 1.2). Local complications include fluid collections around the 
pancreas and pancreatic necrosis, which can be sterile or infected (Banks, 
Bollen et al. 2013). Infected pancreatic necrosis accounts for the later organ 
failure in patients with severe AP (figure 1.3). Although the mortality associated 
with AP has decreased over time, overall mortality is now approximately 2%, it 
can approach up to 30% in patients with persistent organ failure (i.e lasting 
more than 48 hours) (Yadav and Lowenfels 2013). Pancreatic necrosis is a key 
determinant of outcome in AP, with mortality rates of up to 43% in patients who 
have infected pancreatic necrosis and organ failure (Petrov, Shanbhag et al. 
2010). Other predictors of mortality include old age, multiple co-morbidities   
(Hong, Qiwen et al. 2011, Krishna, Hinton et al. 2015) and hospital acquired 
infections (Wu, Johannes et al. 2008).  
Despite numerous concepts, attempts and randomised controlled trials 
(RCTs) there is still no specific treatment for AP. In fact, despite the unmet 
clinical need for specific therapy for AP, a recent analysis of research trends in 
Gastroenterology over the last 50 years has identified a substantial drop in the 
research activity on AP (Szentesi, Toth et al. 2016). The significant 
improvement in the prognosis of patients has been due to the improved 
intensive care and less-invasive interventional techniques. There has however 
been an increase in the incidence of iatrogenic AP due to the increase in 
number of interventional ERCP’s. The most important development over the 
recent years has been the conceptual change in the management of 
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necrotizing pancreatitis from a primarily surgical disease to a non-surgical 
management, electively supported by late minimal interventions(van Grinsven, 
van Santvoort et al. 2016, van Brunschot, Hollemans et al. 2017). There are 
further opportunities to improve the outcome of patients with pancreatitis, such 
as rationalising the use of antibiotics in AP (Baltatzis, Jegatheeswaran et al. 
2016) and management of gallstones in patients with gallstone pancreatitis 
(Siriwardena and O'Reilly 2017). Findings of the 2016 UK National Confidential 
Enquiry into Patient Outcome and Death (NCEPOD) evaluating the care 
provided to patients admitted to hospital with AP identified that only 56% of 
hospitals treating patients with AP reported that patients with gallstone 
pancreatitis underwent cholecystectomy either during the index admission or 
within 2 weeks (Siriwardena and O'Reilly 2017) as recommended by the 
guidelines (Working Group 2013). Results of the Dutch multicentre randomized 
PONCHO trial, comparing cholecystectomy during index admission with 
interval surgery in patients with mild gallstone AP, provides good evidence that 
early surgery reduces the rate of recurrent gallstone-related complications 
without an increase in surgical morbidity (da Costa, Dijksman et al. 2016).   
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Figure 1.2 - Therapeutic window for treatment of AP 
Time course of AP progression, cytokine profile and onset of organ dysfunction. 
Majority of patients develop systemic complications 2-4 days after onset of 
symptoms, providing a window of opportunity for intervention.  Adapted from 
(Norman 1998).  
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Figure 1.3 - Pancreatic necrosis 
Contrast-enhanced axial computed tomography images showing normal 
pancreas (A). In cases of AP complicated by infected pancreatic necrosis, the 
pancreas gland is swollen along with areas of hypoperfusion compatible with 
pancreatic necrosis and presence of gas indicates infected pancreatic necrosis 
(B). 
  
A 
B 
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1.3 Pathophysiology of acute pancreatitis 
 
1.3.1 Pathological calcium signaling  
 
Disruption of physiological calcium signaling, resulting in sustained cytosolic 
calcium overload within the PAC, is a crucial step in the pathobiology of AP 
(Ward, Sutton et al. 1996, Kruger, Albrecht et al. 2000, Raraty, Ward et al. 
2000). Pancreatic toxins including bile acids (Voronina, Gryshchenko et al. 
2005), oxidative (Shalbueva, Mareninova et al. 2013) and non-oxidative 
metabolites (Criddle, Murphy et al. 2006, Huang, Booth et al. 2014) of ethanol 
and cholecystokinin (CCK) hyperstimulation (Murphy, Criddle et al. 2008, 
Criddle, Booth et al. 2009). These toxins lead to abnormal elevations of Ca2+ 
that are global and sustained which induce premature intracellular enzyme 
activation, mitochondrial dysfunction, impaired autophagy, vacuolization, and 
activation of necrotic cell death pathway; all of which contribute towards the  
pathophysiology of AP (Criddle, McLaughlin et al. 2007). In order to maintain 
this sustained cytosolic calcium overload, continuous emptying of the ER Ca2+ 
store and activation of SOCE and Ca2+-release activated Ca2+ currents (CRAC) 
is required in order to replenish the ER store (Gerasimenko, Gryshchenko et al. 
2013, Shalbueva, Mareninova et al. 2013).These findings are supported by 
experimental data demonstrating that Ca2+ chelation, which attenuates 
cytosolic calcium overload, prevents activation of ZGs and vacuolization in 
PACs (Saluja, Bhagat et al. 1999, Raraty, Ward et al. 2000) and also reduces 
severity of EAP (Mooren, Hlouschek et al. 2003). The inositol 1,4,5-
trisphosphate receptor (IP3R) Ca2+ channels are primarily responsible for the 
release of Ca2+ from intracellular stores (Gerasimenko, Lur et al. 2009). This 
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IP3R mediated sustained elevation in cytosolic calcium can be inhibited by 
genetic deletion in the form of double knockout IP3R types 2 and 3 mice 
(Futatsugi, Nakamura et al. 2005) or pharmacological inhibition with caffeine 
(Gerasimenko, Lur et al. 2009). 
 
1.3.2 Trypsinogen activation in acute pancreatitis  
 
The Austrian pathologist Hans Chiari in 1896 was the first to propose that 
pancreatitis was a disease of autodigestion in which 'the organ succumbs to its 
own digestive properties’ (pancreadpedia 2017). Trypsin is synthesised in the 
PAC in its inactive form – trypsinogen within the rough ER and subsequently 
transported to the Golgi apparatus for sorting. Trypsinogen is always co-
synthesised and packed alongside a pancreatic secretory trypsin inhibitor 
(PSTI) which inhibits its premature activation. Within the Golgi apparatus, 
trypsinogen and other digestive enzymes are condensed in the form of ZGs. In 
this condensed state the enzymes are stable and not susceptible to activation. 
In response to secretory stimuli, these ZGs are released in to the lumen of the 
pancreatic duct, and on reaching the duodenum activated by the action of 
enteropeptidases, which remove the 7-10 amino acid chain from the N-terminal 
region of trypsinogen known as trypsinogen activation peptide (TAP). Removal 
of TAP induces a conformational change that results in active trypsin (Abita, 
Delaage et al. 1969). 
Under pathological conditions, lysosomal enzymes and zymogens fuse 
to form ‘co-localisation organelles’ and the lysosomal protease cathepsin B 
activates trypsinogen leading to the activation of trypsin within the pancreas 
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(Saluja, Hashimoto et al. 1987, Teich, Bodeker et al. 2002). In EAP, trypsin 
inhibition with the use of protease inhibitors has shown to ameliorate the 
severity of disease (Van Acker, Saluja et al. 2002, Van Acker, Weiss et al. 
2007) and expression of active trypsin in the pancreas can induce AP (Gaiser, 
Daniluk et al. 2011). Furthermore genetic deletion or pharmacological inhibition 
of cathepsin B, both of which limit trypsinogen activation, reduce pancreatic 
injury in AP (Halangk, Lerch et al. 2000). It is however interesting to note that 
inhibition of trypsinogen activation reduces local pancreatic injury but does not 
have any significant impact on leucocyte infiltration in the pancreas or lung 
(Halangk, Lerch et al. 2000). Further studies using the genetically modified 
mouse lacking trypsinogen isoform-7 also revealed that trypsin is only partly 
responsible for PAC necrosis in AP, and local and systemic inflammation is 
independent of trypsin (Dawra, Sah et al. 2011). Trypsin induces PAC injury by 
making the co-localised vesicles fragile, allowing cathepsin B to escape into the 
cytosol and subsequent activation of apoptotic cell death pathway (Talukdar, 
Sareen et al. 2016). Interestingly, the amount of cathepsin B in the cytosol also 
determines the mode of cell death in PACs. Small quantities of cathepsin B 
activate apoptosis, whereas larger amounts lead to activation of necrotic cell 
death pathway (Moriwaki and Chan 2013, Talukdar, Sareen et al. 2016). 
 
1.3.3 Cytokines and inflammation in acute pancreatitis  
 
Pancreatic acinar cells synthesise and release cytokines and chemokines in 
response to injury, (Grady, Liang et al. 1997, Gukovskaya, Gukovsky et al. 
1997, Norman 1998) and upregulate the expression of adhesion molecules 
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such as the intercellular adhesion molecule-1 (Zaninovic, Gukovskaya et al. 
2000). Cell death also leads to the release of damage-associated molecular 
patterns (DAMPs); such as histones, high-mobility group box1 protein 
(HMGB1), nuclear and mitochondrial DNA, heat shock proteins and ATP 
(Kang, Lotze et al. 2014, Yu, Wan et al. 2014) which initiate an acute 
inflammatory response. These factors promote neutrophil and monocyte 
infiltration (Frossard, Saluja et al. 1999) and can exacerbate tissue injury 
(Bhatia, Saluja et al. 1998, Frossard, Saluja et al. 1999, Gukovsky, Li et al. 
2013). There is a complex interplay of several pathways, mediators and 
inflammatory cells that leads to the inflammatory response in AP that can 
contribute to early onset organ failure in patients with AP (Oiva, Mustonen et al. 
2010, Oiva, Mustonen et al. 2013). The recruitment and activation of 
neutrophils and macrophages contributes to elevated levels of pro-
inflammatory mediators such as tumor necrosis factor (TNFα), interleukins (IL) 
– IL-1, IL-2, IL-6, and other chemokines and anti-inflammatory factors such as 
IL-10 (Davies and Hagen 1997, Makhija and Kingsnorth 2002). TNFα, a soluble 
inflammatory cell mediator, is a product of the activated NF-κB pathway. It is 
also shown to directly induce premature trypsinogen activation and necrosis in 
PACs, suggesting a contribution of inflammatory signaling in disease initiation 
and progression (Sendler, Dummer et al. 2013). 
The magnitude of cellular injury and the extent of inflammatory response 
determine the severity of disease. Although in most cases of human AP, 
cellular injury and local inflammation associated with pancreatitis resolve 
spontaneously, in some cases, the disease progresses to systemic illness. 
Systemic inflammatory response syndrome (SIRS) is a result of uncontrolled 
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local inflammation and predisposes to acute respiratory distress syndrome 
(ARDS) and multiple organ failure (Robertson, Basran et al. 1988). A summary 
of the important cytokines and chemokines mediating the inflammatory 
response in AP is presented in table 1. 
The concept of compensatory anti-inflammatory response syndrome 
(CARS) explains how prolonged disease activity is associated with immune 
anergy in AP. CARS is primarily mediated by TGF-β, IL-4, IL-10, and CCL2 
which are released by neutrophils and monocytes (Takahashi, Tsuda et al. 
2006, Ho, Chiu et al. 2011). These cytokines are responsible for promoting a 
Th2-type adaptive immune response, thereby increasing susceptibility to 
superinfections (Kobayashi, Kobayashi et al. 1998). Evaluation of cytokine 
profile of patients in human AP reveals that the temporal relation and 
magnitude of pro- and anti-inflammatory cytokine release is similar in patients, 
(Gunjaca, Zunic et al. 2012) with peak cytokine concentration within 48 hours of 
disease onset. These findings indicate that the anti-inflammatory cytokines play 
an important role in limiting the extent of SIRS.  
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Table 1 - Key cytokines and chemokines mediating the inflammatory 
response of pancreatitis 
 
 
Signaling 
molecule 
 
 
Source in 
AP 
 
Receptors and targets 
 
Function 
 
Cytokines 
    
TNFα Acinar cells, 
endothelium, 
monocytes, 
Kupffer cells 
TNFR1: widely expressed; 
TNFR2: immune and 
endothelial cells 
Pro-inflammatory; regulates 
apoptosis, mediates trypsin 
activation in acinar cells 
IL-1β Pancreas 
(beta cells, 
stellate 
cells), lung, 
liver, spleen, 
monocytes 
Secreted as a pro-
enzyme, converted by ICE 
or neutrophil proteases to 
its active form; acts on IL-
1R (widely expressed) 
Pro-inflammatory; increases 
vascular permeability. 
Soluble IL-1ra inhibits IL-1β 
activity 
IL-6 Ubiquitous 
expression 
IL-6R: hepatocytes, 
neutrophils, macrophages; 
soluble sIL-6R mediates 
trans-signaling 
Pro-inflammatory; 
contributes to lung injury in 
AP; lethal if administered in 
the context of EAP 
IL-10 Lymphocytes 
(B- and T-), 
monocytes/ma
crophages, 
dendritic cells, 
Kupffer cells 
IL-10R: widely expressed Anti-inflammatory; inhibits 
pro-inflammatory cytokine 
release from lymphocytes 
via STAT3; downregulates 
MHCII costimulatory 
molecules CD80/CD86, 
reducing clonal expansion of 
T-lymphocytes 
 
Chemokines 
 
   
CCL2 Acinar cells 
and possibly 
other cell types 
in the 
pancreas 
CCR2, CCR4 Pro-inflammatory, monocyte 
chemo-attractant, mediates 
pancreas and lung injury in 
EAP 
CXCL1/2 Acinar cells, 
macrophages 
CXCR2: neutrophils 
and myeloid derived 
suppressor cells 
Pro-inflammatory, strong 
neutrophil chemo-attractants 
 
Modified from (Szatmary 2016)  
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1.3.4 Endoplasmic stress in acute pancreatitis  
 
The endoplasmic reticulum (ER) are key cellular organelles involved in 
metabolic processes such as; folding and aggregation of proteins, 
gluconeogenesis, lipid synthesis and intracellular calcium storage (Fu, Watkins 
et al. 2012). The initial steps of protein maturation that take place at the ER are 
crucial for the proper folding of proteins that regulate secretory pathways (Hetz 
2012). The dynamic changes in the protein-folding requirements are tightly 
regulated by feedback mechanisms which affect almost every aspect of the 
secretory pathway (Ron and Walter 2007). The protein-folding machinery in the 
ER of the PAC is constantly under stress due to the high demand for protein 
synthesis. The quality control function of ER is activated when proteins are 
subjected to improper processing or modification. These unfolded or misfolded 
proteins are retained within the ER and subsequently cleared through the 
ubiquitin-proteasome pathway (UPP) or ER-associated degradation (ERAD) 
(Kozutsumi, Segal et al. 1988). Factors such as oxidative stress and alterations 
in calcium homeostasis can lead to the accumulation of excessive misfolded 
proteins within the ER, leading to ER stress (ERS) (Wu, Li et al. 2016). 
Feedback mechanisms are activated in response to ERS, protecting cells 
against endogenous and exogenous stresses. Through a number of signal 
transduction pathways, the protein folding and degradation capacity of the cell 
are augmented whereas translation of most proteins is stopped thereby 
reducing the burden on the organelle by decreasing the number of proteins in 
the ER. These effects are achieved by the unfolded protein response (UPR) 
(Boyce and Yuan 2006). In eukaryotes, the three ER membrane-associated 
proteins that regulate the UPR in ER include: 
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(i). protein kinase RNA-like ER kinase (PERK), 
(ii). inositol-requiring enzyme 1 (IRE1) and  
(iii). activating transcription factor 6 (ATF6).  
During physiological conditions, these three proteins bind to the ER chaperone 
immunoglobulin heavy chain-binding protein (BiP) and maintain signal 
transduction factors in a non-activated state. Under conditions of ERS, as the 
unfolded proteins aggregate within the ER lumen, these chaperone proteins 
dissociate from the luminal surface of the ER membrane proteins and bind to 
unfolded proteins. This binding activates the other ER membrane proteins and 
leads to the initiation of UPR (Hotamisligil 2010). The level and duration of ERS 
dictates the extent to which each UPR pathway becomes activated. Initially, 
new protein synthesis is attenuated to limit the protein load entering the ER. 
Sustained ERS leads to induction of gene expression via nuclear signaling to 
promote protein folding and degradation of misfolded proteins. When ER 
damage becomes irreversible and normal functions cannot be restored, 
apoptotic cell death pathway is activated (Hotamisligil 2010). 
Pancreatic acinar cells contain abundant ER in order to meet the 
physiological demands of protein synthesis. The newly synthesised digestive 
enzymes are transported to the ER and bind to BiP, which exhibits ATPase 
activity. BiP relies on the energy produced by ATP hydrolysis to accomplish 
proper folding and post-translational modifications of proteins, which are 
assembled into ZGs in the Golgi (Low, Shukla et al. 2010). Given the high rates 
of protein synthesis and energy requirements, PACs are more susceptible to 
external stimuli in case of ERS (Kubisch and Logsdon 2008). There is evidence 
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to suggest that ERS plays a vital role in the development and progression of 
AP (Thrower, Gorelick et al. 2010). Alterations in the morphology of ER and 
formation of vesicle particles (Bhatia, Neoptolemos et al. 2001) have also been 
observed in experimental pancreatitis, indicating the role of ERS in the 
pathogenesis of AP (Hartley, Siva et al. 2010, Deng, Chen et al. 2011). 
Furthermore, these observations were associated with the activation of ERS-
related receptors PERK, IRE1 and ATF6 along with their downstream pathways 
(Kubisch, Sans et al. 2006). ERS has also been shown to induce inflammatory 
response mediated via NF-κB-dependent pathway in several diseases 
(Kitamura 2011, Walter and Ron 2011). In experimental studies, ERS induced 
NF-κB activation and PAC necrosis leads to the development of pancreatitis 
(Sah, Garg et al. 2012, Huang, Liu et al. 2013, Sah, Garg et al. 2014). Recent 
studies have shown that ERS destroys PACs due to the action of misfolded 
trypsin by gene mutation (Masamune 2014). The activation of UPR pathways 
has also been demonstrated in several models of EAP, implicating the role of 
ERS in the pathogenesis of AP (Kubisch, Sans et al. 2006, Kowalik, Johnson et 
al. 2007, Ye, Mareninova et al. 2010, Fazio, Dimattia et al. 2011, Seyhun, Malo 
et al. 2011). 
 
1.3.5 Heat shock proteins  
 
Heat shock proteins (HSPs) are highly conserved proteins expressed in 
response to stress in all species. These were identified in initial experiments 
where exposure of heat shock lead to the synthesis of certain polypeptides and 
it was later discovered that these proteins are upregulated in response to other 
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stresses including; inflammation, ischaemia, anoxia and exposure to heavy 
metals (Tissieres, Mitchell et al. 1974). These proteins have a protective role 
against toxic inflammatory mediators (Polla, Perin et al. 1993, Jacquier-Sarlin, 
Fuller et al. 1994) whose synthesis is mediated via activation of transcription 
factor heat shock factor-1(HSF-1) (Morimoto 1993), under conditions of stress. 
Experimental evidence suggests that synthesis of HSP27 and HSP70 is 
increased in isolated pancreatic acini as well as in the pancreata of animals 
with caerulein-induced pancreatitis (Weber, Gress et al. 1995, Ethridge, Ehlers 
et al. 2000, Bhagat, Singh et al. 2002) and other models of EAP (Weber, 
Wagner et al. 2000, Tashiro, Schafer et al. 2001). Furthermore severity of 
caerulein-induced AP is much more pronounced in HSF-1 knockout mice 
whereas overexpression of HSP27 ameliorates severity of AP (Frossard, 
Pastor et al. 2001). Pre-exposure to sublethal stress, by water immersion or 
exposure to hyperthermia, which leads to expression of HSPs, has also been 
found to have a protective effect on severity of EAP (Weber, Gress et al. 1995, 
Wagner, Weber et al. 1996, Tashiro, Schafer et al. 2001). HSP70 prevents the 
ZG/lysosomal co-localisation thereby reducing intracellular activation of 
trypsinogen in PACs (Hietaranta, Singh et al. 2001) and overexpression of HSP 
70 also provides protection against NFkB activation (Bhagat, Singh et al. 2008). 
Clinical studies correlating the severity of AP with HSP70 gene polymorphism 
status identified that HSP70-2 expression was linked to the severity of 
pancreatitis. The HSP70-2G allele, which is associated with low HSP70-2 
expression, was more prevalent in patients with severe AP compared with mild 
disease or healthy subjects. On the contrary, patients with the “protective” AA 
genotype were found to be less vulnerable to severe form of AP (Balog, Gyulai 
et al. 2005).  
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Figure 1.4 - Intracellular and extracellular factors in pathophysiology of 
AP 
This schematic diagram shows that acinar cell injury is the primary event in the 
pathogenesis of AP and the interplay between extracellular and intracellular 
factors contributing to the pathogenesis of AP. Cytosolic calcium overload is 
the hallmark of PAC injury leading to ZG activation, trypsinogen activation, and 
increased transcription of NFkB and expression of other pro-inflammatory 
cytokines. Once released, these cytokines contribute to reduced microperfusion 
and ischaemia as well as recruitment and activation of inflammatory cells which 
could lead to SIRS. Sustained elevation of cytosolic calcium also leads to ER 
stress, mitochondrial dysfunction and ATP depletion which drives the cell 
towards necrosis.  
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1.4 Pancreatic acinar cell mitochondrial function 
 
1.4.1 Physiological role of mitochondria in pancreatic acinar cell 
 
Mitochondria, within the PAC are classically distributed in the peri-apical, peri-
nuclear and sub-plasmalemmal regions (figure 1.5). These organelles are the 
powerhouses of the PAC, providing energy for various cellular processes 
including the secretion of inactive digestive enzyme precursors. Mitochondria 
are unique cellular organelles as they contain their own genome and protein 
synthesis machinery. Mitochondria respond to physiological calcium signals 
induced by hormonal and neuronal stimulation by CCK or acetylcholine, 
respectively (Voronina, Sukhomlin et al. 2002, Murphy, Criddle et al. 2008, 
Criddle, Booth et al. 2009). This leads to an increase in NADH generation via 
stimulation of Ca2+-dependent dehydrogenases of the Krebs cycle, feeding into 
the electron transport chain thereby promoting ATP production. Mitochondria 
maintain a membrane potential (m) of 150-180 mV across the inner 
mitochondrial membrane (IMM), negative inside, by pumping protons into the 
inter-membrane space (Rizzuto and Pozzan 2006). By regulating the 
bioenergetics of the cell, mitochondria play an important role in the regulation of 
cell death pathways in PACs (Criddle, Gerasimenko et al. 2007).  
Mitochondria within the acinar cell also play a crucial role in maintaining 
Ca2+ homeostasis (Tinel, Cancela et al. 1999, Park, Ashby et al. 2001, 
Voronina, Sukhomlin et al. 2002). The peri-apical mitochondria take up local 
cytosolic Ca2+ spikes through the Ca2+ uniporter (Kirichok, Krapivinsky et al. 
2004) and prevent further spread of the signal which is terminated via the 
mitochondrial Na+/Ca2+ exchanger (Rizzuto and Pozzan 2006). This regulation 
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of Ca2+ signals prevents further emptying of the Ca2+ stores, additional large 
frequent Ca2+ fluxes, and reduces metabolic demands for ATP production. In 
the PAC, physiological Ca2+ signals always begin within the apical pole. 
However under pathological conditions of Ca2+ overload, the immediate 
buffering capacity of peri-apical mitochondria is exceeded, leading to the 
spread of Ca2+ signals into the basolateral region. Ca2+ entry into the peri-
nuclear and sub-plasmalemmal mitochondria initiates cellular responses in the 
basolateral region of the cell (Ashby and Tepikin 2002, Petersen 2005). These 
mitochondrial groups again respond to and assist in termination of the signal, 
supplying ATP for SERCA and PMCA activity.  
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Figure 1.5 - Mitochondrial distribution within PAC 
Transmitted light and TMRM (tetramethylrhodamine, methyl ester) shown in red 
(left) and confocal TMRM flourescence shown in green (right) demonstrating 
the classical distribution of mitochondria in an isolated murine PAC.  
Note: TMRM is a cell-permeant, cationic, fluorescent dye that is readily 
sequestered by active mitochondria.  
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Healthy mitochondria are also involved in mitochondrial dynamics, 
mitophagy, mitochondrial biogenesis and repair (Green and Van Houten 2011). 
Mitochondrial dynamics refers to a combination of fission and fusion processes 
(Westermann 2010) which sustain healthy mitochondria as mitochondrial 
components are mixed during fusion and fission which allows damaged regions 
of a mitochondrion to be isolated and removed by mitophagy. Mitophagy is 
triggered by the loss of m which activates pathways that lead to the 
recruitment of autophagic machinery required for the formation of double-
membrane vesicles around damaged mitochondria. These vesicles fuse with 
lysosomes to destroy the mitochondria (Youle and Narendra 2011). 
 
1.4.2 Role of mitochondrial dysfunction and necrosis in acute 
pancreatitis 
 
The potential role of mitochondrial injury in the pathophysiology of human AP 
was suggested by the observation of mitochondrial alterations on electron 
microscopy on patients with AP and gallstones (Lee, Sheen et al. 1988). 
Furthermore results of phase II trials of the anti-viral agent Fialuridine in the 
1990s showed that the drug led to significant mitochondrial injury and patients 
developed AP amongst other diseases (Honkoop, Scholte et al. 1997). It is now 
well established that pancreatic toxins cause impairment of mitochondrial ATP 
production (Orrenius, Zhivotovsky et al. 2003, Criddle, Murphy et al. 2006, 
Davidson and Duchen 2006, Petersen and Sutton 2006, Rizzuto and Pozzan 
2006, Criddle, Gerasimenko et al. 2007, Mukherjee, Mareninova et al. 2015). 
Non-oxidative metabolism of ethanol and fatty acids (FAs) results in the 
formation of fatty acid ethyl esters (FAEEs) which have shown to induce 
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experimental pancreatitis and have been found in high concentrations within 
pancreatic autopsy samples of people who have died from alcohol intoxication 
(Lange and Sobel 1983, Werner, Laposata et al. 1997, Werner, Saghir et al. 
2002). FAEEs bind to and accumulate within the inner mitochondrial 
membrane, where hydrolases release locally high concentrations of FAs, which 
uncouple oxidative phosphorylation, deplete m and impair ATP production 
(Laposata and Lange 1986, Criddle, Murphy et al. 2006). Diminished ATP 
production reduces the capacity of the acinar cell to clear Ca2+, and hence the 
peri-granular mitochondria are unable buffer apical Ca2+ elevations. The 
resulting elevation of Ca2+ increases the Ca2+ load on mitochondria leading to 
further collapse of m and impairment of ATP production (figure 1.6). Cell 
death via activation of apoptotic cell death pathway is an energy consuming 
process and this loss of ATP production resulting from mitochondrial 
dysfunction drives the cell death towards activation of necrotic cell death 
pathway (Laposata and Lange 1986). Experimental evidence suggests that the 
aforementioned sequence of events can be prevented by excluding Ca2+ from 
the external medium (Raraty, Ward et al. 2000, Voronina, Longbottom et al. 
2002, Criddle, Raraty et al. 2004) or providing supplementary intracellular ATP 
(Criddle, Murphy et al. 2006).  
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Figure 1.6 - Role of mitochondrial injury in pathophysiology of AP 
Physiological calcium signaling is required for secretory function of PAC and is 
facilitated by ATP production via mitochondria. Pancreatic toxins lead to 
cytosolic calcium overload, overwhelming the buffering capacity of 
mitochondria which leads to loss of mitochondrial membrane potential. 
Mitochondrial impairment inhibits ATP production, activation of mitochondrial 
protein phosphatase PGAM5 which is a mitochondrial executor of necrosis 
(Wang, Jiang et al. 2012) resulting in activation of necrotic cell death pathway.   
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1.4.3 The mitochondrial permeability transition pore (MPTP) 
 
In 1965, Crofts and Chappell reported that energised mitochondria exposed to 
calcium overload underwent significant swelling characterised by a large 
decrease in light scattering which could be partially reversed with calcium 
chelation (Chappell and Crofts 1965). It was initially believed that this swelling  
was due to a nonspecific permeabilisation of the inner mitochondrial membrane 
(IMM) via activation of Ca-sensitive lipases (Gunter and Pfeiffer 1990). 
However, Howarth and Hunter (Hunter and Haworth 1979) and later Crompton 
et al. (Crompton, Costi et al. 1987) provided evidence that the increased 
permeability was the sequale of a non-specific channel which became known 
as the mitochondrial permeability transition pore (MPTP). 
The MPTP has now been identified as the instrument of mitochondrial 
impairment and necrosis in the PAC (Werner, Laposata et al. 1997, Schild, 
Matthias et al. 1999, Rizzuto and Pozzan 2006, Shalbueva, Mareninova et al. 
2013, Mukherjee, Mareninova et al. 2015). Over the last 30 years, a number of 
models of the MPTP have been proposed. However the opening of the MPTP, 
now recognised to be formed by  the F0F1 ATP synthase (Giorgio, von 
Stockum et al. 2013, Jonas, Porter et al. 2015), allows an uncontrolled proton 
flow across the IMM leading to an unregulated entry and exit of ions and 
solutes up to 1.5 kDa, as well as water, into and out of the mitochondrial matrix 
(figure 1.7). This results in the loss of inner mitochondrial-membrane potential 
(m), essential for ATP production (Halestrap 2010, Rasola and Bernardi 
2011). The effect of MPTP opening on mitochondrial dysfunction by Ca2+ 
overload was first demonstrated by addition of Ca2+ to isolated cow heart 
mitochondria (Hunter, Haworth et al. 1976), which resulted in mitochondrial 
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swelling and rupture of the outer mitochondrial membrane (OMM). MPTP 
opening is physiological in transitory, low conductance mode releasing calcium 
and reactive oxygen species (ROS) to match metabolism with workload. 
However, opening of the MPTP is pathological in persistent, large conductance 
mode compromising ATP production and inducing cell death by activation of 
necrotic cell death pathway (Hunter, Haworth et al. 1976, Rasola and Bernardi 
2011).  
 MPTP inhibition using cyclosporin A (CsA) has shown significant cardio-
protective effects in the setting of ischaemic/reperfusion injury (Griffiths and 
Halestrap 1995). Studies from various other biological disciplines have led to a 
consensus that MPTP formation regulates cell death and hence inhibition of the 
MPTP affords significant cellular protective capacity (Bernardi, Krauskopf et al. 
2006, Baines 2009). It has now been discovered that MPTP opening mediates 
zymogen activation in AP through impaired autophagy (Mukherjee, Mareninova 
et al. 2015), which is also considered a key initiating event in the pathobiology 
of AP (Gukovskaya and Gukovsky 2012). Experimental data suggest that in 
CER-AP, the levels of microtubule-associated protein 1A/1B-light chain 3 (LC3) 
-II which is an autophagosomal marker of autophagic activity and p62, another 
marker for the induction of autophagy and clearance of protein aggregates are 
significantly reduced in the pancreata of knockout mice in which MPTP 
formation is inhibited, compared with wild type animals, indicating more efficient 
autophagy. These findings are consistent with reduced CCK-8-induced trypsin 
activity in knockout mice compared with wild type animals, despite no 
differences in the amount of trypsinogen. 
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The most important regulator of MPTP formation is the mitochondrial 
matrix protein cyclophilin D (CypD), which has enzymatic peptidyl-prolyl cis-
trans isomerase activity, essential for protein folding in vivo (Vandenabeele, 
Galluzzi et al. 2010).  
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Figure 1.7 - Opening of the MPTP and its consequences 
 CypD is the most important regulator of the MPTP, which interacts with the 
oligomycin sensitivity conferring protein (OSCP). The voltage dependent anion 
channel (VDAC) in the outer mitochondrial membrane (OMM) and adenine 
nucleotide translocase (ANT) in the inner mitochondrial membrane (IMM) also 
regulate the MPTP, but are dispensable. The mitochondrial translocator protein 
(TSPO) also modulates the MPTP but the mechanism is unknown.  
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1.4.4 Cyclophilin D and cyclophilins 
 
Cylophilins are ubiquitous, highly conserved proteins with sixteen isoforms 
found in humans, CypA being the most abundant (Wang and Heitman 2005). 
Cyclophilins were discovered in 1984 by Fischer et al. as these proteins were 
found to accelerate the cis-trans isomerization of prolyl peptide bonds in short 
oligopeptides, and subsequently named peptidyl-prolyl cis-trans isomerase 
(PPIase) (Fischer, Bang et al. 1984). The enzymatic activity of cyclophilins 
catalyzes a 180° rotation about the C-N linkage of the peptide bond preceding 
proline and they bind very strongly to CsA (Fischer, Wittmann-Liebold et al. 
1989). 
CypD is a mitochondrial matrix protein with PPIase activity (Elrod and 
Molkentin 2013) and recent studies have shown that it binds the lateral stalk of 
F-ATP synthase (OSCP, b and d subunits) (Giorgio, Bisetto et al. 2009).The 
definitive proof that CypD is central to necrotic signaling came in 2005 from 
genetic deletion of the Ppif gene encoding CypD (Baines, Kaiser et al. 2005, 
Nakagawa, Shimizu et al. 2005, Schinzel, Takeuchi et al. 2005). These studies 
found that Ppif null cells were highly resistant to cell death induced by cytosolic 
calcium overload, ROS stress and thapsigargin - an endoplasmic reticulum 
calcium stressor. The mode of cell death suggested that the role of CypD is 
prominent in necrotic cell death, but dispensable in apoptotic signaling 
pathway. Experimental evidence in AP demonstrates that the characteristic 
local and systemic pathological responses are greatly reduced or abolished in 
CypD knockout mice confirming that mitochondrial dysfunction through MPTP 
opening is a fundamental pathological mechanism in AP, which can be 
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ameliorated by inhibition of CypD (Elrod and Molkentin 2013, Mukherjee, 
Mareninova et al. 2015).  
CsA, a lipophilic cyclic peptide has nanomolar binding affinity for 
members of cyclophilin family (Handschumacher, Harding et al. 1984), and is 
an immunosuppressant drug widely used as an anti-rejection drug in solid 
organ transplantation (Van Buren, Flechner et al. 1984, Borel and Kis 1991). 
Interaction of CsA with cytosolic CypA generates a complex that has the ability 
to bind to, and inhibit calcineurin (Wiederrecht, Hung et al. 1992). 
Consequently, the calcineurin substrate phospho-NFAT is unable to translocate 
to the nucleus and initiate an immune response (Clipstone and Crabtree 1992, 
Walsh, Zydowsky et al. 1992). Apart from an immunosuppressant action 
through CypA, CsA is also a potent inhibitor of MPTP. MPTP inhibition by CsA 
was demonstrated in two independent studies using isolated rat heart 
mitochondria (Crompton, Ellinger et al. 1988) and isolated liver mitochondria 
(Broekemeier, Dempsey et al. 1989), later discovered to occur through binding 
to mitochondrial CypD (Halestrap and Davidson 1990). These studies provide 
convincing evidence to target CypD as an appropriate strategy to inhibit the 
MPTP which is implicated in a variety of other diseases such as, ischaemia-
reperfusion injury of the heart, brain and kidney, muscular dystrophies, neuro-
degeneration and cancer (Devalaraja-Narashimha, Diener et al. 2009, Wang, 
Carlsson et al. 2009, He, Wang et al. 2017, Wang, Jiao et al. 2017, Wu, Qian et 
al. 2017). 
The exact role of CypD in physiologically healthy cells remains to be 
determined. There are some data to suggest that CypD knockout mice display 
greater levels of anxiety, with reduced tendency to explore and facilitation of 
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avoidance behaviour. These animals also exhibit an abnormal accumulation of 
white adipose tissue resulting in adult onset obesity (Luvisetto, Basso et al. 
2008). It is however not known whether or not the inhibition of MPTP opening 
accounts for these effects.  
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1.4.5 Translocator protein  
 
The translocator protein (TSPO) [18 kDa], which was first described by 
Braestrup and Squires in 1977 (Gavish, Bachman et al. 1999), is a 169 amino 
acid protein with five transmembrane domains located primarily on the outer 
OMM (Anholt, Pedersen et al. 1986). This protein is widely expressed in a 
number of species and predominantly found in steroid synthesizing tissues 
including; gonads, kidneys, brain, adrenals and heart (Rupprecht, 
Papadopoulos et al. 2010). TSPO gene deleted knock-out mice display an 
embryonic lethal phenotype (Papadopoulos, Amri et al. 1997) indicating the 
protein’s vital role in biological processes.  
 Synder et al. (Anholt, Pedersen et al. 1986) described that within 
mitochondria, TSPO can form a multimeric complex with VDAC located on the 
OMM and ANT located on IMM. TSPO is predominantly concentrated at the 
level of the intimate contact sites between the two mitochondrial membranes 
(Culty, Li et al. 1999). This contact site localization of TSPO favours the 
transport of lipophilic molecules across mitochondrial membranes and is in 
keeping with its biological function of translocation of cholesterol and 
porphyrins across the OMM (Taketani, Kohno et al. 1994). 
 In addition to the role of TSPO in steroid synthesis, it is also involved in 
other biological functions including apoptosis, cell differentiation and 
proliferation, mitochondrial porphyrin and protein import as well as regulation of 
mitochondrial respiration (Morin, Musman et al. 2016). Although the exact 
structural role of TSPO in the formation of MPTP complex has been 
controversial (Izzo, Bravo-San Pedro et al. 2016), the TSPO ligand TRO40303 
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(3,5-Seco-4-nor-cholestan-5-one oxime-3-ol) - initially developed by a French 
pharmaceutical Trophos, now acquired by Roche - is found to be 
cardioprotective in MPTP induced ischaemia-reperfusion injury. TRO40303 has 
shown to reduce infarct size in murine models of ischaemia-reperfusion, 
provide functional recovery and reduce oxidative stress in the isolated rat heart 
models (Schaller, Paradis et al. 2010). TSPO may indirectly modulate opening 
of the MPTP by acting on well-known activators of the pore such as ROS, Ca2+ 
and/or other proteins that have been involved in MPTP opening such as ATP 
synthase (Cleary, Johnson et al. 2007, Giorgio, von Stockum et al. 2013) and 
can therefore represent an alternative strategy to develop new pharmacological 
agents to inhibit MPTP formation. Other potential clinical applications of TSPO 
include the treatment of various neurological disorders and chemotherapy as 
certain TSPO ligands have been shown to exhibit anti-proliferative effects 
against a variety of cancer cell types (Morin, Musman et al. 2016). 
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1.5 Study aims and objectives 
 
Since MPTP formation plays a critical role in the pathobiology of AP (Lerch, 
Halangk et al. 2013, Shalbueva, Mareninova et al. 2013, Mukherjee, 
Mareninova et al. 2015, Ray 2015, Maleth and Hegyi 2016) the overall aim of 
this translational research project is to evaluate MPTP inhibitors in different 
stages of drug development as potential therapy of AP. In the first instance a 
thorough review of the published literature evaluating the current evidence for 
the treatment of EAP and the translation of these preclinical studies into RCTs 
in patients with AP was undertaken to identify the pitfalls in pre-clinical studies 
and understand the reasons for attrition from bench to bedside. 
The next part of the study examined the effects of CypD inhibition on 
mitochondrial protection in response to fatty acid ethyl esters (FAEEs) and the 
efficacy of CsA and DEB025 (a non-immunosuppressive CypD inhibitor) in 
reducing necrotic cell death in human PACs. Mitochondrial function is 
preserved in CypD knockout mice in response to TLCS, however the effect of 
FAEEs on mitochondrial function in Ppif -/- had not been evaluated. Similarly 
the protective effects of CsA and DEB025 on necrotic cell death pathway 
activation had been established in murine PACs but not been studied in human 
PACs. The first key hypothesis addressed by the initial phase of the study was 
twofold: 
1. Genetic deletion of CypD will have similar mitochondrial 
protection in response to FAEEs when compared with TLCS. 
Isolated cells from human pancreatic tissue when treated with 
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CsA and DEB025 will have similar profile of protection from bile 
acid induced necrotic cell death as in murine PACs. 
 
Although CsA is a potent inhibitor of the MPTP through CypD binding, 
the immunosuppressive action of CsA is undesirable in AP, since infection 
increases mortality in AP. Non-immunosuppressive inhibitors of CypD such as 
NIM811(Argaud, Gateau-Roesch et al. 2005), DEB025 (Gomez, Thibault et al. 
2007) or Sanglifehrin A (Clarke, McStay et al. 2002) have been developed. Like 
CsA, however, these drugs inhibit all cyclophilins to varying degrees, with 
inhibitory effects on cell stress responses, e.g. on CypB that facilitates the 
unfolded protein response in the endoplasmic reticulum. Moreover, poor 
solubility and large molecular weight also limit the use of these drugs. 
Therefore, a small molecule inhibitor of CypD with high selectivity would be an 
ideal target to maintain mitochondrial function by preventing the opening of 
MPTP in AP. In the next part of this study, a number of novel small molecular 
inhibitors of CypD were evaluated. Thus, the second key hypothesis addressed 
in this phase of the study was: 
2. Inhibition of MPTP using novel small molecular CypD inhibitors 
will preserve PAC mitochondrial function and reduce necrotic 
cell death responses following exposure to pancreatic toxins. 
 
In the last phase of this study an alternative approach was adopted to 
inhibit MPTP opening in AP. TRO40303 (3, 5-Seco-4-nor-cholestan-5-one 
oxime-3-ol) a cholesterol-oxime is an MPTP modulator that mediates its affect 
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by binding to the outer mitochondrial translocator protein (TSPO) and has 
shown to reduce ischaemia reperfusion-injury (Schaller, Paradis et al. 2010). 
The efficacy of TRO40303, both in vitro and in vivo, has been comprehensively 
studied in this part of the study. Thus, the third key hypothesis in this study 
was: 
3. Preservation of mitochondrial acinar cell mitochondrial function 
using TRO40303 will preserve mitochondrial function and 
reduce necrotic cell death responses following exposure to 
pancreatic toxins in vitro, and ameliorate the severity of 
experimental acute pancreatitis in vivo. 
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2. Chapter 2 – Methods 
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2.1 Solutions 
 
Na HEPES buffered salt solution 
The standard isolation solution used for in vitro PAC experiments was Na 
HEPES buffered salt solution, contained the following chemicals (in mM) 
dissolved in distilled water : NaCl 140, KCl 4.7, MgCl2 1.13, HEPES 10, 
glucose 10, CaCl2 1. The pH was adjusted to 7.3 using NaOH and osmolarity 
checked at 300+10 mOsm. Agents used during experimentation were diluted in 
this solution from stock solutions. 
 
2.2 Animals 
 
Wild type CD1 mice were purchased from Charles River laboratories. Typically, 
male CD1 mice about 8-12 weeks old, weighing about 30 grams were used for 
PAC isolation and in vitro experiments. C57Bl/6 male mice over 25 grams each 
from Charles Liver laboratories were used for in vivo experiments. CypD 
deficient mice (Ppif-/-) generated by the targeted deletion of Ppif gene encoding 
for mitochondrial CypD (Baines, Kaiser et al. 2005) were purchased from 
Jackson laboratory (Jax mice – USA). The first three coding exons were 
replaced with a neomycin resistance cassette. A 129-dervived embryonic stem 
cell line was used to create the mutation. Chimeras were crossed to C57BL/6 
and the strain was maintained on a mixed C57BL/6 and 129 genetic 
background by the donating laboratory. Subsequently breeding pairs were used 
to develop a colony which was maintained in Liverpool. Genotyping was 
performed to confirm absence of CypD protein (section 2.5). All mice were 
Chapter 2 - Methods 
- 46 - 
 
housed in standardized conditions with a 12-hour dark/light cycle with free 
access to water and standard rodent chow. All animal procedures were 
performed in accordance with protocols defined by the Scientific (Animal) 
Procedures Act 1986.  
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2.3 Preparation of isolated pancreatic acinar cells 
 
2.3.1 Isolation of murine pancreatic acinar cells 
 
Mice were sacrificed by cervical dislocation in accordance with the Schedule 1 
procedures of Home Office. The peritoneal cavity was exposed via midline 
incision and pancreas identified at the point of attachment to the spleen. The 
pancreas was dissected, immediately placed in 4-5 ml of Na HEPES buffered 
salt solution and then injected with 1ml of warm collagenase (220 units/ml, 
Worthington Biochemical Corporation, Lakewood, NJ) solution at multiple 
points to introduce collagenase into the ductal structure. The pancreas was 
incubated at 36.5 °C for 18 to 20 minutes. After collagenase incubation the 
pancreas was placed in a 15 ml polycarbonate tube (Sarstedt, Leicester UK) 
with 4 ml of Na HEPES solution. The pancreatic tissue was dissociated 
mechanically using micropipette tips of progressively decreasing diameter. A 
cloudy supernatant was formed by cells suspended in the solution which was 
filtered through a 70 µm nylon mesh cell strainer (BD Falcon, MA, USA) to 
remove large clusters of cells and connective tissue to be collected in an 
additional identical tube and replaced with fresh Na HEPES solution. This 
process was continued until cloudy solution was no longer obtained. The 
second tube was then centrifuged at 260 G for 1 minute to form a pellet. This 
pellet was then re-suspended in Na HEPES solution for loading with 
fluorescent indicators.  
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2.3.2 Isolation of human pancreatic acinar cells 
 
Normal human pancreatic tissue samples were obtained from  patients 
undergoing elective pancreatic surgery for left-sided pancreatic tumours, 
duodenal tumours, non-obstructive right sided cancer resections in patients 
with no history of jaundice or chronic pancreatitis as described in (Murphy, 
Criddle et al. 2008) at the Royal Liverpool University hospital (sampling 
approved by Liverpool Adult Local Research Ethics Committee [Reference: 
03/12/242/A]). On the day before the patient was due to undergo the 
appropriate pancreatic surgery, written informed consent for sampling of 
macroscopically normal pancreas from the transection margin during the 
operative procedure was obtained. During resection a 1-3 cm3 piece of normal 
pancreas was taken from the transection margin of the remaining pancreas 
(figure 2.1) with a new scalpel blade to limit gross macroscopic cell damage. 
The sample was  immediately washed by transfer between two 50 ml tubes of 
ice-cold extracellular solution to remove debris and blood products such as 
neutrophils or macrophages which can potentially induce oxidative stress and 
tissue damage. The sample was added to a third tube containing ~ 50 ml ice-
cold extracellular solution plus soya bean trypsin inhibitor, protease inhibitors 
and sodium pyruvate (Criddle, Murphy et al. 2006) and immediately transported 
on ice to the laboratory to commence isolation within 10 minutes of sampling. 
The process of human PAC isolation was similar to murine acinar isolation - 
however microscopic confirmation of human PACs using transmitted light 
microscopy was always performed before starting the experiment, as the 
quality of the cells varied between patients and experiments were conducted on 
high quality samples only. As described by (Murphy, Criddle et al. 2008) cells 
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that look damaged morphologically were positive for  BZiPAR fluorescence 
indicating massive premature trypsin activity, Experiments were performed at 
room temperature and (23-25o C, except when indicated) and cells were used 
within 4 hours of isolation.  
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Figure 2.1 - Isolation of human PACs 
Magnified image of gross normal human pancreatic tissue sample obtained 
intra-operatively (A). Representative transmitted light, confocal microscopy 
image showing clusters of freshly isolated human PACs loaded with fluorescent 
dye Hoescht used to stain nuclei (B).  
A 
B 
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2.4 Confocal fluorescence microscopy 
2.4.1 Acinar cell intoxication 
 
Isolated PACs were continuously perfused with a supramaximal concentration 
of 500 µM TLCS (Sigma, Gillingham, UK), 10 nM CCK (Sigma, Gillingham, UK) 
or 100 µM POAEE (Cambridge Bioscience UK, in 5% ethanol) directly 
dissolved in Na HEPES for mitochondrial membrane potential (m), NAD(P)H 
and cytosolic calcium assays as described in section 2.43 . Cells were pre-
treated with MPTP inhibitors for 30 minutes prior to addition of toxins. 
For cell death assays, PACs were incubated with  500 µM TLCS 
dissolved in Na HEPES or 100 µM POAEE (Cambridge Bioscience UK) 
dissolved in 5% ethanol to induce in vitro abnormalities typical of AP in vivo 
(Criddle, Murphy et al. 2006). Cells were co-treated with MPTP inhibitors and 
pancreatic toxins for 30 minutes prior to imaging. 
 
2.4.2 Cell imaging 
 
Acinar cells were loaded with appropriate dye(s) (table 2) and imaged using 
state-of-the-art confocal microscopes including Zeiss LSM 510 (for m, 
NAD(P)H and cytosolic calcium measurements) and LSM710 (for necrotic cell 
death assays), equipped with multiple laser lines and an automated stage (710) 
for multi-field, time-lapse imaging. In all cases cells were visualized with a C-
Apochromat 63X water immersion objective. About 150-180 µl of PACs 
suspended in Na HEPES were placed in a microplate and healthy looking 
duplets or triplets of acinar cells with good loading of fluorescent dyes were 
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selected for recording of m, NAD(P)H and Ca
2+. Imaging parameters for cell 
death assay using confocal microscopy are further described in section 2.44. 
 
2.4.3 Mitochondrial membrane potential, NAD(P)H and cytosolic Ca2+ 
measurements 
 
To assess mitochondrial function live acinar cells were loaded with 50 nM 
tetramethylrhodamine methyl ester (TMRM; Invitrogen, Paisley, UK; excitation 
543 nm, emission >550 nm), a dye used to measure m (Voronina, Barrow et 
al. 2004). Similarly, cells were loaded with Fluo-4 (Invitrogen, Paisley, UK; 
excitation 488 nm, emission 505 nm) by incubation in solution containing 3 µM 
Fluo-4AM to measure changes in cytosolic calcium. Simultaneous 
measurements of NAD(P)H auto-fluorescence (excitation 351 nm, emission 
385-470 nm) were done to assess mitochondrial metabolism (figure 2.2). 
Typically cells were pre-treated for 30 min with test compounds or vehicle prior 
to the start of the experiment. After assessing baseline fluorescence levels 
(Fo), cells were stimulated with 500 µM TLCS, 10 nM CCK or 100 µM POAEE, 
for 10 minutes and then treated with 10 μM carbonyl cyanide m-
chlorophenylhydrazone (CCCP; Sigma, Gillingham, UK), as a positive control. 
Cells were imaged every 5-10 seconds under confocal microscopy for 
measurement of m, NAD(P)H and calcium in the absence or presence of 
MPTP inhibitors. TMRM, NAD(P)H and Fluo-4 fluorescent signals were 
normalized versus baseline fluorescent level (F/Fo). 
 
 
 
Chapter 2 - Methods 
- 53 - 
 
Table 2 - Fluorescent indicator loading protocols 
 
Flouresect 
indicator 
Loading 
conc. 
Loading 
time (min) 
Excitation 
(nm) 
Emission 
(nm) 
Target 
organelle / 
species 
 
TMRM 50 nM 25-30 543 580-680 Mitochondria  
m 
Fluo-4 AM 3µM 25-30 488 500-550 Cytosolic 
calcium 
 
Propidium 
iodide 
1 µM 25-30 488 630-693 Nucleus (cell 
impermeant) 
 
Hoechst 1 µM 25-30 361 486 Nucleus (cell 
permeant) 
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Figure 2.2 - Confocal fluorescence microscopy of isolated PACs 
(A) Transmitted light and confocal images of triplet of mouse PACs showing 
NAD(P)H autoflourescence (blue). (B) Transmitted light and confocal images of 
PAC doublet, loaded with TMRM (red) demonstrating mitochondrial distribution 
within PAC. (C) Transmitted light and confocal images of pancreatic acini, 
loaded with Fluo-4AM (green) showing calcium distribution within PAC. 
Note: All images acquired under physiological conditions  
A 
B 
C 
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Figure 2.3 - Effects of TLCS stimulation on m and calcium  
Confocal images of doublet of murine PACs loaded with TMRM (red) and Fluo-
4 (green) showing changes to m and Ca
2+
 in response to TLCS stimulation 
respectively. Exposure to TLCS leads to loss of m indicated by loss of TMRM 
fluorescence signal (A) and a corresponding increase in Fluo-4 fluorescence 
signal indicating cytosolic calcium overload (B).   
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2.4.4 Necrotic cell death assay 
 
In order to assess activation of necrotic cell death pathway, 1 µM propidium 
iodide (PI; excitation 488 nm, emission 630-693 nm) was used to evaluate 
plasma membrane rupture (Criddle, 2006). Isolated PACs from each animal 
were divided into the following groups: 
(i) control – PAC only; acinar cells incubated with Na HEPES for 30 
minutes and imaged,  
(ii) PAC + 500 µM TLCS; acinar cells incubated with 500 μM TLCS for 30 
minutes and imaged,  
(iii) PAC + 500 µM TLCS + MPTP inhibitors simultaneously and, 
(iv) in case of assessment of novel CypD inhibitors; PAC + small molecular 
CypD inhibitor (for evaluation of toxicity of test compound).  
Incubation time was 30 minutes for each group and all experiments were 
conducted at room temperature. Similarly acinar cells were also incubated with 
100μM POAEE in the presence or absence of test compound and imaged. 
Sixteen randomly selected fields of view were taken of each mouse isolate 
(figure 2.4) and the total number of cells displaying PI uptake were counted per 
field to give a percentage ratio for each field, averaged across fields, and 
converted to a mean +/- SEM for a minimum of three mice and two or three 
humans samples per experimental group. The experiments were performed in 
a blinded fashion, such that the observer choosing the fields and the observer 
undertaking image analysis was blinded with respect to the treatment groups.  
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Figure 2.4 - Necrotic cell death assay 
(A). Representative image of murine PAC doublet showing uptake of propidium 
iodide (PI), a membrane impermeable dye (shown in red) indicating necrotic 
cell death pathway activation. (B). Incubation of PAC with TLCS (500 µM) at 
room temperature for 30 minutes causing plasma membrane rupture and 
increase in PI uptake, compared to control. 
 
  
A 
B 
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2.5 Genotyping for Ppif null mice 
 
A standard Polymerase Chain Reaction (PCR) assay for genotyping the Ppif 
animals was used. After the tail prep, the genomic DNA was suspended in 75 
µl of TE (Tris and EDTA) buffer and hydrated. The sample was diluted in a ratio 
of 1:20 and 1 ml of this dilution was used for the PCR (50 ml reaction volume). 
The three primers used in a single reaction were: 
 Exon3-F: CTC TTC TGG GCA AGA ATT GC 
Neo-F: GGC TGC TAA AGC GCA TGC TCC 
Exon4-R: ATT GTG GTT GGT GAA GTC GCC 
 Reaction conditions: 95°C for 3 min 
                  95°C for 0.5 min 35 cycles 
               56°C for 0.5 min  
               72°C for 1 min  
                                    72°C for 10 min 
 
2.6 Synthesis of recombinant cyclophilin D 
 
Human CypD clone (LIFESEQ7721956) was bought from Thermo Scientific 
Open Biosystem. By using the forward primer 5’-
CCGTGGATCCATGGGGAACCCGCTCGTGTAC-3’ and the reverse primer 5’- 
CCGT CTCGAGTTAGCTCAACTGGCCACAGTC-3’, the PCR product was sub 
cloned into the vector pET28b (+) (NOVAGEN) between the BamH1 and Xho1 
sites to obtain the expression of pET28b-CypD. Sequencing was carried out to 
confirm the insertion. In order to increase the solubility of the protein for 
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crystallographic studies, a mutation of Lys133 into Ile was introduced on the 
CypD gene. 
Expression was conducted in E. coli BL21 cells. Four 2 litre flasks each 
with 500ml culture media were inoculated with an overnight culture of freshly 
pET28b-CypD transformed cells supplemented with 30µg/ml kanamycin. The 
bacteria at 37 °C were grown until the OD600 reached 0.6, and isopropylthio-β-
D-galactoside (IPTG) was added to final concentration of 1mM to induce 
HisTag-CypD expression at 30 °C overnight. Bacteria were harvested and re-
suspended in 25mM Tris-HCl pH 7.8, 500mM NaCl and 20mM imidazole buffer 
and were lysed with a French press at 60 MPa. The lysate was centrifuged and 
supernatant was collected. HisTag-CypD protein was purified by using Ni 
Sepharose HisTrap FF column (GE Healthcare Life Sciences). 
 
2.7 Surface Plasmon Resonance assay for screening of small 
molecules 
 
The Surface Plasmon Resonance (SPR) technology-based Biacore X100 (GE 
Healthcare) was used for screening of small molecules based on their 
interaction with CypD. All experiments were carried out using buffer containing 
Tris-HCl pH 7.6, NaCl 150mM, 0.05% surfactant p20 and 5% of dimethyl 
sulfoxide (DMSO) as a running buffer at a constant flow rate of 30 µl/min at 
room temperature. The protein, CypD, was immobilized directly and covalently 
on hydrophilic carboxymethylated dextran matrix of the CM5 chip sensor chip 
(BIAcore) by using the standard primary amine coupling. The protein (25 µg/ml) 
was immobilized on CM5 sensor ship to achieve ~2500 response units. All data 
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analyses were carried out using BIA evaluation software and the sensorgrams 
were processed using the automatic correction method for nonspecific bulk 
refractive index effects. The kinetic analyses of the ligand-binding to the protein 
were performed based on the 1:1 Langmuir binding fit model according to the 
procedure described in the software.   
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2.8 Induction of experimental acute pancreatitis 
 
2.8.1 Caerulein induced experimental acute pancreatitis 
 
The first model tested was hyperstimulation with caerulein, a cholecystokinin 
analogue, which is the most widely used model of experimental acute 
pancreatitis (CER-AP), the severity of which can be graded depending on the 
extent of hyperstimulation (Pandol, Saluja et al. 2007). The clinical parallel of 
this model is hyperstimulation-induced AP by scorpion bites (notably Tityus 
species), frequent in the West Indies and South America, or by 
organophosphate insecticides. Compounds in scorpion venom and 
organophosphates irreversibly inhibit cholinesterase and provoke excessive 
cholinergic stimulation. A standard model of seven, hourly intraperitoneal 
injections of 50 µg/kg caerulein (dissolved in saline solution) was used, with 
controls receiving saline alone; sacrifice was made 12 hours after the first 
injection. Three doses (1mg/kg, 3mg/kg or 10 mg/kg) of liposomal preparation 
of TRO40303 were administered after the third caerulein injection. The most 
effective dose was tested in subsequent models.  
 
2.8.2 Bile acid induced acute pancreatitis 
 
The next model was the bile acid-induced murine acute pancreatitis (TLCS-
AP), similar to gallstone-induced clinical AP, which results from retrograde 
passage of bile into the pancreatic duct when gallstones get impacted at the 
sphincter of Oddi. A retrograde injection of 3 mM TLCS was administered into 
the pancreatic duct, perfused for 10 minutes and 3mg/kg of TRO40303 was 
administered intraperitoneally one hour after the TLCS injection. In order to 
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ensure appropriate technique and adequate pancreatic duct infusion in each 
case, characteristic ballooning and blue stippling of the pancreas was observed 
for each mouse. Controls had the same procedure without ductal infusion; 
sacrifice was made 24 hours later. The previously described technique was 
modified (Laukkarinen, Van Acker et al. 2007) and intraperitoneal anaesthesia 
was substituted with gaseous anaesthesia using a combination of O2, N2O and 
isoflurane to facilitate a more controlled induction and recovery process. 
Analgesia was administered prior to induction; mice were given 1mg/kg 
bodyweight of buprenorphine subcutaneously. Following laparotomy, the 
common duct was cannulated via trans-duodenal puncture using 30 guage 
blunt needle on the anti-mesenteric border of the duodenum. The needle was 
secured in position with a 10/0 prolene stitch and micro vessel clip applied at 
the liver hilum to ensure preferential perfusion of the pancreas rather than 
biliary tree. The solution (dissolved in Na HEPES solution with methylene blue 
~ 300 µM) was perfused at a rate of 5 µl/min for 10 minutes using infusion 
pump (Harvard apparatus) and blue discolouration of the pancreas was 
monitored to ensure consistent pancreatic infusion and delivery of TLCS. The 
needle was removed at the end of infusion period followed by closure of the 
duodenal defect, abdomen and mouse recovered. 
 
2.8.3 Alcoholic acute pancreatitis 
 
The third model of experimental murine AP with a clinical parallel was tested by 
intraperitoneal injection of ethanol and palmitoleic acid (FAEE-AP), a fatty acid 
that combines with ethanol in the pancreas to form fatty acid ethyl esters, the 
principal agents of PAC injury from ethanol excess (Huang, Booth et al. 2014). 
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Mice received two intraperitoneal injections of 1.32 g/kg ethanol and 1.5 mg/kg 
palmitoleic acid (dissolved in peanut oil), each one hour apart; to induce AP. 
Controls received intraperitoneal saline injections and in treatment group, 
3mg/kg of TRO40303 was administered intraperitoneally one hour after the last 
injection. Humane killing was performed 24 hours after the first injection and 
analgesia administered (1mg/kg bodyweight of buprenorphine subcutaneously) 
prior to induction of AP and 12 hours after the first injection.  
All experiments complied with a Project Licence, under the terms of the 
Animals (Scientific Procedures) Act 1986, authorising the proposed 
experiments, granted by the Home Secretary UK. TRO40303 stock solution in 
liposomes (20 mg/ml) was diluted into saline to prepare 2.5 fold concentrated 
working solutions (0.4, 1.2 and 4 mg/ml, for the three doses 1, 3 and 10 mg/kg, 
respectively), which were injected intraperitoneally using a constant volume of 
2.5 ml/kg. 
Standard times for assessment after the start of the induction of EAP 
were 12 hours after the first injection of CER-AP and 24 hours after the first 
injection of TLCS-AP and FAEE-AP. At these time points the local and 
systemic disease is well established, and various parameters most severe, 
representing the time point when a difference between control and treatment 
groups is most likely to be found. Before sacrifice (at 12 hours after the first 
injection of CER-AP or 24 hours after the first injection of TLCS-AP and FAEE-
AP), blood samples were harvested on Lithium Heparin tubes (VenoJect®, 
TERUMO®) and centrifuged immediately for 15 minutes at 2.500 rpm at 4°C. 
Pancreata were then immediately isolated for extract preparation and histology 
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slides. Lungs were also isolated for extract preparation. Each group of mice at 
each time point undergoing each protocol were constituted of six animals.  
 
2.9 Biochemical parameters of severity of experimental acute 
pancreatitis 
  
2.9.1 Serum amylase, IL-6 and pancreatic trypsin activity determination 
 
Amylase levels were tested using a kinetic method by Roche automated clinical 
chemistry analysers. IL-6 was measured using enzyme-linked immunosorbent 
assay (ELISA) - Quantikine from R&D systems. Trypsin activity was measured 
with a fluorogenic assay, using Boc-Gln-Ala-Arg-AMC substrate converted by 
trypsin to a fluorescent product (excitation 380 nm, emission 440 nm). 
 
2.9.2 Myeloperoxidase assay 
 
Myeloperoxidase (MPO) activity, indicative of neutrophil infiltration, was 
measured in pancreas and lungs (Dawra, Ku et al. 2008). For measuring MPO 
activity, 20 µl of extract was added into the assay mix consisting of 200 µl  
phosphate buffer (100 mM, pH 5.4 with 0.5% HETAB), 20 µl 3,3′,5,5′-
tetramethylbenzidine (TMB) 20 mM in DMSO. This mixture was incubated at 
37oC for 3 minutes, followed by addition of 50 µl of H2O2 (0.01%) which was 
further incubated for 3 minutes. The difference of absorbance between 0 
minutes and 3 minutes at 650 nm was calculated by a standard curve triggered 
by human MPO. 
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2.10 Histopathological parameters of severity of experimental 
acute pancreatitis 
 
Pancreatic tissue was fixed in formaldehyde and standard haemotoxylin and 
eosin sections were prepared. Scoring of oedema, leucocyte infiltration and 
necrosis (0-3) was undertaken by two independent, blinded investigators (free 
marginal ĸ = 0.75) in X 10 high power fields/slide/mouse (Wildi, Kleeff et al. 
2007) [Table 3]. X 200 magnification was used throughout. Scores were 
summated then means +/- SEM calculated for mice in each experimental 
group.  
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Table 3 - Criteria used for histological analysis of severity of EAP  
 
Condition Score Indication 
Oedema 
0 Absent 
1 Focally increased between  lobules 
2 Diffusely increased 
3 Acini disrupted and separated 
Inflammatory cell 
infiltrate 
0 Absent 
1 In ducts (around ductal margins) 
2 
In the parenchyma (<50% of the 
lobules) 
3 
In the parenchyma (>50% of the 
lobules) 
Acinar necrosis 
0 Absent 
1 Periductal necrosis (<5%)* 
2 Focal necrosis (5–20%) 
3 
Diffuse parenchymal necrosis (20–
50%) 
 
- Criteria  described by Van Laetham and colleagues  
*Approximate percentage of cells involved per field examined.  
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2.11 TRO40303 plasma level measurements 
 
Preliminary pharmacokinetic (PK) analysis was performed at Trophos with the 
liposomal intraperitoneal administration in C56B7 naive mice at 3 and 10 
mg/kg. A maximum of 0.25 mL of blood was collected into lithium heparin tubes 
at 15 and 30 minutes, 1 hr, 2 hr, 4 hr, 8 hr and 24 hr after drug administration (3 
mice per time point). The blood samples were cooled on ice and plasma 
samples were prepared within 60 minutes of sampling by centrifugation at 1500 
g at 4˚C for 10 minutes and stored at -20°C until analysis.  
For pancreata level measurements, TRO40303 was administrated 
intraperitoneally to mice at the dose of 3 mg/kg in liposomes, pancreata were 
isolated at 15 min, 2hr and 24hr (3 mice per time point) and washed with saline. 
Samples were frozen and stored at -20°C until analysis. 
TRO40303 level was also assessed both on the plasma and pancreata 
in the cearulin model at the doses of 1, 3 and 10 mg/kg of TRO40303 15 
minutes after TRO40303 administration. Plasma was harvested and stored at   
-20°C in eppendorf for shipment to Trophos for bio-analysis. 
Thawed samples were extracted with acetonitrile, centrifuged, purified 
on SPEC C2 cartridge (Varian) and analysed by HPLC-MS/MS along with 
calibration standards. Analysis was carried out using the Alliance 2695 
(Waters) system interfaced to an API Quattro Micro (Waters) MS detector. 
Waters Quan Lynx software was used for calculations.  
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2.12 Statistical analyses 
 
Biological data were distributed normally and therefore presented as mean +/- 
SEM.  Non-normally distributed variables (section 3.3) are presented as 
median and interquartile range (IQR). Statistical evaluation was performed 
using OriginPro 9 (Origin Lab corporation, USA). Two-tailed student’s t-test 
(two groups) and ANOVA (more than two groups) were performed for 
parametric data. Unpaired t-test was used to calculate the difference in means 
of independent samples. Null hypotheses were rejected at the 
5% significance level and P values <0.05 were considered significant. Although 
no formal calculation of sample size was undertaken for experiments involving 
experimental acute pancreatitis, at least six animals were included in each 
group, which is considered an adequate sample size by many researchers 
(Charan and Kantharia 2013) and has been the standard sample size in peer 
reviewed publications from our group (Huang, Booth et al. 2014, Mukherjee, 
Mareninova et al. 2015, Wen, Voronina et al. 2015, Javed, Wen et al. 2018). 
The kappa statistic was calculated to test interrater reliability of the two 
independent reviewers undertaking blinded assessment of histological markers 
of severity in pre-clinical models of experimental acute pancreatitis .
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qualitative assessment of studies evaluating 
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3.1 Introduction 
 
Experimental murine models of AP have been used to investigate the 
molecular mechanisms underlying the disease process and screen potential 
therapies for testing in humans (Gorelick and Lerch 2017). Rodents have 
several advantages over other model organisms; the mouse genome shares 
similarity with the human genome (99%), provides an appropriate genetic and 
molecular toolbox to produce relevant knockout species and the animal's small 
size facilitates high throughput studies making it a cost-efficient model. 
Although a number of agents have shown efficacy in pre-clinical studies, it has 
not been possible to translate the experimental therapeutic results into clinical 
practice in human AP. This may be due to the difficulty in designing clinical 
studies capable of giving reliable, statistically significant answers regarding the 
benefits of the various proposed therapeutic agents previously tested in 
experimental settings. It is however, important to try and understand other 
factors that may contribute towards the lack of translation of potential 
therapeutics from bench to bedside. Drug development for stroke is a relevant 
example where the efficacy of drugs in pre-clinical models has failed to 
translate into clinical trials; a reported attrition rate of 99% at the stage of 
clinical trial alone, since the animal experiments did not model human disease 
with sufficient fidelity to provide a useful guide for translation (Sena, van der 
Worp et al. 2007). These pitfalls have been addressed by a better 
understanding of pathophysiology, recognition for the need of early 
intervention, establishment of stroke units and a multidisciplinary approach in 
the form of recommendations from the Stroke Therapy Academic Industry 
Round Table to suggest guidelines for the preclinical evaluation of 
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neuroprotective drugs (Stroke Therapy Academic Industry 1999). A similar 
approach may need to be adopted by the pancreatic community for developing 
a treatment of AP. 
The following systematic review and qualitative assessment of all 
studies evaluating agents used for the treatment of AP in murine models of 
experimental pancreatitis provides an up to date analysis of all agents that 
have been tested pre-clinically and aims to identify any factors that may 
contribute towards this significant translational gap and for the clinical treatment 
of AP. 
 
3.2 Methods 
 
3.2.1 Study Identification 
 
Multiple electronic databases including Pubmed, Medline, Embase and 
Cochrane library were searched from the time of inception to December 2015 
by two independent reviewers using Medical Subject Headings (MeSH) terms 
‘acute pancreatitis’, ‘treatment’ and ‘therapy’ to identify the studies (figure 3.1). 
The search process was augmented by manual review of the lists of references 
cited in identified studies and review articles, by scanning abstracts from 
conference proceedings and contacting investigators if required. 
 
3.2.2 Inclusion Criteria 
 
 Studies published in the English language 
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 Studies published as full reports 
 Pre-clinical studies evaluating efficacy of an agent in murine models of 
EAP only 
 Studies aimed at evaluating therapeutic potential of an agent rather than 
patho / physiology of AP 
Studies evaluating combination treatments or agents used for treatment of 
complications were excluded. Agents were classified according to their putative 
mechanism of action into the following categories: 
 Anti-inflammatory agents   
 Enzyme inhibitors 
 Anti-oxidants 
 Secretion inhibitors 
 Agents affecting blood flow and microcirculation 
 Eicosanoids 
 Others (miscellaneous and multiple actions) 
 
3.2.3 Quality assessment 
 
A newly devised scoring system was formulated in consultation with two 
internationally renowned pancreatologists (Professor Robert Sutton, UK and 
Professor Markus Lerch, Germany) and used for qualitative assessment of 
each publication. The scoring system comprised a checklist of 10 points that 
included; adequate number of animals per group, reference to posology, 
clinical relevance and number of models of AP, prophylactic vs therapeutic 
administration of treatment, adequate description of husbandry, biochemical 
Chapter 3 - Results: Agents tested in EAP 
- 73 - 
 
and histological markers of severity and evaluation of other organs. Each study 
was scored by two independent reviewers. In case of a lack of consensus, a 
third reviewer was invited to score the study and to adjudicate. Studies fulfilling 
the following criteria were analysed in further detail including a semi-
quantitative assessment of whether an agent reduced the biochemical or 
histological markers of severity by more than 50% or not, as these were 
considered to be the most clinically relevant and objective parameters of 
assessment. 
(i) Adequate number of animals (n> 6), 
(ii) clinically representative model (caerulein, bile acid, ethanol induced 
or pancreatic duct ligation), 
(iii) treatment administered therapeutically i.e after induction of 
pancreatitis. In caerulein model treatment was considered 
therapeutic after the 3rd caerulein injection in mice or 4 hours of 
caerulein infusion in rats. In all other models therapeutic 
administration defined as commencement of treatment after 
completion of induction of EAP. 
(iv) Blinded assessment of pancreatic histology.  
Chapter 3 - Results: Agents tested in EAP 
- 74 - 
 
3.3 Results 
 
3.3.1 Literature review process 
 
The flow diagram depicting the literature search, subsequent study 
identification and inclusion process is shown as figure 3.1. Essentially, 771 
studies were identified using appropriate and relevant MeSH terms. Six 
hundred and sixty were found to be eligible. Out of these, 230 were excluded 
as they were testing a combination of treatments, primarily aimed at treating 
complications of AP rather than pancreas or were mechanistic and therefore 
not testing efficacy of a therapeutic agent. Finally, 430 studies were included in 
the qualitative synthesis and categorised according to the agent’s putative 
mode of action. 
  
 
 
 
 
 
 
 
 
Figure 3.1 - Flow diagram describing literature review process  
Number of studies 
screened  
n = 771 
Full text articles assessed 
n = 660 
Records excluded n = 111 
 47 - other languages 
 24 - full text articles not 
available 
 40 - non rodents 
Studies included in  
Qualitative synthesis 
 n = 430    
Full text articles excluded n = 230 
Mechanistic studies, combinations or 
therapies targeting complications of AP 
Categorised based on primary mode of 
action 
 
 Anti-inflammatory agents: n = 172 
 Enzyme inhibitors: n = 28 
 Anti-oxidants: n = 52 
 Secretion inhibitors: n = 40 
 Agents affecting blood flow & 
microcirculation: n = 53 
 Eicosanoids: n = 24 
 Others : n = 61 
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3.3.2 Experimental models of acute pancreatitis and variation in pre-
clinical experimental design 
 
A wide range of murine experimental models of AP have been used to test the 
therapeutic efficacy of potential AP treatments which have been summarised in 
table 4. Caerulein and bile acid induced AP were by far the two most common 
models tested in experimental studies. A majority of experimental studies have 
been conducted on rats (74.2%) and efficacy of agents have been tested 
prophylactically (58.8%) – figure 3.2 A,B. In 28.8% of publications, treatment 
was administered therapeutically and in 53 studies, both prophylactic as well as 
therapeutic effects of an agent were evaluated (figure 3.2B). There was 
significant variation in the timing of therapeutic administration of treatment 
(figure 3.3A) as well as the severity of experimental pancreatitis in CER-AP and 
TLCS-AP (figure 3.3 B-D). The vast majority of studies were undertaken using 
a single model of EAP, less than 10% evaluated the therapeutic potential of a 
test compound in two models and only ten publications used more than two 
models of EAP (figure 3.2C).   
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Table 4: Experimental models of acute pancreatitis 
 
 
1. Caerulein induced pancreatitis 
(Niederau, Ferrell et al. 1985)* 
 
 
2. Bile acid infusion model of 
pancreatitis*(Wittel, Wiech et al. 2008) 
3. Pancreatic duct (PD) 
ligation*(Walker, Winterford et 
al. 1992) 
 
4. Bile acid infusion combined with PD 
ligation*(Osman, Lausten et al. 1999) 
5. Intraductal contrast infusion 
(Folch-Puy, Granell et al. 2006) 
 
6. Ethanol induced (Hirano 1994) 
7. Closed duodenal loop 
(Nevalainen and Seppa 1975) 
 
8. L- Arginine induced  (Mizunuma, Kawamura et 
al. 1984) 
9. Caerulein combined with bile 
acid (Schmidt, Rattner et al. 
1992) 
 
10. Choline deficient ethionine (CDE) – diet 
induced (Lombardi, Estes et al. 1975) 
11. Bile acid + trypsin infusion 
(Grewal, Kotb et al. 1994) 
 
12. Caerulein combined with lipo-polysaccharide 
(LPS) administration (Ding, Li et al. 2003) 
13. Intraductal infusion of TLCS and 
phospholipase A2 (Hatao 1969) 
14. Ischaemia induced (Dembinski, Warzecha et al. 
2001) (Ceranowicz, Dembinski et al. 2008) 
 
 
15. Intraductal trypsin infusion 
(Lankisch, Winckler et al. 1974) 
 
16. Ethanol induced combined with caerulein 
(Yuasa, Irimura et al. 1998) 
17. Traumatic pancreatitis (Ren, Luo 
et al. 2012) 
 
18. Alcoholic pancreatitis (Huang, Booth et al. 
2014)  
 
  
 
* Highlighted models were considered clinically relevant  
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Figure 3.2: Variation in experimental models of acute pancreatitis 
 
 
 
 
 
Rats  
n=319 
 
 74.2% 
Mice 
n=111 
 
 25.8% 
Prophylactic 
n=253 
 
 58.8 % 
Therapeutic 
n= 124 
 
28.8% 
Both n=53 
 
 12.3% 
 
In caerulein model therapeutic administration of treatment defined as: 
 After the 3rd caerulein injection in mice 
 After 4 hours of intravenous infusion in rats 
In all other models therapeutic administration defined as commencement of 
treatment after completion of induction of experimental acute pancreatitis 
A: Species 
Species 
B: Administration of treatment 
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Figure 3.2 - Variation in protocols of EAP models 
Pie chart showing the different species used in EAP (A), timing of        
treatment in pre-clinical studies (B) and number of models tested in individual 
studies (C).  
One model  
n=380 
 
88.4 % 
Two models 
 n=40 
 
 9.3 % 
> 2 models 
  n=10 
 
2.3 % 
C: Number of models tested in each study 
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Figure 3.3: Variation in toxicity of experimental models of acute 
pancreatitis 
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Figure 3.3 - Variation in toxicity of EAP models 
Therapeutic administration of testing agent can vary from just after AP 
induction up to 12 hours post induction (A). Significant variation in the dose (B) 
and number of injections (C) in CER-AP is also evident. Concentration of bile 
acid can vary from 1.5%-10% in bile acid induced AP (D).  
 
C: Variation in number of injections of caerulein 
 
D: Variation in TLCS model 
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3.3.3 Targets and trends in publications over time 
 
Agents were categorised according to their putative mechanism of action for 
the purposes of classification. Table 5 shows the number of agents tested 
within each category in preclinical studies and details of all the compounds that 
have been tested in murine models of AP are summarised in tables 8-14. 
Premature digestive enzyme activation is considered to be a cardinal feature of 
pancreatic injury in pancreatitis, with activated zymogens contributing to intra- 
and extra-cellular damage. Hence considerable attention has been focused on 
pharmacological agents that inhibit activated proteases (n=28). It is generally 
believed that the severity of pancreatitis is determined by events that occur 
after acinar cell injury. Pancreatic acinar cells synthesize and release cytokines 
and chemokines, resulting in the recruitment of inflammatory cells such as 
neutrophils and macrophages. Recruitment and activation of various 
inflammatory cells leads to further acinar cell injury and causes an elevation of 
various pro-inflammatory mediators such as TNF α, IL-1, IL-2, IL-6, and other 
chemokines and anti-inflammatory factors such as IL-10. These inflammatory 
cells and mediators play a role in the systemic manifestations besides 
modulating PAC injury. Systemic inflammatory response syndrome (SIRS) is a 
result of uncontrolled local inflammation and predisposes to multiple organ 
failure. The suppression of the inflammatory cytokines secretion may reduce 
pancreatitis intensity and mortality (Bhatia, Brady et al. 2000). Anti-
inflammatory agents (n=172) and eicosanoids (n=24) have by far been the 
most commonly investigated treatment modalities in experimental studies of 
AP. Reactive oxygen species (ROS) play an important mediator function in the 
early and late course of AP and have a direct inﬂuence on lipids and proteins in 
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the cell membrane and disrupt their functions. Although the role of ROS is 
pathogenesis of AP is complex (Booth, Murphy et al. 2011), inhibition of ROS 
has been tested as a treatment strategy for AP (n=52). Cholecystokinin (CCK) 
is a gastrointestinal hormone and neurotransmitter located in the digestive 
tract. Since it stimulates secretion of the pancreatic digestive enzymes via CCK 
receptors, it is considered to play a key role in the progression and aggravation 
of AP - it has been targeted as a treatment strategy along with other inhibitors 
of gastrointestinal secretions (n=40). The release of activated enzymes in 
pancreatitis results in the activation of plasma proteases of the kallikrein-kinin, 
complement, coagulation, and fibrinolytic systems and consumption of protease 
inhibitors. Disturbances within the cascade systems play a crucial role in the 
clinical outcome and therefore inhibitors of coagulation have been used as a 
potential treatment modality for pancreatitis (n=53). The trends in published 
literature regarding treatment strategies tested for the treatment of AP over 
time are shown in figure 3.4, demonstrating a shift towards targeting of the 
inflammatory pathway in the last two decades.  
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Table 5 - Pre-clinical EAP treatment; qualitative assessment 
 
Treatment Number 
of pre- 
studies 
Median 
quality 
score 
(IQR) 
# of 
studies 
fulfilling 
modified 
score 
# of agents showing > 50 
% improvement in 
biochemical and 
histological parameters 
Anti-
inflammatory 
172 5.5 (5-
6) 
25 Benzamide (Yasar, Uysal et 
al. 2010), IL 10 (Rongione, 
Kusske et al. 1997)  (Chen, 
Tang et al. 2004), Duchengqi 
Decoction (Wang, Chen et 
al. 2012) and Thymosin 
alpha 1(Wang, Zeng et al. 
2015) 
Enzyme 
inhibitors 
28 4 (3-5) 2 Ulinastatin (Maciejewski, 
Burdan et al. 2005) 
Anti-oxidants 52 4 (4-6) 9 Caffeic acid phenethyl ester 
(Buyukberber, Savas et al. 
2009) and ozone (Uysal, 
Yasar et al. 2010) 
Secretion 
inhibitors 
40 5 (3-5) 5 None 
Microcirculation 
and blood flow 
53 5 (4-6) 6 Activated protein C (Babu, 
Genovese et al. 2012) 
Eicosanoids 24 5 (5-6) 4 None 
Others 61 6 (5-7) 15 Pentoxifylline (Matheus, 
Coelho et al. 2009), 
GSK7975A (Wen, Voronina 
et al. 2015), DEB025 and 
TRO40303 (Mukherjee, 
Mareninova et al. 2015), 
Obestatin (Bukowczan, 
Cieszkowski et al. 2016) and 
polyenoylphosphatidylcholine 
(Li, Wu et al. 2015) 
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Figure 3.4 - Trends in publications over time 
After an initial surge of research involving anti-secretory agents, enzyme 
inhibitors, compounds affecting blood flow and anti-oxidants; researchers seem 
to have focused on evaluating anti-inflammatory agents and compounds with 
multiple actions during the last 15 years.
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3.3.4 Quality assessment 
 
Median quality score for all the studies included in the analysis was 5 (IQR: 4-
6). The percentage of each reported parameter of the modified scoring system 
is shown in table 6. Most studies were undertaken in an adequate number of 
animals, on a clinically relevant model and provided adequate description of 
approved animal husbandry including board / home office or other standards. 
Posology was adequately addressed in 45% of the studies, 52% of the studies 
had evaluated two or more biochemical markers of severity, one of which was a 
digestive enzyme the other an inflammatory marker. Although 62% publications 
reported blinded assessment of histological markers of severity, only 19% used 
two independent assessors and 31% of the studies commented on the effects 
of an agent on an organ other than pancreas. 
Table 5 also summarises the quality assessment of treatments tested in 
EAP within each category. There were only thirty studies which had a score of 
> 8 (Warzecha, Dembinski et al. 1999, Mayer, Laine et al. 2000, Gloor, Uhl et 
al. 2001, Paszkowski, Rau et al. 2002, Alhan, Kalyoncu et al. 2004, Mumcu, 
Alhan et al. 2005, Yamanel, Mas et al. 2005, Alhan, Turkyilmaz et al. 2006, 
Alsfasser, Warshaw et al. 2006, Machado, Coelho et al. 2006, Turkyilmaz, 
Alhan et al. 2008, Liu, Dou et al. 2010, Warzecha, Ceranowicz et al. 2010, You, 
Tao et al. 2010, Ceyhan, Timm et al. 2011, Paterniti, Mazzon et al. 2012, 
Wenhong, Jia et al. 2012, Cao and Liu 2013, Nuhn, Mitkus et al. 2013, Huang 
and Cao 2014, Alhan, Usta et al. 2015, Bukowczan, Warzecha et al. 2015, 
Chen, Dai et al. 2015, Huang, Cane et al. 2015, Huang, Cash et al. 2015, 
Mukherjee, Mareninova et al. 2015, Wang, Zeng et al. 2015, Wen, Voronina et 
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al. 2015, Bukowczan, Cieszkowski et al. 2016, Liu, Zhou et al. 2016). Of all the 
studies included in the analysis, there were 66 publications which fulfilled the 
aforementioned clinically relevant criteria, and these have been highlighted in 
tables 8-14. Further analysis of these publications identified fourteen agents – 
benzamide (Yasar, Uysal et al. 2010) , IL 10 (Rongione, Kusske et al. 1997) , 
thymosin alpha 1 (Wang, Zeng et al. 2015), Duchengqi Decoction (Wang, Chen 
et al. 2012) , ulinastatin (Maciejewski, Burdan et al. 2005) , caffeic acid 
phenethyl ester (Buyukberber, Savas et al. 2009) , ozone (Uysal, Yasar et al. 
2010) , activated protein C (Babu, Genovese et al. 2012) , pentoxifylline 
(Matheus, Coelho et al. 2009), GSK7975A (Wen, Voronina et al. 2015), 
DEB025 and TRO40303 (Mukherjee, Mareninova et al. 2015), Obestatin 
(Bukowczan, Cieszkowski et al. 2016) and polyenoylphosphatidylcholine (Li, 
Wu et al. 2015) - which showed a greater than 50% improvement in 
biochemical and histological parameters of severity of EAP. 
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Table 6 - Quality assessment score and reporting of each parameter 
 
 
PARAMETER SCORE 
% studies reporting 
each parameter 
1 Adequate number of animals per group (6 or more) * 0 or 1 90 
2 Reference to data that inform dose or > 2 doses tested 0 or 1 45 
3 Clinically representative model* 0 or 1 78 
4 2 or more models tested 0 or 1 13 
5 Therapeutic administration of treatment* 0 or 1 43 
6 
Description of approved animal husbandry including 
board / home office or other standards 
0 or 1 84 
7 
Biochemical blood markers; 2 or more, one of which is 
digestive enzyme another of which is an inflammatory 
marker 
0 or 1 52 
8 Blinded histopathology score (pancreas) * 0 or 1 62 
9 Two independent blinded assessors of histology score 0 or 1 19 
10 
Other organ evaluation by biochemical or blinded 
histological means 
0 or 1 31 
 
* Highlighted parameters comprised the modified score  
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3.3.5 Translation into clinical trials 
 
Table 7 shows the number of agents that have been tested in pre-clinical 
studies and highlights the ones which have been tested for the treatment of 
human AP. Although the majority of agents have been evaluated in randomised 
controlled trials in humans, there are examples of treatment strategies such as 
hypothermia (da Silva and McWilliams 2013) and use of hyperbaric oxygen 
(Christophi, Millar et al. 2007) which have been tested in a small number of 
patients. In summary 282 agents that have been tested pre-clinically as 
potential treatments for AP and 42 of these have been evaluated for treatment 
of human AP. Compounds such as oxyphenonium, clonidine, pirenzepine, 
atropine, valdecoxib and GTN (Cameron, Mehigan et al. 1979, Essardas 
Daryanani, Santolaria Fernandez et al. 1983, Moreno-Otero, Rodriguez et al. 
1989, Lechin, Van der Dijs et al. 1992, Bhatia, Ahuja et al. 2011) have been 
used for the treatment of human AP without pre-clinical evaluation, although 
agents of similar category have been tested in experimental models of AP. 
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Table 7 - Pre-clinical EAP treatment; translation into clinical studies 
 
Treatment 
Number 
of pre-
clinical 
studies 
# of 
agents 
tested in 
pre-
clinical 
studies 
 
Agents tested for treatment of human 
acute pancreatitis 
Anti-
inflammatory 
172 123 Methyl prednisolone (Dumot, Conwell et al. 
1998), Dexamethasone(Wang, Liu et al. 
2004), Hydrocortisone (De Palma and 
Catanzano 1999, Manolakopoulos, 
Avgerinos et al. 2002, Kwanngern, 
Tiyapattanaputi et al. 2005), IL 10 (Deviere, 
Le Moine et al. 2001, Dumot, Conwell et al. 
2001), Lexipafant (Kingsnorth, Galloway et 
al. 1995, McKay, Curran et al. 1997, 
Johnson, Kingsnorth et al. 2001), 5 FU 
(Tonetti and Calvi 1989), Thymosin alpha 1 
(Wang, Li et al. 2011), Aprepitant (Shah, 
Liddle et al. 2012) , Salvia miltiorrhizae 
(Wang, Wen et al. 2013), Duchengqi 
decoction (Zhang, Zhang et al. 2008, Wan, 
Li et al. 2011), Acetylhydrolase (Sherman, 
Alazmi et al. 2009)  and  hypothermia* (da 
Silva and McWilliams 2013) 
Enzyme 
inhibitors 
28 21 Gabexate (Andriulli, Solmi et al. 2004, 
Manes, Ardizzone et al. 2007, Pezzilli, 
Uomo et al. 2007, Ino, Arita et al. 2008), 
Nafamostat (Choi, Kang et al. 2009, 
Piascik, Rydzewska et al. 2010, Yoo, Huh 
et al. 2011, Park, Jeon et al. 2014), 
Urinastatin  (Yoo, Ryu et al. 2008, Itaba, 
Nakamura et al. 2013, Park, Jeon et al. 
2014, Wang, Su et al. 2014),  Aprotinin 
(Pederzoli, Cavallini et al. 1993, Berling, 
Genell et al. 1994),  Magnesium (Fluhr, 
Mayerle et al. 2013), FFP (Leese, Holliday 
et al. 1987, Leese, Holliday et al. 1991) and 
Camostat (Freise, Schmidt et al. 1985) 
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Anti-oxidants 52 32 N-acetylcysteine (Katsinelos, Kountouras et 
al. 2005, Milewski, Rydzewska et al. 2006, 
Siriwardena, Mason et al. 2007), Selenium 
(Virlos, Mason et al. 2003, Siriwardena, 
Mason et al. 2007) , Allopurinol 
(Budzynska, Marek et al. 2001, Katsinelos, 
Kountouras et al. 2005, Romagnuolo, 
Hilsden et al. 2008, Martinez-Torres, 
Rodriguez-Lomeli et al. 2009), Vitamins 
A,B, C ,E  (Du, Yuan et al. 2003, Bansal, 
Bhalla et al. 2011), Hyperbaric oxygen* 
(Christophi, Millar et al. 2007) and β-
carotene†(Lavy, Karban et al. 2004) 
Secretion 
inhibitors 
40 20 Octreotide (Li, Pan et al. 2007, Yang, Wu et 
al. 2012, Wang, Yang et al. 2013), 
Loxiglumide* (Ochi, Harada et al. 1999), 
Sandostatin (Saenko, Lupal'tsov et al. 
1999), Secretin (Jowell, Branch et al. 2011), 
Cimetidine (Loiudice, Lang et al. 1984, 
Navarro, Ros et al. 1984), Glucagon 
(Debas, Hancock et al. 1980, Kronborg, 
Bulow et al. 1980, Regan, Malagelada et al. 
1981), Clonidine*† (Lechin, Van der Dijs 
et al. 1992), Pirenzepine†, (Moreno-
Otero, Rodriguez et al. 1989), 
Oxyphenonium†(Essardas Daryanani, 
Santolaria Fernandez et al. 1983) and 
Atropine†(Cameron, Mehigan et al. 1979) 
Microcirculat
-ion and 
blood flow 
53 38 Heparin (Berger, Quera et al. 2001) , 
LMWH (Rabenstein, Fischer et al. 2004, 
Barkay, Niv et al. 2008, Lu, Qiu et al. 2009), 
Activated protein C (Pettila, Kyhala et al. 
2010),human recombinant Activated 
protein C *  (Miranda, Mason et al. 2015), 
Thyrotropin releasing hormone (Kiviniemi, 
Laitinen et al. 1986) and Dextran* (Klar, 
Foitzik et al. 1993, Wang, Liu et al. 2004)  
Eicosanoids 24 23 Indomethacin (Elmunzer, Scheiman et al. 
2012, Dobronte, Szepes et al. 2014), 
Omega 3 fatty acids (Lasztity, Hamvas et 
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* Compounds tested in non-randomised clinical trials, others evaluated in 
RCT’s 
 
† Compounds tested directly in clinical trials without being tested in EAP 
 
al. 2005), Diclofenac† (Otsuka, Kawazoe et 
al. 2012, Park, Chung et al. 2015), 
Valdecoxib†(Bhatia, Ahuja et al. 2011) 
and  CaNa2EDTA (Tykka, Vaittinen et al. 
1985)  
Others 61 25 GTN† (Bhatia, Ahuja et al. 2011), 
peritoneal dialysis(Yang, Guanghua et al. 
2010), Nifedipine (Prat, Amaris et al. 2002), 
Insulin (Svensson 1975), Calcitonin 
(Martinez and Navarrete 1984) and 
Pentoxifylline (Kapetanos, Christodoulou et 
al. 2009, Vege, Atwal et al. 2015)  
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Table 8 -  Anti-inflammatory agents tested in EAP 
 PMID Agent 1st author 
Year of 
publication 
Method of inducing 
pancreatitis 
Prophylactic or 
Therapeutic 
Effect on 
biochemical 
parameters 
Effect on 
histological 
parameters 
1 16979620 3-aminobenzamide Mazzon 2006 CER-AP Prophylactic Improved Improved 
2 16127429 3-aminobenzamide Mota 2005 CER-AP Prophylactic Improved Improved 
3 19399939 5 Fluorouracil Cheng 2009 TLCS-AP Therapeutic Mild effect Not reported 
4 21400110 a,ß-amyrin Melo 2001 CER-AP Prophylactic Improved Improved 
5 20818810 a,ß-amyrin Melo 2010 L – arginine  Therapeutic Improved Improved 
6 20531239 Adalimumab Yilmaz 2010 TLCS-AP Prophylactic Improved Improved 
7 23625750 
Adenosine A3 receptor agonist 
–  
IB-MECA 
Prozorow-Krol  2013 TLCS-AP Prophylactic Mild effect Mild effect 
8 17928102 Adrenomedullin  Onur 2007 CER-AP Therapeutic  Improved Improved 
9 8540653 Anti TNF α polyclonal antibody Hughes 1996 
Retrograde infusion of 
bile acid + trypsin 
Prophylactic Mild effect Improved 
10 8311136 Anti TNF α polyclonal antibody Grewal 1994 
Retrograde infusion of 
bile acid + trypsin 
Prophylactic Improved No effect 
11 25895924 Anti-Gr-1 antibody  Cheng 2015 L - Arginine Prophylactic Improved Improved 
12 17014919 Antileukinate Bhatia 2007 CER-AP Prophylactic  Improved Improved 
13 23918150 Apamin - bee venom derivative Bae 2013 CER-AP Prophylactic Improved Improved 
14 12643851 Batimistat Muhs 2003 TLCS-AP Prophylactic  Improved Improved 
15 21939783 Bee venom  Yun Sw 2011 CER-AP Prophylactic Improved Improved 
16 18376296 Bee venom  Seo 2008 CER-AP Prophylactic Improved Improved 
17 20705631 Benzamide Yasar 2010 TLCS-AP Therapeutic  Improved Improved 
18 20382594 Bindarit Zhout 2010 TLCS-AP Prophylactic Improved Improved 
19 15691869 Bindarit Bhatia 2005 CER-AP Prophylactic Mild effect Improved 
20 19486901 Bortezomib  Szabolcs  2009 CER-AP Prophylactic No effect Mild effect 
21 21528054 Breviscapine  Zhang 2011 Bile acid induced Therapeutic Improved Improved 
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22 8370981 C1 - choline-esterase inhibitor Vesentini 1993 TLCS-AP Prophylactic Not reported No effect 
23 7622941 C1 esterase inhibitor  Niederau 1995 
CER-AP, TLCS-AP 
and CDE diet 
Prophylactic No effect No effect 
24 22626927 Caesalpinia pyramidalis extract Santanu  2012 Bile duct ligation Prophylactic Improved Not reported 
25 15168010 Calpain I inhibitor  Virlos 2004 CER-AP Prophylactic Improved Improved 
26 14625479 
Calpain I inhibitor - Pyrrolidine 
dithiocarbamate 
Virlos 2003 CER-AP Prophylactic Improved Improved 
27 19997973 
Calpain I inhibitor- Pyrrolidine 
dithiocarbamate 
Zhang 2010 TLCS-AP Prophylactic Improved Improved 
28 25287011 
Calpain I inhibitor- Pyrrolidine 
dithiocarbamate 
Xu 2015 TLCS-AP Prophylactic Improved Improved 
29 22850623 Cannabidiol & 01607 Li 2013 CER-AP Prophylactic Improved Improved 
30 17484889 Cannabinoids  Michalski 2007 CER-AP Prophylactic Improved Improved 
31 19629004 Capsaicin Schneider 2009 
Bile acid and 
caerulein infusion 
Prophylactic Improved Improved 
32 16707851 Captopril Cheng 2006 TLCS-AP Prophylactic Improved Improved 
33 24334457 CO-releasing molecule–2  Xue 2014 CER-AP and CDE diet Prophylactic Improved Improved 
34 22199113 Curcuma longo (tumeric) Yu Wg 2011 CER-AP Prophylactic Improved Not reported 
35 23000891 
Desferrioxamine, Biliverdin 
and Methylene Chloride 
Nuhn 2013 TLCS-AP 
Prophylactic & 
Therapeutic  
Improved Improved 
36 17625291 Dexamethasone Zhang 2007 TLCS-AP Therapeutic  Not reported Improved 
37 19050604 Dexamethasone  Yubero 2009 TLCS-AP 
Prophylactic & 
Therapeutic 
Improved Not reported 
38 26770346 Diclofenac Ozer 2015 CER-AP Therapeutic No effect Improved 
39 24966921 Diosmentin  Yu 2014 CER-AP Prophylactic Improved Improved 
40 22768339 Duchengqi Decoction  Wang 2012 TLCS-AP Therapeutic Improved Improved 
41 17653597 Enalaprilat Turkyilmaz 2007 CER-AP Therapeutic Improved Improved 
42 19840765 Etanercept  Yilmaz 2009 TLCS-AP Prophylactic Improved Improved 
43 17438460 Etanercept Malleo 2008 CER-AP Prophylactic Improved Improved 
44 18680237 Ethyl pyruvate Yang 2008 TLCS-AP Therapeutic   Improved Improved 
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45 17895847 Ethyl pyruvate Cheng 2007 TLCS-AP Prophylactic Improved Not reported 
46 23600830  Ethyl pyruvate Luan  2013 TLCS-AP Therapeutic  Improved Improved 
47 22717227 Ethyl Pyruvate Luan  2013 TLCS-AP Therapeutic  Improved Improved 
48 2370242 Eucalyptol Lima 2013 CER-AP Prophylactic Improved Improved 
49 26668524 Everolimus Özkardeş 2015 CER-AP Therapeutic No effect No effect 
50 24177139 Fucoidan Carvalho 2014 
CER-AP and TLCS-
AP 
Prophylactic Improved Improved 
51 25479110 G5 PAMAM dendrimers Tang 2015 CER-AP Prophylactic improved improved 
52 18985809 Gardenia jasminoides Jung 2008 CER-AP Prophylactic Improved Improved 
53 15378786 
Gene therapy - Human IL-10 
gene 
Chen  2004 TLCS-AP Therapeutic Improved Improved 
54 25759121 Gentiopicroside Lv 2015 TLCS-AP Prophylactic improved improved 
55 21474970 Glycine  Ceyhan  2011 
CER-AP and TLCS-
AP 
Prophylactic Improved Mild effect 
56 18074481 GSK-3beta inhibitor - TDZD 8 Cuzzocrea  2007 CER-AP Prophylactic  Improved Improved 
57 25843255 Guggulsterone Kim 2015 CER-AP Prophylactic Improved Improved 
58 18486906 
Human leukocyte elastase 
inhibitor 
Jo 2008 CER-AP Prophylactic Improved Improved 
59 11680590 Hydrocortisone Gloor 2001 
CER-AP and TLCS - 
AP 
Therapeutic  Improved No effect 
60 17406762 Hyperthermia  Almeida 2006 CER-AP Therapeutic No effect Mild effect 
61 11753044 
IL 1 beta converting enzyme 
inhibitor  
Paszkowski  2002 TLCS - AP Therapeutic Improved Mild effect 
62 7539389 IL-10 Van Laethem 1995 CER-AP Prophylactic Improved Improved 
63 15804946 IL-10 Keceli 2005 CER-AP Prophylactic Improved Improved 
64 9041259 IL-10 Rongioneet  1997 CER-AP 
Prophylactic & 
Therapeutic 
Improved Improved 
65 8751594 IL-10 Kusske 1996 CDE diet induced 
Prophylactic & 
Therapeutic 
Improved Improved 
66 7539942 IL-1ra Norman 1995 CER-AP Prophylactic  Improved Improved 
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67 7794067 IL-1ra Norman 1995 CDE diet 
Prophylactic & 
Therapeutic 
Improved Improved 
68 7736749 IL-1ra Tanaka 1995 TLCS-AP Prophylactic Improved Improved 
69 26026064 IL-6 antagonist - LMT-28 Hing 2015 CER-AP 
Prophylactic &  
Therapeutic  
Improved Improved 
70 10189850 IL-8 antibody  Osman 1998 Bile acid + PD ligation  Prophylactic Improved Mild effect 
71 22982818 Inflexinol  Ahn 2013 CER-AP Prophylactic Improved Mild effect 
72 14707742 Infliximab Oruc 2004 
CER-AP and TLCS-
AP 
Prophylactic Improved Improved 
73 25869565 Infliximab Tekin 2015 TLCS-AP    Prophylactic Improved Improved 
74 16531145 Inosine Schneider 2006 
Bile acid followed by 
caerulein   
Prophylactic & 
Therapeutic 
Not reported Improved 
75 14767733 Inosine Yamagiwa  2004 CER-AP Prophylactic Improved Mild effect 
76 17513789 Interferon gamma Hayashi 2007 CER-AP 
Prophylactic & 
Therapeutic  
Improved Improved 
77 21369693 
JAK/STAT inhibitors - 
Rapamycin & AG490 
Cheng 2011 CER-AP Prophylactic Improved Improved 
78 15454338 JNK inhibitor - SP600125  Minutoli 2004 CER-AP Prophylactic Improved Improved 
79 19770782 Leflunomide Kutluana 2010 TLCS-AP Prophylactic Mild effect Improved 
80 12510863 Leptin  Warzecha 2002 Ischemia-induced Therapeutic  
time course 
measurements 
time course 
measurements 
81 11469912 Lexipafant Lane  2001 CER-AP Prophylactic Improved No effect 
82 9629507 Lexipafant Rivera 1998 
Bile acid + CER and 
Enterokinase + CER  
Therapeutic  Not reported No effect 
83 25265022 Lipoxin A4 Yang 2014 Bile acid infusion Therapeutic Improved Improved 
84 25102438  Lithospermum erythrorhizon  Choi 2015 CER-AP Prophylactic Improved Improved 
85 26407655 Loganin Kim 2015 CER-AP 
Prophylactic & 
therapeutic 
Improved Improved 
86 14643897 Losartan and PD 123319 Tsang 2004 CER-AP 
Prophylactic & 
Therapeutic 
Mild effect Mild effect 
87 16079481 Lovastatin  Choi 2005 CER AP Prophylactic Improved Not reported 
88 26179197 Lupeol Kim 2015 CER-AP Prophylactic Improved Improved 
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89 12370536 
MAP kinase inhibitors 
PD98059 & U0126  
Clemons 2002 CER-AP Prophylactic  Improved Improved 
90 12484556 Methimazole  Yonetci 2002 CER-AP Prophylactic Improved Improved 
91 12162412 Methyl prednisolone Takaoka 2002 Closed duodenal loop Prophylactic Improved Improved 
92 18437083 Methyl prednisolone  Paszt 2008 L-arginine-induced  Prophylactic Improved Improved 
93 15841032 Mild hypothermia  Wang 2005 TLCS - AP Therapeutic Improved Mild effect 
94 20467345 Montelukast Ozkan 2010 CER-AP Prophylactic Improved Not reported 
95 20924190 Mycophenolate mofetil Tasdogan 2010 CER-AP Therapeutic  Improved Improved 
96 25914464 Na HS (H2S donor) Rao 2015 L- Arginine Prophylactic Improved Improved 
97 19940795 Nardostachys jatamanis  Bae 2010 CER-AP Prophylactic Improved Improved 
98 22783046 
Nardostachys jatamanis 
extract 
Bae 2012 CER-AP Prophylactic Improved Improved 
99 23029434 Netrin-1 Cheng 2013 L-arginine  Therapeutic Improved Improved 
100 25742430 Nicotine Zheng 2015 TLCS-AP Prophylactic Improved Improved 
101 12826913 
NK1 receptor antagonist –  
CP-96345 
He 2003 
Intraductal infusion of 
meglumine  
Prophylactic Mild effect Mild effect 
102 22850625 Noggin Cao 2013 CER-AP Prophylactic Improved Improved 
103 25931351 Oleuropein  Caglayan 2015 
Bile-pancreatic duct 
obstruction 
Prophylactic No effect No effect 
104 24326366 Opuntia humifusa Choi 2014 CER-AP Prophylactic Improved Improved 
105 11034471 Orthoclone & Tacrolimus Mayer 2000 CER-AP Therapeutic  Mild effect Improved 
106 17895833 
Oxidized 1-palmitoyl-2-
arachidonoyl-sn-glycero-3-
phosphorylcholine  (OXPAPC) 
Li 2007 
CER-AP and TLCS-
AP 
Prophylactic & 
Therapeutic 
Improved Improved 
107 21633783 Oxymatrine Zhang 2012 L-Argnine Therapeutic Improved Not reported 
108 25655298 
p38 MAPK inhibitor - 
SB203580 
Cao 2015 CER-AP Prophylactic Improved Improved 
109 16534854 Patrinia scabiosaefolia  Seo 2006 CER-AP Prophylactic Improved Not reported 
110 23275617  Pepducin  Michael 2012 
CER-AP and TLCS-
AP 
Prophylactic Mild effect Mild effect 
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111 25950520 Pepducin or anti-Ly6G Steele 2015 CER-AP 
Prophylactic & 
Therapeutic 
Improved Improved 
112 6526613 Phenylbutazone Louagie  1984 
Intraductal injection of 
trypsin 
Prophylactic No effect Improved 
113 22677361 Pioglitazone Wan 2012 CER-AP Prophylactic Improved Improved 
114 21663734 Piperine  Bae 2011 CER - AP Prophylactic Improved Improved 
115 7827939 
 Platelet-activating factor 
antagonist - BB-882 
Formela 1994 
Microvascular 
ischaemia  
Therapeutic  Improved Improved 
116 1294265 
 Platelet-activating factor 
antagonist - TCV-309 
Tomaszewska 1992 CER-AP Prophylactic Improved Improved 
117 1571504 
Platelet-activating factor 
antagonists - CV-6209 
Fujimura 1992 CER-AP Prophylactic Improved Improved 
118 7537159 
Platelet-activating factor 
antagonists BN-52021 & WEB-
2170  
Jancar 1995 CER-AP Prophylactic Improved Not reported 
119 26302488 Polysialic acide & DNAse1 Merza 2015 
TLCs-AP and  L-
arginine 
Prophylactic Improved Improved 
120 22722259 PPAR α agonist - WY14643 Ding  2013 CER-AP Prophylactic Improved Improved 
121 22521259 PPAR β/δ agonist - GW0742  Paternitis 2012 
CER-AP and TLCS-
AP 
Prophylactic & 
Therapeutic 
Improved Improved 
122 16966031 PPAR-gamma agonists  Rollins 2006 CER-AP 
Prophylactic & 
Therapeutic 
Improved Improved 
123 19530045 Propolis  Büyükberber 2009 CER-AP 
Prophylactic & 
Therapeutic 
Mild effect Mild effect 
124 17724800 Protasome inhibitor - MG132 Letoha 2007 CER-AP Prophylactic Improved Improved 
125 16214030 Protasome inhibitor - MG132 Letoha 2005 CER-AP Prophylactic Improved Improved 
126 17347056 
Protease and PKC inhibitors - 
aprotinin, pefabloc, trypsin 
inhibitor & polymyxin B, 
staurosporine 
Shi 2007 Bile acid induced Prophylactic Improved Not reported 
127 10360224 
Protease inhibitors :C1-
esterase inhibitor, α-2 anti-
plasmin, antithrombin III,α -1-
macroglobulin and α-1-
Kruse  1999  TLCS-AP  Prophylactic Mild effect No effect 
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protease inhibitor 
128 20006347 Proteasome Inhibitor - PS-341 Dong 2010 Caerulein + LPS Prophylactic Improved Improved 
129 22481287 Rapamycin, cortisol & FTY720 Muller 2012 TLCS-AP Therapeutic  Mild effect Mild effect 
130 25460024 
Ras inhibitor - 
farnesylthiosalicylic acid 
Yu 2015 TLCS-AP Prophylactic Improved Improved 
131 20600562 Recombinant fibrinogenase II Luo 2010 TLCS-AP Therapeutic Improved Not reported 
132 10975706 Recombinant human IL-11  Shimizu  2000 Caerulein + LPS Prophylactic Improved Mild effect 
133 26702138 Resolvin D1 Liu 2015 CER-AP & LPS Prophylactic Improved Improved 
134 15641139 Resveratrol  Meng 2005 TLCS-AP Therapeutic  Improved Improved 
135 23240749 Rhubarb Feng 2012 TLCS - AP Therapeutic  Mild effect Mild effect 
136 15052683 Rhubarb Zhao 2004 
CER +5 hr restraint 
water immersion 
stress 
Prophylactic Improved Improved 
137 19117125 Rolipram  Mersin  2009 TLCS-AP Prophylactic Improved Improved 
138 16759642 Rolipram  Sato 2010 CER-AP Prophylactic Improved Improved 
139 14985957 Rosiglitazone Cuzzocrea 2004 CER-AP Prophylactic Improved Improved 
140 17072978 Rosiglitazone Folch-Puy  2006 Intraductal contrast  Prophylactic Improved Improved 
141 20408879 Rosiglitazone Sindhu 2011 
L-Arginine and L-
Arginine followed by 
CCK 
Therapeutic  Improved Improved 
142 19114961 Rosiglitazone Celinski  2009 TLCS-AP Prophylactic Improved Improved 
143 19238530 Salvia miltiorrhizae Zhang 2009 TLCS-AP Therapeutic  Mild effect Improved 
144 12657946 Saralasin Ips 2003 CER-AP Prophylactic Improved Improved 
145 12609748 Saralasin & Ramiprilat Tsang 2003 CER-AP Prophylactic Mild effect Mild effect 
146 24738018 Shen Fu  Huang 2014 CER-AP Therapeutic Improved Improved 
147 23201088 Shiknoin Xiong 2013 CER-AP Prophylactic Improved Improved 
148 18648134 Simvastatin Almeida  2008 
CER - AP and TLCS-
AP 
Prophylactic Mild effect No effect 
149 23794035 Sivelestat Cao 2013 CER-AP Therapeutic  Improved Improved 
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150 25686746 Sodium butyrate Zhang 2015 L - Arginine Therapeutic Improved Improved 
151 25948069 
Sphingosine-1-phosphate 
type-1 receptor  agonist - 
SWE2871  
Zou 2015 CER-AP Prophylactic Improved Improved 
152 22396778 S-propargyl-cysteine  Sidhapuriwala 2012 CER-AP Prophylactic Improved Not reported 
153 18815555 Synacthen and cortisol Muller 2008 TLCS-AP Therapeutic  Mild effect Mild effect 
154 20402659 Tacrolimus  Liu 2010 TLCS-AP 
Prophylactic & 
Therapeutic 
Improved Improved 
155 15641154 Taraxacum officinale  Seo 2005 CER-AP Prophylactic Improved Not reported 
156 26557854 Tetrandrine Wu 2015 TLCS-AP Therapeutic Improved Improved 
157 18246603 Thalidomide  Malleo  2008 CER-AP Prophylactic Improved Improved 
158 17295769 Thalidomide Xiong 2007 Intraductal contrast  Prophylactic Improved Improved 
159 21437599 
Thalidomide analog - 
Pomalidomide  
Tsai 2011 CER-AP 
Prophylactic & 
Therapeutic 
Improved Improved 
160 17914961 Thymosin  α 1 Yao 2007 TLCS-AP Therapeutic  Mild effect Improved 
161 26330363 
Thymosin α1 and interferon 
α 
Wang 2015 TLCS-AP Therapeutic Improved Improved 
162 26668646 Thymosin β4 He 2015 TLCS-AP Prophylactic Improved Improved 
163 25492506 Trichostatin  Hartman 2015 TLCS-AP Prophylactic Improved Improved 
164 18308855 Tripeptide analog - feG Rifai  2008 CER-AP 
Prophylactic & 
Therapeutic  
Improved Improved 
165 21778460 
Trismethoxymethoxy chalcone 
(TMMC) 
Kim 2011 CER-AP Prophylactic Improved Improved 
166 21778460 TMMC Kin 2011 CER-AP Prophylactic  Improved Improved 
167 12666696 
Tyrosine kinas inhibitor - 
Tyrphostin AG 556 
Alhan  2002 CER + bile acid Therapeutic  Improved Improved 
168 11044526 Whole gut washout  Yol 2004 
Pancreatic duct 
ligation 
Therapeutic Improved Improved 
169 22529518 Zerumbone Wenhong  2012 TLCS - AP Prophylactic Improved Improved 
170 17895846 Zerumbone Szabolcs 2007 CER-AP Prophylactic Improved No effect 
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171 15003365 
α-melanocyte stimulating 
hormone  
Jahovic 2004 CER-AP Prophylactic Improved Improved 
172 22982349 α-pinene Bae 2012 CER-AP Prophylactic Improved Improved 
 
*Highlighted studies are the ones which fulfilled criteria for most clinically relevant and objective parameters of assessment from scoring 
system   
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Table 9 - Enzyme inhibitors tested in EAP 
 PMID Agent 1st author 
Year of 
publication 
Method of inducing 
pancreatitis 
Prophylactic or 
Therapeutic 
Effect on 
biochemical 
parameters 
Effect on 
histological 
parameters 
1 313758 Aprotinin and chlorophyll a Manabe  1989 CDE diet Prophylactic No effect No effect 
2 6199589 Aprotinin and Dextran 40   Crocket  1984 
 Closed-duodenal-
loop 
Prophylactic Improved Improved 
3 1689237 Camostat (FOY-305) Otsuki  1990 CER-AP Therapeutic  Improved Improved 
4 12181196 Cathepsin B inhibitor   Van Acker  2002 
CER-AP and TLCS-
AP 
Prophylactic Improved Improved 
5 9094156 Chloroquine Guillaumes  1997 CDE diet Prophylactic Improved Not reported 
6 8500736 Chloroquine Lerch  1993 
CER - AP and CDE 
diet 
Prophylactic No effect No effect 
7 20448143 Dantrolene Orabi 2010 Caerulein + LPS Prophylactic Improved Improved 
8 8071570 
E3123 (synthetic protease 
inhibitor) 
Sata 1994 CER-AP 
Prophylactic & 
Therapeutic 
Mild effect Improved 
9 1383065 
E-3123 (synthetic protease 
inhibitor) 
Hirano  1992 CER-AP Prophylactic Improved Improved 
10 7826181 Gabexate mesilate  Hirano  1994 i.v ethanol infusion  Prophylactic Improved Improved 
11 1717033 Gabexate mesilate  Hirano  1991 CER-AP Prophylactic Improved Improved 
12 2442741 Gabexate mesilate  Wisner  1987 CER-AP Prophylactic Improved Improved 
13 2414198 Glutaryl-trialanine-ethylamide Fric  1985 TLCS-AP 
Prophylactic & 
Therapeutic 
Improved Improved 
14 10206480 
Guamerin-derived synthetic 
peptide 
Song  1999 CER-AP Prophylactic Improved Improved 
15 1459347 
Human pancreatic secretory 
trypsin inhibitor  
Funakoshi  1992 CER-AP Prophylactic Improved Improved 
16 6363018 
Human urinary trypsin inhibitor 
- MTI 
Ohnishi 1984 
Closed duodenal loop 
and trypsin + bile acid  
Prophylactic Improved Not reported 
17 6182054 Leupeptin Jones  1982 Bile acid + trypsin Therapeutic  Not reported Not reported 
18 24277728 Magnesium Schick  2014 CER-AP Prophylactic Improved Improved 
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19 18362838 Nafamostat  Lee  2008 CER-AP Prophylactic Improved Improved 
20 15782103 Nafamostat Mikami  2005 TLCS-AP Therapeutic  Improved Improved 
21 2732529 Nafamostat Wisner  1989 CER-AP Prophylactic Improved Improved 
22 1381836 ONO3307 & FOY007  Hirano  1992 CER-AP Prophylactic Improved Improved 
23 10467964 Sepimostat  Yuasa 1999 
CER-AP, Caerulein + 
ethanol and ethanol 
induced 
Prophylactic Improved Mild effect 
24 9717766 
Trifluoroacetyl-L-lysyl-L-
alaninanilide hydrochloride  
Yamano M  1998 
CER-AP, closed 
duodenal loop and 
bile acid + trypsin 
infusion 
Prophylactic Improved Improved 
25 1374785 Trypsin inhibitor - FUT-175  Suzuki 1992 CDE diet 
Prophylactic & 
Therapeutic 
Mild effect No effect 
26 15816359 Ulinastatin Maciejewski  2005 TLCS-AP Therapeutic  Improved Mild effect 
27 2459695 Urinastatin Tani  1988 CER-AP Prophylactic Mild effect Improved 
28 7681748 Urinastatin Hirano 1993 CER-AP Prophylactic Improved Improved 
 
*Highlighted studies are the ones which fulfilled criteria for most clinically relevant and objective parameters of assessment from scoring 
system  
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Table 10 - Antioxidants tested in EAP 
 PMID Agent 1st author 
Year of 
publicatio
n 
Method of inducing 
pancreatitis 
Prophylactic or 
Therapeutic 
Effect on 
biochemical 
parameters 
Effect on 
histological 
parameters 
1 8530831 
4-hydroxy-TEMPO (superoxide 
dismutase mimic) 
Sledzinski  1995 CER-AP Prophylactic Not reported Improved 
2 19371263 Acetyl-L-carnitine Arafa  2009 CER-AP Prophylactic Improved Improved 
3 17287560 Allopurinol Isik  2006 TLCS-AP Therapeutic  Improved Improved 
4 2762273 Allopurinol  Lankisch  1989 
TLCS-AP and CDE 
diet induced 
Prophylactic No effect No effect 
5 2456257 Allopurinol  Wisner  1988 CER-AP Prophylactic Improved Not reported 
6 16097064 Alpha-lipoic acid  Park  2005 CER-AP Prophylactic Mild effect Improved 
7 9700946 
Artemisia asiatica extract - DA 
9601 
Hahm  1998 CER-AP Prophylactic No effect Mild effect 
8 19891017 Caffeic acid phenethyl ester  Buyukberber 2009 CER-AP 
Prophylactic & 
Therapeutic 
Improved Improved 
9 18028950 Caffeic acid phenyl Ester Turkyilmaz 2008 CER-AP Therapeutic  Mild effect Improved 
10 26093481 Carvacrol Kılıç  2016 CER-AP Therapeutic Improved Improved 
11 15028960 Chondroitin sulphate Campo  2004 CER-AP Prophylactic Improved Not reported 
12 18408139 Chondroitin sulphate Campo 2008 CER-AP Prophylactic Improved Not reported 
13 1723549 Dimethylsulfoxide-hydroxyl  Dabrowski  1991 CER-AP Prophylactic Mild effect No effect 
14 12792821 Edaravone  Araki 2003 
Closed duodenal 
loop 
Prophylactic Improved Improved 
15 1370933 
Free radical scavenger -  
CV3611 
Nonaka 1992 CER-AP Prophylactic Improved Improved 
16 1710198 
Free radical scavenger -  
CV3611 
Nonaka  1991 CDE diet induced   
Prophylactic & 
Therapeutic  
Improved Not reported 
17 14697296 
Gingko biloba extract - EGb 
761  
Zeybek  2003 TLCS-AP Prophylactic Improved No effect 
18 15613745 Grapefruit seed extract Dembinski 2004 
Ischemia- 
reperfusion 
Prophylactic Improved Not reported 
19 7479668 Green tea catechins - Takabayasi 1995 Ethionine induced Prophylactic Improved Not reported 
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Polyphenon) 
20 19672210 Green tea polyphenol Babu  2009 CER-AP Prophylactic Improved Improved 
21 22695421 Hydrogen rich saline Ren  2012 
 Traumatic 
pancreatitis  
Therapeutic  Mild effect No effect 
22 20138831 Hydrogen rich saline Chen  2010 L-arginine Therapeutic  Improved Not reported 
23 25214720 Hydrogen rich saline   Ren 2014 CER-AP Therapeutic  Improved Mild effect 
24 19174608 Hyperbaric oxygen  Yu  2009 TLCS-AP Therapeutic  Improved Improved 
25 17623267 Hyperbaric oxygen  Nikfarjam  2007 TLCS-AP Therapeutic  No effect Improved 
26 18469439 Hyperbaric oxygen  Festugato  2008 
Pancreatic duct 
ligation 
Therapeutic  Not reported No effect 
27 19823101 Hyperbaric oxygen & ozone Uysal  2010 TLCS-AP Therapeutic  Improved Mild effect 
28 16525355 Hypericum perforatum Genovese  2006 CER-AP Prophylactic Improved Improved 
29 7686520 Lactoferrin  Koike  1993 CER-AP Prophylactic Improved Improved 
30 11373483 Lazaroid  Schulz  2001 TLCS-AP Therapeutic  Mild effect No effect 
31 16557023 Lazaroid Alhan  2006 CER-AP Therapeutic  Mild effect No effect 
32 25878403 Mitoquinone Huang 2015 
CER-AP and TLCS-
AP  
Prophylactic & 
Therapeutic 
Effective in 
CER-AP 
only 
Effective in 
CER-AP 
only 
33 16088183 N-acetylcysteine Mumcu  2005 
Caerulein + bile 
acid 
Therapeutic  Improved Mild effect 
34 15065005 N-acetylcysteine Yagci  2004 TLCS-AP Prophylactic Mild effect Improved 
35 12949437 N-acetylcysteine Sevillano  2003 
Pancreatic duct 
obstruction 
Prophylactic Improved Not reported 
36 10707932 N-acetylcysteine Demols  2000 
CER-AP and CDE 
diet 
Prophylactic Improved Mild effect 
37 10707932 N-acetylcysteine  Demols  2000 
CER-AP and CDE 
diet  
Prophylactic  Improved Improved 
38 19050604 
N-acetylcysteine & 
dexamethasone 
Yubero  2009 TLCS-AP Prophylactic Improved Not reported 
39 12747737 Raxotelast Altavilla 2003 CER-AP Prophylactic Improved Improved 
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40 16499907 Resveratrol Szabolcs  2006 CER-AP Prophylactic Mild effect Mild effect 
41 16186664 Selenium Hardman  2005 L-arginine Therapeutic  No effect Improved 
42 15980666 
Selenium, ascorbate & N-
acetylcysteine  
Hardman  2005 L-arginine Therapeutic  Mild effect Mild effect 
43 22076497 Sesamol Chu  2012 CER-AP Prophylactic Improved Improved 
44 8174416 Superoxide dismutase Schoenberg  1994 TLCS-AP Prophylactic Improved Mild effect 
45 15316396 
Superoxide dismutase mimetic 
- M40401 
Cuzzocrea 2004 CER-AP Prophylactic Improved Improved 
46 26011211 Syringic acid  Cikman  2015 L-Arginine Therapeutic Not reported Improved 
47 11408826 Taurine  Ahn 2001 CER-AP Prophylactic Mild effect Improved 
48 23536517 Taurine Akay  2013 TLCS-AP Therapeutic  Mild effect No effect 
49 26770650 Tempol Marciniak  2016 CER-AP Prophylactic Improved Improved 
50 26376346 Tempol Erbıs  2015 Caerulein + bile acid Therapeutic Improved Improved 
51 12667389 Tiopronin  Cui  2003 TLCS-AP Prophylactic Improved Improved 
52 23484468 Trimetazidine Yenicerioglu  2013 L-arginine  Therapeutic  Improved Improved 
 
*Highlighted studies are the ones which fulfilled criteria for most clinically relevant and objective parameters of assessment from scoring 
system   
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Table 11 - Secretion Inhibitors tested in EAP 
 PMID Agent 1st author 
Year of 
publication 
Method of inducing 
pancreatitis 
Prophylactic or 
Therapeutic 
Effect on 
biochemical 
parameters 
Effect on 
histological 
parameters 
1 2453874 Asperlicin Wisner  1988 TLCS-AP Prophylactic Improved Not reported 
2 2465158 CCK antagonist - L 364,718  Sjovall  1988 TLCS-AP Prophylactic No effect Not reported 
3 2813332 CCK antagonist - L364,718 Ohshio  1989 
CER-AP and CDE 
diet  
Prophylactic No effect No effect 
4 9788544 CCK antagonist - TS-941 Wang  1998 
CER-AP and 
intraductal infusion of 
bile acid + trypsin 
Prophylactic Improved Not reported 
5 15331911 
CCK-1 antagonist - IQM-
97,423 
Latorre  2004 
Pancreatic duct 
ligation and CER-AP 
Prophylactic Improved Not reported 
6 9074944 CCK-A antagonist - T-0632 Taniguchi  1997 
CER-AP and 
pancreatic duct 
ligation  
Prophylactic Improved Not reported 
7 8975946  CCK-antagonist - CR1409 Niederau  1996 
Pancreaticobiliary 
duct obstruction 
Therapeutic  Improved Improved 
8 3104890  CCK-antagonist - CR1409 Makovec  1986 
CER-AP and TLCS-
AP 
Prophylactic Improved Not reported 
9 7524065  CCK-antagonist - KSG 504 Ha  1994 
Closed duodenal 
loop  
Therapeutic  Improved mild effect 
10 2474165 CR 1392  Otsuki  1989 CER-AP 
Prophylactic & 
Therapeutic  
Improved no effect 
11 20664821 Diphenhydramine  You N 2010 TLCS-AP Therapeutic  Improved Improved 
12 602326 Glucagon  Durr HK  1977 
TLCS-AP and 
pancreatic duct 
ligation 
Prophylactic & 
Therapeutic  
Not reported Not reported 
13 7517544 L-364,718  
Garcia-
Montero  
1994 CER-AP 
Prophylactic & 
Therapeutic  
Improved Improved 
14 1696383 L-364,718 Murayama  1990 
Gastric, duodenal, 
bile, pancreatic 
fistulae and CER-AP 
Prophylactic Improved not reported 
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15 1380426 
Long-acting somatostatin 
analogue -  
van Ooijen  1992 TLCS-AP 
Prophylactic & 
Therapeutic  
Improved Mild effect 
16 2581647 
Long-acting somatostatin 
analogue - SMS 201-995 
Baxter  1985 
Pancreatic duct 
ligation 
Prophylactic & 
Therapeutic  
Improved Not reported 
17 2343042 Loxiglumide Tani  1990 
CER-AP and TLCS-
AP 
Prophylactic Improved Improved 
18 10026435 Loxiglumide Satake  1999 
CER-AP , TLCS-AP 
and closed duodenal 
loop 
Prophylactic & 
Therapeutic  
Improved Not reported 
19 8720664 MCI-727 (anti-ulcer properties) Tachibana  1996 
CER-AP and TLCS-
AP 
Prophylactic & 
Therapeutic  
Improved Improved 
20 23959212 Neuronostatin  Mo  2013 TLCS-AP Prophylactic Improved Improved 
21 10095153 Ocreotide Greenberg  1999 
Intra-parenchymal 
injections of bile acid 
Therapeutic  Improved Improved 
22 17914962 Octreotide Wenger  2007 Bile acid + caerulein Therapeutic  Improved Improved 
23 12748426 Octreotide Salem  2003 TLCS-AP Prophylactic No effect No effect 
24 10533767 Octreotide Küçüktülü  1999 
CER-AP and TLCS-
AP 
Prophylactic Mild effect Mild effect 
25 9873955 Octreotide Marton  1998 TLCS-AP Therapeutic  Improved No effect 
26 9533643 Octreotide Chen  1998 TLCS-AP 
Prophylactic & 
Therapeutic  
Improved Improved 
27 7523326 Octreotide  Korun  1994 
i.v ethanol infusion & 
trauma induced 
Therapeutic  No effect Not reported 
28 1719527 Octreotide Zhu  1991 TLCS-AP 
Prophylactic & 
Therapeutic  
Mild effect Mild effect 
29 19784727 Octreotide Guler 2009 TLCS-AP Prophylactic Improved Improved 
30 9115817 Octreotide Sanchez  1997 TLCS-AP 
Prophylactic & 
Therapeutic  
No effect No effect 
31 7536997 Octreotide  Tulassay  1995 CER-AP Prophylactic No effect Not reported 
32 6653298 Pancreatic polypeptide Coelle  1983 CDE diet 
Prophylactic & 
Therapeutic  
Improved Improved 
33 11741187 Peptide YY Grise  2002 CDE diet 
Prophylactic & 
Therapeutic  
Improved Improved 
34 7685154 Peptide YY Tito  1993 CER-AP Prophylactic Improved Improved 
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35 2452222 Proglumide Tarpila 1988 
Intraductal infusion of 
bile acid & trypsin 
Prophylactic No effect No effect 
36 8592430 Sandostatin Delany  1996 TLCS-AP Therapeutic  Improved Not reported 
37 9840309 Somatostatin  Berthet  1998 
Pancreatic duct 
ligation 
Therapeutic  Improved Improved 
38 604191 Somatostatin  Lankish  1977 TLCS-AP Prophylactic No effect No effect 
39 2422635 
Somatostatin & N-acetyly 
somatostatin agonist 
Degertekin   1985 CDE diet Prophylactic Not reported Not reported 
40 7542690 Tetraprenylacetone Tachibana   1995 CER-AP & TLCS-AP 
Prophylactic & 
Therapeutic  
Improved Mild effect 
 
*Highlighted studies are the ones which fulfilled criteria for most clinically relevant and objective parameters of assessment from scoring 
system   
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Table 12 - Agents affecting microcirculation tested in EAP 
 PMID Agent 1st author 
Year of 
publication 
Method of inducing 
pancreatitis 
Prophylactic 
or 
Therapeutic 
Effect on 
biochemical 
parameters 
Effect on 
histological 
parameters 
1 16183055 
5-HT2A receptor antagonists - 
R-102444 & R-96544 
Ohawa  2005 
CER-AP, CDE diet 
and pancreatic duct 
ligation 
Prophylactic Improved Improved 
2 26579579 Acenocoumarol Warzecha  2015 
Ischaemia 
reperfusion 
Prophylactic Improved Improved 
3 16847238 
Activated human protein C 
(Drotrecogin alfa) 
Alsfasser 2006 
Caerulein + bile 
acid 
Prophylactic 
& Therapeutic 
Mild effect No effect 
4 19680809 Activated protein C  Ping  2010 TLCS-AP Prophylactic Improved Improved 
5 15987389 Activated protein C Yamanel  2005 TLCS-AP Therapeutic  Improved Improved 
6 18008033 Activated protein C Chen  2007 TLCS-AP Prophylactic Improved Improved 
7 22441146 
 Activated protein C (human 
recombinant - Xigris) 
Babu  2012 CER-AP 
Prophylactic 
& Therapeutic 
Improved Improved 
8 17506000 Anti-factor VIIa Andersson  2007 TLCS-AP Prophylactic Improved Not reported 
9 19546838 Antithrombin III Hagiwara  2009 CER-AP Prophylactic Improved Improved 
10 1735347 Antithrombin III Bleeker 1992 TLCS-AP 
Prophylactic & 
Therapeutic 
No effect No effect 
11 1384910 Bradykinin - HOE140 Griesbacher  1992 CER-AP Prophylactic Improved Not reported 
12 8448591 Bradykinin - HOE140 Griesbacher  1993 CER-AP Prophylactic Improved Not reported 
13 11786477 
Bradykinin  receptor antagonist 
- FR173657  
Hirata  2002 
Pancreaticobiliary 
duct obstruction 
Prophylactic Improved Improved 
14 8884850 
Bradykinin receptor antagonist 
- HOE140 
Kanbe  1996 Trypsin + bile acid Prophylactic Improved Improved 
15 2454196 
Bromocriptine, amantadine & 
domperidone 
Sikiric  1988 
Pancreatic duct 
ligation 
Prophylactic Improved Improved 
16 25773957 Candesartan Bostanci  2015 Caerulein + bile acid Therapeutic Improved Improved 
17 18948846 Danaparoid sodium Hagiwara  2009 CER-AP Prophylactic Improved Improved 
18 9120115 Dextran Schmidt  1996 Caerulein + bile acid Therapeutic  Improved Improved 
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19 6199589 Dextran 40 Crocket  1984 
Closed duodenal 
loop  
Prophylactic  No effect Not reported 
20 8783330 Diltiazem Hughes 1996 Trypsin + Bile acid Prophylactic Improved Improved 
21 18086634 Dopamine  Xhang   2007 TLCS-AP Prophylactic Improved No effect 
22 11775728 Dopexamine  Alhan  2001 Caerulein + bile acid Therapeutic  No effect No effect 
23 15127205 
Endothelin receptor antagonist 
- BSF208075  
Martignoni  2004 
TLCS-AP and CER-
AP 
Prophylactic Mild effect No effect 
24 9833805 
Endothelin receptor antagonist 
- LU-135252 
Foitzik  1998 Caerulein + bile acid Therapeutic Mild effect No effect 
25 9288152 
Endothelin receptor antagonist 
- PD145065  
Todd  1997 CDE diet induced 
Prophylactic & 
Therapeutic 
Improved Not reported 
26 15754391 
Endothelin receptor 
antagonists (LU-302872,LU-
302146)  
Andrzejewska  2005 CER-AP Prophylactic Mild effect Improved 
27 14690481 
Endothelin receptor 
antagonists (LU-302872,LU-
302146)  
Andrzejewska  2003 TLCS-AP Prophylactic Improved Improved 
28 14620534 
Endothelin receptor 
antagonists (LU-302872,LU-
302146)  
Dlugosz  2003 TLCS-AP Prophylactic Mild effect Improved 
29 7540127 Endothelin-1 Kogire  1995 CER-AP Prophylactic No effect No effect 
30 15300904 Heparin Dobosz  2004 CER-AP Prophylactic Improved Not reported 
31 18955758 Heparin Ceranowicz   2008 
 Ischaemia - 
reperfusion 
Prophylactic & 
Therapeutic 
Improved No effect 
32 14739847 Heparin Hackert  2004 
CER-AP, Caerulein + 
bile acid, pancreatic 
duct obstruction and 
duct obstruction + 
ERCP 
Prophylactic 
variable 
results 
different 
models 
33 16340748 Hypertonic saline  Machado  2006 TLCS-AP Therapeutic  Improved No effect 
34 12593711 Hypertonic saline Shields 2001 L-arginine Therapeutic  Improved Improved 
35 11044157 Hypertonic saline Shields 2000 L-arginine Therapeutic  Mild effect Improved 
36 20351627 Hypertonic saline  Coelho  2010 TLCS-AP Therapeutic  Mild effect No effect 
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37 18695645 Kallikrein inhibitors  Griesbacher   2008 CER-AP Prophylactic Improved Not reported 
38 1371180 Ketanserin and Ritanserin Oguchi  1992 CER-AP Therapeutic  Improved Improved 
39 10632781 L-Arginine (nitric oxide donor) Andrzejewska 1999 CER-AP Prophylactic Not reported Not reported 
40 7587783 L-Arginine (nitric oxide donor) Liu  1995 CER-AP Prophylactic Improved Mild effect 
41 7659783 
L-NAME (NG-nitro-L-arginine 
methyl esther)  &  bradykinin 
antagonist (HOE 140) 
Closa  1995 TLCS-AP Prophylactic Improved Not reported 
42 15077884 
L-NAME  & canavanine 
(inducible NO synthase) 
Chen  2004 TLCS-AP Therapeutic  
Improved  
(Canavanine) 
Mild effect  
(Canavanine) 
43 18167214 Low molecular weight heparin Qiu  2007 TLCS-AP Therapeutic  Improved Not reported 
44 10732291 
Mixed endothelin receptor 
antagonist - Bosentan  
Fiedler  1999 TLCS-AP Therapeutic  No effect No effect 
45 19451746 
Monoclonal antibodies of P-
selectin 
Hackert  2009 Caerulein + bile acid Prophylactic Mild effect Improved 
46 19826187 Obestatin  Ceranowicz  2009 CER-AP Prophylactic Improved Improved 
47 6422906 Oxidopamine  Donahue  1984 TLCS-AP Prophylactic Not reported Not reported 
48 15782104 Oxyglobin Strate  2005 Caerulein + bile acid Prophylactic Improved Improved 
49 14578741 Oxyglobin Strate  2003 Caerulein + bile acid Prophylactic Improved Improved 
50 16570348 Relaxin Binker  2006 
Closed-duodenal-
loop 
Prophylactic & 
Therapeutic 
Improved Improved 
51 18832108 Risperidone   Yamaguchi  2009 CDE diet Prophylactic Mild effect Improved 
52 15582722 
Thyrotropin releasing hormone 
(RX 77368) 
Yoneda  2005 CER-AP Prophylactic Improved Improved 
53 7587813 Verapamil Lake  1995 CDE diet induced Prophylactic Not reported Improved 
 
*Highlighted studies are the ones which fulfilled criteria for most clinically relevant and objective parameters of assessment from scoring 
system   
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Table 13 - Eicosanoids tested in EAP 
 PMID Agent 1st author 
Year of 
publication 
Method of 
inducing 
pancreatitis 
Prophylactic 
or 
Therapeutic 
Effect on 
biochemical 
parameters 
Effect on 
histological 
parameters 
1 17511027 Benzenesulfonamide  Seo  2007 CER-AP Prophylactic Improved Improved 
2 16134005 Celecoxib  Alhan  2004 
Caerulein + bile 
acid 
Therapeutic    Improved Improved 
3 12381531 Celecoxib & NS-398  Song  2002 CER-AP Prophylactic Improved Mild effect 
4 16995470 
Cyclooxygenase & 5 
lipoxygenase inhibitor - ER-
34122 
Kalyoncu  2006 CER-AP Prophylactic Improved Improved 
5 20977452 Flavocoxid  Polito  2010 CER-AP Prophylactic Improved Improved 
6 15088642 Iloprost Dlugosz  2004 
Intragastric 
ethanol and  
TLCS-AP 
Therapeutic    Mild effect Mild effect 
7 2599282 Indomethacin Wilderhain 1989 CDE diet Prophylactic Improved Improved 
8 11321505 
Indomethacin, refecoxib, 
resveratrol & LPS  
Jaworek 2001 CER-AP Prophylactic Improved Improved 
9 7690378 
Lipoxygenase inhibitor -  
AA-861  
Kiriyama  1993 TLCS-AP Prophylactic Mild effect Mild effect 
10 19295455 Omega 3 fatty acids Kilian  2009 
Caerulein + bile 
acid 
Therapeutic Improved No effect 
11 16785730 Omega 3 fatty acids Alhan  2006 
Caerulein + bile 
acid 
Therapeutic Improved Improved 
12 16924320 Parecoxib  Almeida 2006 TLCS-AP Therapeutic    Improved No effect 
13 9635806 
Phospholipase A2 inhibitor - 
BM 16.2056 
Uhl  1998 
CER AP & TLCS-
AP 
Prophylactic & 
Therapeutic 
Improved Improved 
14 15467263 
Phospholipase A2 inhibitor - 
S-5920/LY315920Na 
Tomita  2004 
TLCS-AP and 
intraductal PLA2  
Prophylactic & 
Therapeutic 
Improved Improved 
15 10438167 
Phospholipase A2 inhibitor - 
S-5920/LY315920Na 
Yoshikawa 1999 Trypsin + bile acid Therapeutic    Improved Mild effect 
16 20963474 
Polyunsaturated FA: N3, 
N6, N9 fatty acids 
Kilian  2011 Bile acid induced Therapeutic  No effect No effect 
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17 9211498 
Prostacyclin analogue - P-
thiaiminoprostacyclin 
Dlugosz 1997 
Bile acid and 
ethanol (intra-
gastric) 
Prophylactic Improved Improved 
18 1486188 
Prostagandins (MR-356, 
PGE1 oligomer) 
Sakai  1992 Bile acid  + trypsin 
Prophylactic & 
Therapeutic 
Improved Improved 
19 3550789 Prostaglandins (PG E2 & I2) Olazábal  1986 Bile acid induced 
Prophylactic & 
Therapeutic 
No effect No effect 
20 1282294 
Prostaglandins (PGE1 & 
PGE 2) & protease inhibitor 
- ONO3307 
Hirano  1992 CER-AP Prophylactic Mixed effect Mixed effect 
21 1690420 Prostaglandins (PGE1)  Buscail  1990 CER-AP Prophylactic Improved Improved 
22 11995492 Prostaglandins (PGE1)  Yücel  2002 
Caerulein + bile 
acid 
Therapeutic    Mild effect Improved 
23 8720663 Prostaglandins (PGE1)  Pozsar  1996 
Closed duodenal 
loop 
Prophylactic Improved Improved 
24 15028970 Zafirlukast  Oruc 2004 CER-AP Prophylactic Improved Mild effect 
 
*Highlighted studies are the ones which fulfilled criteria for most clinically relevant and objective parameters of assessment from scoring 
system   
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Table 14 - Other agents tested in EAP 
 PMID Agent 1st author 
Year of 
publication 
Method of inducing 
pancreatitis 
Prophylactic or 
Therapeutic 
Effect on 
biochemical 
parameters 
Effect on 
histological 
parameters 
1 12409834 Adenosine uptake inhibitors Noji 2002 CER-AP Prophylactic Improved Improved 
2 25604657 Astragaloside IV Qiu  2015 
TLCS-AP and L-
arginine 
Prophylactic Improved Improved 
3 26393905 Baicalein  Li  2015 TLCS-AP Therapeutic Mild effect Improved 
4 17278194 Baicalin Zhang  2007 TLCS-AP Therapeutic    Mild effect Improved 
5 19657312 Baicalin  Zhang  2009 TLCS-AP Therapeutic    Improved Improved 
6 20038432 Betacellulin Dahlhoff  2010 
CER-AP and L- 
Arginine  
Prophylactic Improved Improved 
7 18571584 Bismethylspermine  Jin  2008 TLCS-AP 
Prophylactic & 
Therapeutic 
Mild effect No effect 
8 26642860 Caffeine Huang 2015 
TLCS, CER- AP and 
FAEE-AP 
Prophylactic& 
Therapeutic 
Improved Improved 
9 24817315 Chaiqin Chengqi Decoction Guo  2015 L-arginine Prophylactic Improved Improved 
10 23892997   Clotrimazole Cekic  2013 Caerulein + bile acid Therapeutic    Improved Improved 
11 23956866 Diazepam  Abed 2013 CER-AP Prophylactic Improved Improved 
12 25486529 Dimethyl fumarate Robles 2015 L-arginine Prophylactic Improved Improved 
13 25351888 Emodin Yao  2015 TLCS-AP Therapeutic Improved Improved 
14 15810074 Emodin & baicalin  Zhang  2005 TLCS-AP Therapeutic    Improved Improved 
15 10394025 Epidermal growth factor  Warzecha  1999 CER-AP Prophylactic Improved Improved 
16 19333535 Erythropoietin Ucan  2009 TLCS-AP Therapeutic    Mild effect Improved 
17 26646279 
Fetal membrane derived 
mesenchymal stem cells 
Kawakubo  2015 Bile acid Therapeutic Improved Improved 
18 16718788 Fibroblast growth factor Yan 2006 CER-AP Prophylactic Improved Improved 
19 10824691 Fibroblast growth factor Hosokawa  2000 CER-AP and TLCS-AP Therapeutic    Mild effect Mild effect 
20 20662791 Galanin receptor antagonist: Bareto 2010 CER-AP Prophylactic Improved Mild effect 
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Galanitide 
21 21242707 
Galanin receptor antagonists: 
C7, M35,M40 & galanitide 
Bhandari  2010 CER-AP Prophylactic 
Improved 
(M35 & 
Galantide) 
Improved 
(M35 & 
Galantide) 
22 19506532 Ghrelin Zhou  2009 TLCS-AP Prophylactic Improved Improved 
23 20814069 Ghrelin Warzecha  2010 CER-AP Therapeutic    Improved Improved 
24 25594510 Ghrelin Bukowczan  2015 Ischemia reperfusion Therapeutic Improved Improved 
25 25145902 Glutamine Alhan  2015 Caerulein + Bile acid Therapeutic Improved Improved 
26 24302175 Glycyrrhizin Yildrim 2013 TLCS-AP Therapeutic    Improved Improved 
27 25917787 GSK7975-A and CM_128 Wen 2015 
TLCS-AP, CER-AP 
and FAEE-AP 
Therapeutic Improved Improved 
28 11698071 Hepatocyte growth factor Warzecha  2001 CER-AP Prophylactic Improved Improved 
29 25142942 
Human bone marrow-derived 
clonal mesenchymal stem cells 
Jung  2015 CER + LPS Therapeutic Improved Improved 
30 24294357 
Human umbilical cord-derived  
mesenchymal stem cells 
Meng  2013 TLCS-AP Therapeutic    Improved Improved 
31 23678547 Lawsone Birudar  2013 L- Arginine Therapeutic    Improved Improved 
32 26100532 L-Lysine Al-Malki  2015 L-Arginine 
Prophylactic & 
therapeutic 
Prophylactic 
better than 
therapeutic 
Prophylactic 
better than 
therapeutic 
33 22079843 Lycopene  Ozkan  2012 CER-AP Prophylactic Improved Improved 
34 22687382 Melatonin Huai  2012 TLCS-AP Prophylactic Improved Improved 
35 20210857 Melatonin Jung  2010 CER-AP Prophylactic Improved Improved 
36 19454824 Melatonin Col  2009 
Pancreatic duct 
ligation  
Therapeutic    Improved Not reported 
37 16499554 Melatonin  
Munoz-
Casares  
2006 Ischaemic reperfusion 
Prophylactic & 
Therapeutic 
Improved Improved 
38 10573371 Melatonin  Qi  1999 CER-AP Prophylactic No effect Improved 
39 22575522 
ND-07 (antioxidant & anti-
inflammatory) 
Lee  2012 Caerulein + LPS Prophylactic Improved Improved 
40 25912801 Obestatin Bukowczan  2015 Ischemia reperfusion Prophylactic Improved Improved 
41 26474436 Obestatin Bukowczan 2015 CER-AP Therapeutic Improved Improved 
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42 26226277 Obestatin Bukowczan  2015 Ischemia reperfusion Therapeutic Improved Improved 
43 25579844 Orlistat Patel  2015 CER-AP Therapeutic Improved Improved 
44 18688721 Pentoxifylline Gül  2009 CER-AP Prophylactic Improved Improved 
45 9561559 Pentoxifylline Marton  1998 TLCS-AP Prophylactic Mild effect No effect 
46 7988133 Pentoxifylline Bassi  1994 Caerulein + Bile acid Therapeutic    No effect No effect 
47 19684433 Pentoxifylline Matheus  2009 TLCS-AP Therapeutic    Improved Improved 
48 22760835 Pentoxifylline Coelho  2012 TLCS-AP Therapeutic    Improved No effect 
49 20599924 Pentoxifylline & alpha lipoic acid Abdin  2010 L-arginine  Prophylactic Improved Improved 
50 23275617 
Pepducin lipopeptide - P2pal-
18S  
MIchael ES  2013 CER-AP 
Prophylactic & 
Therapeutic 
Mild effect Mild effect 
51 25455348 
Percutaneous catheter 
drainage  
Chen  2015 Bile acid Therapeutic Improved Improved 
52 1700770 Peritoneal dialysis   Tilquin  1990 
Intraductal trypsin 
infusion 
Therapeutic    Not reported Not reported 
53 25893772 Peritoneal drainage Zhu  2016 Bile acid Therapeutic Improved Improved 
54 25760428 Polyenoylphosphatidylcholine  Li 2015 Bile acid Therapeutic Improved Improved 
55 25834318 Qingyi Zhang  2015 Bile acid Prophylactic Improved Improved 
56 20823570 Quercetin Carralho  2010 CER-AP Prophylactic Improved Improved 
57 26683606 Recombinant Reg3α protein Yu  2016 L-Arginine Therapeutic Improved Improved 
58 25266882 
S100A12 (calcium binding 
protein) 
Feng 2015 
CER-AP and 
Caerulein + LPS 
Prophylactic Improved Improved 
59 25001186 Trimetazidine  Tanoglu  2015 CER-AP * 4 Therapeutic Improved Improved 
60 26071131 TRO40303 and DEB025 Mukherjee 2015 
TLCS, CER-AP and 
FAEE-AP 
Therapeutic Improved Improved 
61 26608189 Ursodeoxycholic acid  Katona  2016 Bile acid Prophylactic Improved Improved 
 
*Highlighted studies are the ones which fulfilled criteria for most clinically relevant and objective parameters of assessment from scoring 
system  
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3.4 Discussion 
 
Successful pre-clinical assessment of any therapeutic regimen depends on the 
reliability and reproducibility of experimental models used (Hay, Thomas et al. 
2014). Experimental models of AP have been developed to study the 
physiology and pathogenesis of disease and test new therapies. Rodents have 
been the most commonly used species as murine models of AP are 
standardized, relatively inexpensive, can be manipulated genetically to create 
knockout or transgenic animals and reagents such as anti-bodies are readily 
available (Lerch and Gorelick 2013). However it is important to note that the 
natural history of disease in rodents may not be completely representative of 
human pathophysiology and it is therefore important to choose the most 
appropriate model for answering the specific scientific question. This is even 
more relevant in the context of testing therapies in pre-clinical models of AP as 
the lack of clinically relevant and predictive models has been identified as a 
significant limitation in the development of an effective therapeutic for other 
acute conditions such as sepsis (Fink 2014) and stroke (Sena, van der Worp et 
al. 2007). In this analysis, caerulein was the most commonly used toxin for 
induction of AP and testing new treatments in pre-clinical studies. Although the 
secretagogue model of AP is an adequate model for examining the 
pathobiology of disease and evaluate intracellular signaling, protease activation 
pathways as well as cell death pathways; it induces a mild form of pancreatitis. 
An agent’s therapeutic efficacy should therefore be tested in a severe form of 
clinically representative model of EAP, such as bile acid or alcoholic 
pancreatitis before it is considered as a treatment for human AP. It is also 
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important to highlight the significant variation in the severity of CER-AP and bile 
acid induced AP models in the published literature, both in terms of the dose 
and duration of exposure to toxin, as demonstrated in figure 3.3 (A-D). The 
other significant findings are that in approximately 60% of published studies, 
agents have been evaluated as a prophylactic treatment and in 88.4%; 
therapeutic efficacy has been investigated in a single model of EAP. A 
thorough evaluation of any potential agent that is being considered for 
treatment of clinical AP should therefore focus on treating a specific biological 
response, demonstrate a clearly defined mechanism of action and show that a 
proposed treatment is effective in attenuating the pathobiological response 
across several animal models when administered therapeutically. Some 
researchers have even advocated the use of 'co-clinical trials', in which mice 
suffering from a disease are treated in a 'mouse clinical space' in the same way 
as human patients are treated in an ordinary hospital. It is, however, important 
to note that pre-clinical studies have provided useful clinical parallels for 
treatment post-ERCP induced clinical AP and translation of  Indomethacin 
(Foitzik, Hotz et al. 2003, Elmunzer, Scheiman et al. 2012) from bench to 
bedside which highlights the importance of carefully designed pre-clinical 
studies focusing on clinically relevant models.  
A majority of agents that have been tested pre-clinically have been 
shown to be effective in reducing disease severity (tables 8-14) and very few 
negative results have been published. This may point towards publication bias, 
as it is known that laboratory based experimental studies are more susceptible 
to publication bias compared with randomised clinical trials (Easterbrook, Berlin 
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et al. 1991). If positive, rather than neutral studies are published, then any 
conclusions drawn from the published literature would overstate the magnitude 
of any effect seen, which may be the case in therapies tested in EAP. There 
was also a significant lack of consistency in reporting both the biochemical and 
histological outcomes because of which a combined quantitative analysis / 
meta-analysis could not be undertaken. The use of ARRIVE guidelines 
(Kilkenny, Browne et al. 2010) could provide a standardized approach for 
reporting in vivo studies of AP.  
Attempts at inhibition of pancreatic secretion, auto digestion, 
inflammatory pathways, reduction of oxidant free radicals and improving 
microcirculation have been unsuccessful in clinical trials for the therapeutic 
treatment of AP thus far. It is, however, interesting to note that few agents have 
primarily targeted PAC injury – which is probably the cardinal event in the 
pathophysiology of AP. This highlights the need to identify new molecular 
targets and develop novel compounds for the treatment of AP. Alternatively, 
there has been increasing interest in repositioning of existing drugs for new 
indications from pharmaceutical as well as biotech companies over the last two 
decades (Ashburn and Thor 2004) and repositioning could be explored as an 
innovative strategy of drug discovery for AP in the future. 
Unlike clinical trials where instruments such as the Jadad score (Jadad, 
Moore et al. 1996) and CONSORT guidelines (Schulz, Altman et al. 2010) can 
be used to assess the quality of randomised clinical trials, there are no specific 
tools available to evaluate the quality of experimental studies. Researchers in 
stroke have developed a checklist, Collaborative Approach to Meta-Analysis 
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and Review of Animal Data in Experimental Stroke (CAMARADES) (Macleod, 
O'Collins et al. 2005) to address this issue and in an endeavour to evaluate the 
quality of published studies a new, pancreas specific scoring system has been 
developed and used as a standard to evaluate pre-clinical studies. The majority 
of agents included in this review demonstrated efficacy in ameliorating the 
severity of EAP, yet there is no targeted therapy for human AP due to the 
subsequent failure of all investigational medicinal products in clinical trials. 
Analysis of the published literature testing therapeutic efficacy in EAP using the 
newly devised scoring system highlights the heterogeneity in the quality of 
studies and lack of clinically relevant experimental designs. Only 15.3% (66 out 
of 430) fulfilled the most objective and clinically relevant modified criteria and of 
these only fourteen  agents reduced severity of biochemical and histological 
markers of severity by > 50% (table 5). These findings enable us to identify 
potential deficiencies on the bench that would contribute to translational 
inefficiency of developing a treatment for AP on bedside.  
Although designing and conducting high quality clinical trials for AP has 
proved challenging due to the delay in presentation of patients, lack of highly 
sensitive and specific measures of predicting severity of disease and having 
outcomes that would demonstrate clinical as well as statistical significance 
(Mason and Siriwardena 2005); there is room for innovative and adaptive trial 
design to bridge this translational gap. Reducing the door to needle time and 
providing treatment at an earlier time point could have a significant impact on 
the outcome of clinical trials. There is a pressing need for well-developed, 
multi-disciplinary clinical research infra-structure and national as well as 
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international networks to conduct high quality clinical trials. The international 
symposium regarding the progress and challenges of AP (Afghani, Pandol et 
al. 2015) is one such effort; however collaboration between industry, academia, 
regulatory agencies and governments alongside patient involvement would be 
crucial to meet the challenges for therapy development of AP.  
The present review provides a consolidated resource of a wide variety of 
compounds that have been evaluated for the treatment of EAP, summarizing 
their modes of action and also provides a novel and in depth qualitative 
analysis of published literature. Preclinical studies demonstrated efficacy of 
inhibitors of secretion and digestive enzymes, anti-oxidants, metabolic, 
circulatory and immunological agents, but few have targeted primary acinar cell 
injury and only modest qualitative improvements in studies over time. While 
attrition is expected in drug development, our findings identify a significant 
translational gap between animal studies and clinical trials in AP. We propose 
standardised reporting of preclinical studies to improve the quality, 
comparability and translation of EAP treatment. To improve the translational 
efficiency, investigators will need to identify more suitable therapeutic targets, 
improve pre-clinical trial design and their approaches for selecting candidate 
compounds for clinical development and adopt better designs for clinical trials. 
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4. Chapter 4 – Proof of concept: effects of 
Cyclophilin D inhibition on mitochondrial 
dysfunction and necrotic cell death pathway 
activation in murine and human pancreatic 
acinar cells 
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4.1 Introduction 
 
The physiology of PAC mitochondrial function and the role of mitochondrial 
dysfunction secondary to MPTP formation leading to diminished ATP levels has 
been discussed in detail in section 1.4.  
Bile acids are steroid acids found predominantly in the bile of mammals. 
Bile salts are bile acids compounded with a cation, usually sodium. These bile 
acids are synthesised by the hepatocytes by cytochrome P450-mediated 
oxidation of cholesterol. They are conjugated either with the amino acids 
taurine or glycine, or with a sulphate or glucuronide and stored in the gall 
bladder where they are concentrated by removal of water (Bennett 1964). The 
two primary bile acids in humans are cholic acid and chenodeoxycholic acid 
(Kakiyama, Pandak et al. 2013), the latter being the common form. 
Chenodeoxycholic acid is dehydroxylated by intestinal bacteria by removal of 7-
alpha hydroxyl group resulting in the formation of lithocholic acid (litho=stone); 
which only has a 3-alpha hydroxyl group, and is poorly water soluble and toxic 
to cells (Ridlon, Kang et al. 2006). Bile acids synthesised in the liver are termed 
as ‘primary’ bile acids, and those made by bacteria are referred to as 
‘secondary’ bile acids. Chenodeoxycholic acid is therefore a primary bile acid 
and lithocholic acid a secondary bile acid. Taurolithocholic acid 3-sulphate 
(TLCS) is a well characterised bile acid that can induce PAC Ca2+  oscillations 
and at higher doses lead to pathological Ca2+, loss of mitochondrial membrane 
potential (m) and reduced ATP levels (Voronina, Longbottom et al. 2002, 
Voronina, Barrow et al. 2004, Voronina, Barrow et al. 2010). The other common 
taurine-conjugated bile acids include Taurocholic acid and 
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Taurochenodeoxycholic acid which can also trigger similar local as well as 
global calcium signals, however these require higher doses in millimolar 
concentrations, compared to micromolar concentrations required with TLCS 
(Voronina, Longbottom et al. 2002).  
Non oxidative metabolism of ethanol and fatty acids by synthases, 
abundantly found in PACs (Lange and Sobel 1983), leads to the formation of 
fatty acid ethyl esters (FAEEs). These FAEEs cause cytosolic calcium overload 
in PAC via activation of IP3 receptors and inhibition of ATP production which 
results in SERCA and PMCA pump failure (Criddle, Murphy et al. 2006) rather 
than release from ER Ca2+ channels. Both palmitoleic acid ethyl ester (POAEE) 
and its hydrolytic product palmitoleic acid (POA) have the ability to uncouple 
oxidative phosphorylation, an effect independent of mitochondrial 
depolarisation, and exhibit their toxic effects on PACs (Booth, Murphy et al. 
2011, Samad, James et al. 2014). Protection of cells from this sequence can be 
provided by excluding Ca2+ from the external medium (Raraty, Ward et al. 
2000, Criddle, Raraty et al. 2004) or providing supplementary intracellular ATP 
(Criddle, Murphy et al. 2006). This has been demonstrated in patch clamp 
experiments where 4 mM ATP supplied intracellular via patch pipette, has 
shown to maintain the activity of SERCA and PMCA pumps to avoid 
pathological, global, sustained elevations of Ca2+ (see figure 4.1). Insulin pre-
treatment has also shown to prevent the POA induced Ca2+ overload, ATP 
depletion and cell death via necrosis in rat PACs (Samad, James et al. 2014). 
The pancreas produces more FAEE than any other organ in the human body 
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Figure 4.1 - PAC mitochondrial impairment induced by POA  
(A) Fall in NADH autoflourescence after exposure to POA in a cell pre-treated 
with a Ca2+ chelator results in minimal change in Ca2+ , or fall in m 
suggesting diminished ATP production without an immediate loss in 
electrochemical gradient (B) Large sustained rise in Ca2+  in response to POA 
application is seen in cell not treated with Ca2+ chelator and accompanied by a 
fall in m (C) POA induces a pathological, sustained rise in Ca
2+
, that is 
prevented by adding ATP to the cytosol by patch pipette for calcium clearance. 
An adjacent cell, that can receive some ATP via gap junctions, shows a 
dampened rise, not as significant as the non-patched cell. Modified from 
(Criddle, Murphy et al. 2006)  
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(Laposata and Lange 1986, Gukovskaya, Mouria et al. 2002) and therefore 
FAEE mediated toxicity plays an important role in the pathophysiology of AP. 
Importantly though, agents that cause pancreatitis - TLCS, POAEE, POA - all 
lead to reduced cytosolic and mitochondrial ATP (Voronina, Barrow et al. 
2010). 
Pharmacological and genetic deletion of CypD inhibits MPTP formation 
and is shown to preserve mitochondrial function and reduce cell death in 
murine PACs in response to CCK and TLCS (Mukherjee, Mareninova et al. 
2015). The protective effects of CypD inhibition in response to POA however 
have not been characterised. This chapter describes experiments that examine 
the relevance of murine findings with protective effects of CsA and DEB025 on 
TLCS induced necrotic cell death in human PACs and the protective effects of 
CypD deletion on POA induced mitochondrial dysfunction. As a prelude to 
undertaking these experiments, the findings of CypD inhibition using CsA and 
cells isolated from Ppif-/- mice were replicated as proof of concept.  
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4.2 Methods 
 
All experiments were undertaken on freshly isolated PACs as described in 
section 2.3. Samples of normal pancreas from patients undergoing surgery for 
left-sided or non-obstructing pancreatic head tumours were used for these 
experiments. The time from sampling to the start of cell isolation was less than 
10 minutes in every case to ensure high quality cells. Mitochondrial membrane 
potential (m), NAD(P)H autoflourescence and necrotic cell death assays 
were performed as previously described in sections 2.43 and 2.44 respectively. 
Details of the standard PCR assay used for genotyping of Ppif-/- mice are 
described in section 2.5.  
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4.3 Results 
 
4.3.1 Confirmation of CypD knockout in Ppif -/- colony 
  
Genotyping confirmed the absence of CypD in PAC homogenates extracted 
from Ppif-/- mice and was detected in wild type control mice. Blots were 
repeated in triplicate with a representative blot demonstrated (see figure 4.2). 
 
Figure 4.2 - PCR confirming the absence of CypD in Ppif -/- mice 
Cyclophilin D (~ 300 bp) is not detected in PAC homogenates extracted from 
Ppif-/- strain of mice and is detected in strain matched controls. The band ~900 
bp in the bottom gel B represents the wild type mouse and the band ~600 bp in 
the top gel A represents the knockout mouse. 
Note: Empty band in lane 6 (left to right) of Gel A is a loading artefact  
 Wild - type (WT) 
 Knockout (KO) 
Gel A 
Gel B 
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4.3.2 Pathological acinar mitochondrial membrane potential responses 
to TLCS with CypD knockout  
 
Changes in m were recorded in freshly isolated murine PACs using confocal 
fluorescence microscopy. Cells from wild type controls showed significant loss 
of m in response to pathological concentration of TLCS (500 µM) (red trace 
fiigure 4.3A and top panel 4.3B). Cells isolated from Ppif -/- animals maintained 
m when perfused with TLCS (500 µM) (blue trace figure 4.3 and bottom 
panel 4.3B). The Ppif -/- cells did not show any difference in maximal 
depolarisation compared to controls, when CCCP (10 μM) – a protonophore 
that uncouples the proton gradient and oxidative phosphorylation – was applied 
at the end as an internal control. 
 
.  
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Figure 4.3 - Pathologic PAC m responses to TLCS, in Ppif -/- and Wt 
mice 
Mean changes in TMRM fluorescence, from at least three biological replicates 
(n=number of cells), over baseline are shown (F/Fo) +/- SEM, with respective 
number of recordings shown in the key (A). m changes in response to TLCS 
(500 µM) show significant depolarisation (top panel 4.3B) in acinar cells 
isolated from WT mice with complete depolarisation on application of 
protonophore CCCP, used as a positive control. PACs isolated from Ppif-/- 
displayed a markedly reduced depolarisation in response to TLCS, preserving 
m (bottom panel 4.3B).   
Control                       
   200 sec  400 sec  600 sec  900 sec 
Ppif-/-                          
A 
B 
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4.3.3 Pathological acinar mitochondrial membrane potential responses 
and NAD(P)H to POA + EtoH with CypD knockout  
 
Changes in NAD(P)H were measured by detecting autofluorescence of the 
isolated PACs using confocal fluorescence microscopy. NAD(P)H is produced 
during the tricarboxylic acid cycle and provides energy for cellular functions. 
NADH levels are an indicator of mitochondrial metabolism and a surrogate 
marker of ATP levels within the cell. A combination of ethanol (10 mM) and 
POA (20 μM) induced  mitochondrial depolarisation (red trace figure 4.4A) and 
a profound reduction of NAD(P)H autofluorescence (red trace figure 4.4B) in 
the mitochondrial perigranular region, indicative of mitochondrial inhibition in 
PACs isolated from wild type animals. NAD(P)H (blue trace figure 4.4B) 
changes and m (blue trace figure 4.4A) are significantly reduced in PACs 
from Ppif -/- mice suggesting prevention of mitochondrial dysfunction in the 
absence of CypD. 
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Figure 4.4 - Pathologic PAC m and NAD(P)H responses to POA and 
ethanol, in Ppif -/- and Wt mice 
m changes in response to POA (20 µM) and ethanol (10 mM) show 
significant depolarisation and reduction in NAD(P)H levels in acinar cells 
isolated from WT mice with complete depolarisation on application of 
protonophore CCCP, used as a positive control. PACs isolated from Ppif-/- 
displayed reduced depolarisation and fall in NAD(P)H levels in response to 
POA and ethanol, preserving mitochondrial function. Mean changes in TMRM 
fluorescence, from at least three biological replicates, over baseline are shown 
(F/Fo) +/- SEM, with respective number of recordings shown in the key.  
A 
B 
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4.3.4 Acinar mitochondrial membrane potential responses to TLCS in the 
presence of CsA  
 
Chemical inhibition of MPTP using CsA (10 µM), non-selective cyclophilin 
inhibitor, showed a similar profile of markedly reduced loss of m in response 
to pathological concentration of TLCS (500 µM) (blue trace figure 4.5) similar to 
cells isolated from Ppif -/- animals (blue trace figure 4.3 and bottom panel 4.3). 
Cells pre-treated with CsA did not show any difference in maximal 
depolarisation compared to controls, when CCCP (10 μM) was applied at the 
end as an internal control.  
Chapter 4 - Results: Proof of concept 
- 134 - 
 
 
 
0 200 400 600 800
0.2
0.4
0.6
0.8
1.0
1.2
 CsA pre treatment_10 M, n = 9
  Control_ untreated cells, n = 10
CCCP
500 M TLCS
Na Hepes
T
M
R
M
 -
 F
/F
o
Time (sec)
 
 
Figure 4.5 - Pathologic PAC m responses to TLCS, in the presence or 
absence of CsA 
m changes in response to TLCS (500 µM) show significant depolarisation 
with complete depolarisation on application of protonophore CCCP, used as a 
positive control. Pre-treatment with CsA (10 µM) decreased the level of 
depolarisation, preserving m. Mean changes in TMRM fluorescence, from at 
least three biological replicates, over baseline are shown (F/Fo) +/- SEM, with 
respective number of recordings shown in the key.  
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4.3.5 Necrotic cell death responses to TLCS in murine and human 
pancreatic acinar cells in the presence of CsA and DEB025 
 
CsA inhibits CypD, but also binds to CypA, to form a complex that binds to 
calcineurin, suppressing transcription and immune responses. D-MeAla3-
EtVal4- cyclosporine (Alisporivir, DEB025) is a non-immunosuppressive 
cyclosporine derivative with a strong affinity for CypD that does not have 
significant affinity for calcineurin, hence avoiding immunosuppressive effects. In 
order to evaluate the protective effects of MPTP inhibition by targeting CypD on 
activation of necrotic cell death pathway, necrosis assays were conducted on 
murine as well as human PACs. Freshly isolated acinar cells were exposed to 
TLCS (500 µM) in the presence or absence of CypD inhibitors CsA (10 µM in 
murine PAC and 100 nM in human PAC) and DEB025 (100nM). Activation of 
necrotic cell death pathway was detected by PI uptake - a marker of plasma 
membrane disruption. Cells were untreated in the control group, treated with 
TLCS (500 µM) in the TLCS group and co-incubated with MPTP inhibitors (CsA 
or DEB025) and TLCS for 30 minutes. MPTP inhibition with CsA (10 µM) 
significantly reduced necrosis in murine PAC (figure 4.6A). In human PACs, 
both chemical inhibitors of MPTP (CsA and DEB025 at 100 nM) significantly 
reduced activation of necrotic cell death pathway (figure 4.6B).  
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Figure 4.6 - Necrotic cell death responses to TLCS in the presence or 
absence of CypD inhibitors 
Percentage cells showing PI uptake indicative of early plasma membrane 
rupture. * p<0.05, effect of uninhibited toxins vs no toxin vs TLCS with inhibitor. 
CsA protected murine cells from plasma membrane disruption. Each bar is 
mean ± SEM of 16 fields of view from each of a minimum of three mice (A). 
Both CsA and DEB025 protected human PACs from plasma membrane 
disruption. Each bar is mean ± SEM of 16 fields of view from each of a 
minimum of three human pancreatic samples (B).  
Control                    TLCS               TLCS + CsA 
A 
B 
          Control        TLCS    TLCS+DEB025   TLCS+CsA 
Human PACs 
Murine PACs 
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4.4 Discussion 
 
Lack of experimental data on human pancreatic specimens has been a major 
limitation of previous experimental studies and this important aspect has been 
addressed in the present study. These data support the notion that isolated 
PAC responses are similar in murine and human cells (Murphy, Criddle et al. 
2008). Significant reduction in necrotic cell death in response to TLCS 
observed in freshly isolated human PACs, pre-treated with CsA and DEB025 
support the translatability of these findings. These data suggest that other 
murine findings concerning the MPTP could translate to human AP as well, but 
clearly further experiments examining the effects of MPTP inhibition in high 
quality human pancreatic samples would be required. 
The exocrine pancreas uses both oxidative as well as non-oxidative 
metabolism of ethanol to degrade alcohol. The non-oxidative metabolism 
pathway yields the lipophilic FAEEs due to the combination of ethanol with fatty 
acids (Gukovskaya, Mouria et al. 2002) which are potent pancreatic toxins as 
previously described. The preservation of mitochondrial function in response to 
POA + ethanol application is a novel and important result. These findings 
demonstrate the importance of CypD inhibition in mitochondrial protection from 
pancreatic toxicity induced by non-oxidative metabolism of ethanol. 
Subsequent in vivo experiments (Mukherjee, Mareninova et al. 2015) revealed 
that genetic MPTP inhibition in Ppif-/- mice markedly reduced the biochemical 
and histological responses of alcoholic pancreatitis (Huang, Booth et al. 2014). 
Hence CypD mediated MPTP inhibition could potentially be a valid treatment 
strategy for the treatment of AP secondary to excess alcohol intake. 
Chapter 5 - Results: CypD inhibitors 
- 138 - 
 
 
 
 
 
 
 
 
 
5. Chapter 5 – Development and assessment of 
novel small molecule inhibitors of 
Cyclophilin D on pancreatic acinar cell 
function and cell death 
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5.1 Introduction 
 
Cyclophilins have been highly conserved throughout evolution and are found in 
all prokaryotic and eukaryotic cells. All cyclophilins share a common domain of 
approximately 109 amino acids, the cyclophilin-like domain (CLD). The CLD is 
surrounded by domains which are unique to each member of the family and are 
associated with the subcellular compartmentalization and functional 
specialization (Marks 1996, Arevalo-Rodriguez, Wu et al. 2004). Cyclophilins 
act to stabilize the cis-trans transition state and accelerate isomerization, a 
process considered important in protein folding and assembling of multi-domain 
proteins (Gothel and Marahiel 1999).  
Peptide bonds can exist in two distinct isomeric forms: cis and trans. The 
lower energy state trans peptide bonds have side chains 180 degrees opposite 
to each other are sterically favoured and ribosomes tend to synthesize peptide 
bonds in this form. Many proline containing proteins however have a preceding 
peptide bond (peptidyl-prolyl) in cis form with side chains adjacent to each 
other. De novo protein folding and the refolding processes involved in cellular 
membrane trafficking require isomerization of peptide bonds in cis form. The 
spontaneous isomerization of peptidyl-prolyl bonds requires energy, is a slow 
process and therefore a rate-limiting step in folding which is accelerated by the 
cis-trans isomerase activity (see figure 5.1) of cyclophilins (Gothel and Marahiel 
1999).  
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Figure 5.1 - Schematic illustration of the mechanism of cyclophilin action 
The interconversion between trans and cis isomers of the peptide bond 
between proline and another amino acid is catalysed by cyclophilins acting as 
peptidyl-prolyl isomerases (PPIases). Modified from (Shore, Awais et al. 2016) 
 
 
 
 
 
 
  
PPIase 
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As previously mentioned CypD, a mitochondrial targeted PPIase, is a 
key modulator of MPTP opening. Since MPTP formation and subsequent 
mitochondrial dysfunction play a critical role in pancreatic necrosis as well as 
the pathophysiology of AP, CypD appears to be a valid target for the treatment 
of AP. There is further evidence to suggest that the characteristic local and 
systemic pathological responses are significantly reduced in CypD knockout 
mice (Elrod and Molkentin 2013, Mukherjee, Mareninova et al. 2015). Although 
CsA, a lipophilic cyclic peptide used as an immunosuppressant drug, has 
nanomolar binding affinity for cyclophilins (see figure 5.2), this interaction is 
non-specific as CsA binds to CypA, CypB and CypD (Gaither, Borawski et al. 
2010, Hopkins and Gallay 2012). Interaction of CsA with cytosolic CypA 
generates a complex that has an ability to bind to, and inhibit calcineurin. As a 
consequence, the calcineurin substrate phospho-nuclear factor of activated T-
cells is unable to translocate to the nucleus for initiation of an immune response 
(Liu, Farmer et al. 1991). Theoretically, this immunosuppressive effect could be 
counterproductive in AP as it may predispose sterile pancreatic necrosis to 
secondary infections. Interestingly, there is however evidence to suggest that 
high doses of CsA aggravate AP (Foitzik, Forgacs et al. 1998) and 
therapeutically recommended doses of CsA can lead to abnormal pancreatic 
enzyme secretion and induce AP under conditions of pancreatic stimulation by 
caerulein (Ito, Kimura et al. 1993). Prolonged exposure to CsA in combination 
with caerulein has also been shown to distort pancreatic repair, transforming 
caerulein induced pancreatitis into a fibrotic chronic-like disease. The 
mechanism involves TGF-beta, myofibroblasts, and defective collagenase 
activation (Vaquero, Molero et al. 1999). 
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Non-immunosuppressant semisynthetic analogues of CsA, such as 
DEB025 and NIM811 although maintain inhibition of cyclophilins but do not 
bind to calcineurin (Hopkins and Gallay 2012), have unfavourable drug-like 
characteristics with high molecular weights, limited solubility and poor 
bioavailability (Dunsmore, Malone et al. 2011). It would therefore appear logical 
to initiate a drug discovery programme to identify novel, small molecule 
inhibitors of CypD which would exhibit high selectivity for CypD over other 
cyclophilins, have improved pharmacokinetic / pharmacodynamic properties 
and do not have immunosuppressive effect. The aim of this aspect of the study 
is to identify and develop novel, small molecular inhibitors specific for CypD; 
characterise their effectiveness in inhibiting the MPTP and their efficacy in 
reducing activation of necrotic cell death pathway in PACs.  
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Figure 5.2 - Crystal structure of human CypD in complex with CsA 
(A) Overall structure of CypD in complex with CsA. CypD is composed of eight 
β-strands, two α helices and one 310 helix. CypD and CsA are shown as ribbon‐ 
and stick‐models, respectively. (B) Close‐up view of CsA superimposed on its 
Fo‐Fc omit electron density map, shown as a blue mesh. Adapted from 
(Kajitani, Fujihashi et al. 2008)  
A 
B 
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5.2 Methods 
 
Compounds predicted to bind strongly to CypD were identified using 
computational molecular modelling. A virtual screening database was used to 
select compounds that have properties similar to the active part of CsA which 
interacts with CypD. Firstly, molecules with “bad” sub structures and chiral 
compounds were excluded. Next, molecular modelling approach was used to 
examine protein ligand docking and identify compounds that are predicted to 
bind strongly to CypD (see figure 5.3). Recombinant CypD was produced as 
previously described (section 2.6) and binding of the screened low molecular 
weight CypD inhibitors was evaluated using a biophysical assay (surface 
plasmon resonance – section 2.7) to identify potential ‘hits’. The compounds 
selected were small molecular weight molecules, more likely to be membrane 
permeable and easily absorbed, that obeyed the Lipinski’s Rule of Five 
(Lipinski, Lombardo et al. 2001) which states that an orally active drug has no 
more than one violation of the following: 
(i) No more than 5 hydrogen bond donors 
(ii) No more than 10 hydrogen bond acceptors 
(iii) Molecular weight of less than 500 daltons 
(iv) Octanol-water partition co-efficient log P not more than 5 
Candidates with high affinity for CypD were subsequently tested in live murine 
PACs using confocal microscopy to measure m and activation of necrotic cell 
death pathway. Cells were exposed to TLCS in the presence and absence of 
the newly identified ‘hits’ to evaluate protection against m and compounds 
which conferred mitochondrial protection were tested further in necrosis 
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assays. In order to evaluate the potential in vitro toxicity of the newly identified 
small molecular CypD inhibitors, PACs were incubated with the test 
compounds in the necrotic cell death assays. All compounds were purchased 
from Enamine Ltd (Ukraine) or synthesised by our collaborators in medicinal 
chemistry.  
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Figure 5.3 - Virtual screening for selecting novel small molecular CypD 
inhibitors 
(A) Firstly, molecules with “bad” sub structures and chiral compounds were 
excluded. Next, molecular modelling approach was used to examine protein 
ligand docking and identify compounds that were predicted to bind strongly to 
CypD. (B) Molecular modelling showing binding site of CsA on human CypD 
and (C) newly identified small molecule CypD inhibitor binding to CypD in same 
region as CsA. Courtesy Neil Berry  
A 
B C 
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5.3 Results 
 
Evaluation of small molecule CypD inhibitors; binding with CypD, effects 
on mitochondrial function and necrotic cell death 
 
Twenty- three compounds were predicted to bind with CypD using the virtual 
screening protocol and subsequently evaluated using SPR assay as previously 
described. The results of the biophysical SPR assay identified six compounds 
namely; 4256, 9094, 3326, 6256, EA4 and AP-1A02 that showed binding 
affinity with mutant CypD. Pre-treatment with compounds 4256 (see figure 5.5) 
and 9094 (see figure 5.7) prevented loss of m in response to 500 µM TLCS, 
however showed little effect on PI uptake. Compound 4256 displayed toxicity 
on its own in the cell death assay. Compounds 3326 (see figure 5.9) and 6256 
(see figure 5.11) showed little or no mitochondrial protection in response to 500 
µM TLCS and were therefore not tested in cell death assay. Compounds EA4 
and E6 were synthesised by our collaborators in medicinal chemistry. Pre-
treatment with compound EA4 at a dose of 10 µM  prevented TLCS induced 
loss of m and reduced necrosis (see figure 5.12) and compound E6, which 
did not show any binding with CypD in SPR, was tested as an internal control 
and did not prevent bile acid induced mitochondrial depolarisation or necrotic 
cell death (see figure 5.13) as predicted. Out of 23 compounds screened by 
SPR, one lead compound named AP-1A02 was identified (see figure 5.14 for 
chemical structure and molecular docking). AP-1A02 showed strong binding 
with Cyp D (Kd = 0.8 µM) and inhibited its enzymatic activity (Ki = 1.7 µM) as 
shown in figure 5.15. AP-1A02 protected m, prevented necrotic cell death 
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pathway activation of freshly isolated murine as well as human PACs at a dose 
of 5 µM (see figure 5.16).  
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5.3.1 Evaluation of small molecule CypD inhibitor - compound 4256; 
binding with CypD, effects on mitochondrial function and necrotic 
cell death 
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Figure 5.4 - SPR analysis of binding of compound 4256 to CypD 
Screening was performed by adding 100µM of each compound over 
recombinant CypD immobilized on a CM5 sensor chip and CsA used as a 
positive control. Compound 4256 showed strong binding with CypD compared 
to other compounds (A). Concentration dependent binding of 4256 with CypD 
showed highest binding at 1 mM (B), the dose at which this compound was 
tested in subsequent cell based assays.  
A 
B 
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Figure 5.5 - Pathologic PAC m and necrotic cell death responses to 
TLCS, in the presence or absence of 4256 
m changes in response to TLCS (500 µM) show significant depolarisation 
(red trace) with complete mitochondrial depolarisation on application of 
protonophore, CCCP. Pre-treatment with 4256 (1mM) decreased the level of 
depolarisation (green trace), whereas at a dose of 100 µM failed to preserve 
m (yellow trace). Mean changes in TMRM fluorescence, from at least three 
biological replicates, over baseline are shown (F/Fo) + SEM, with respective 
number of recordings shown in the key (A). Compound 4256 (1mM) did not 
protect murine cells from plasma membrane disruption and on its own 
increased PI uptake. Each bar is mean ± SEM of 16 fields of view from each of 
a minimum of three mice (B).  
Control           TLCS       TLCS + 4256   PAC + 4256 
A 
B * 
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5.3.2 Evaluation of small molecule CypD inhibitor - compound 9094; 
binding with CypD, effects on mitochondrial function and necrotic 
cell death 
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Figure 5.6 - SPR analysis of binding of compound 9094 to CypD 
Screening was performed by adding 100µM of each compound over 
recombinant CypD immobilized on a CM5 sensor chip and CsA used as a 
positive control. Compound 9094 showed strong binding with CypD compared 
to other compounds (A). Concentration dependent binding of 9094 with CypD 
showed highest binding at 1 mM (B) and significant binding at 500 µM, 
therefore tested at lower dose (500 µM) in subsequent cell based assays. 
A 
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Figure 5.7 - Pathologic PAC m and necrotic cell death responses to 
TLCS, in the presence or absence of 9094 
m changes in response to TLCS (500 µM) show significant depolarisation 
(red trace) with complete mitochondrial depolarisation on application of 
protonophore, CCCP. Pre-treatment with 9094 (500 µM) decreased the level of 
depolarisation (green trace). Mean changes in TMRM fluorescence, from at 
least three biological replicates, over baseline are shown (F/Fo) + SEM, with 
respective number of recordings shown in the key (A). Compound 9094 (500 
µM) partially protected murine cells from plasma membrane disruption and on 
its own did not increase PI uptake. Each bar is mean ± SEM of 16 fields of view 
from each of a minimum of three mice (B).  
Control         TLCS       TLCS + 9094   PAC + 9094 
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5.3.3 Evaluation of small molecule CypD inhibitor - compound 3326; 
binding with CypD and effects on mitochondrial function 
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Figure 5.8 - SPR analysis of binding of compound 3326 to CypD 
Screening was performed by adding 100µM of each compound over 
recombinant CypD immobilized on a CM5 sensor chip and CsA used as a 
positive control. Compound 3326 showed strong binding with CypD compared 
to other compounds (A). Concentration dependent binding of 3326 with CypD 
showed highest binding at 1 mM (B) and significant binding at 500 µM, 
therefore tested at lower dose (500 µM) in subsequent cell based assays. 
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Figure 5.9 - Pathologic PAC m responses to TLCS, in the presence or 
absence of 3326 
 
m changes in response to TLCS (500 µM) show significant depolarisation 
(red trace) with complete mitochondrial depolarisation on application of 
protonophore, CCCP. Pre-treatment with 3326 (500 µM) had no significant 
effect on the level of depolarisation (green trace) and was therefore not tested 
in necrosis assays. Mean changes in TMRM fluorescence, from at least three 
biological replicates, over baseline are shown (F/Fo) + SEM, with respective 
number of recordings shown in the key.   
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5.3.4 Evaluation of small molecule CypD inhibitor - compound 6256; 
binding with CypD and effects on mitochondrial function 
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Figure 5.10 - SPR analysis of binding of compound 6256 to CypD 
Screening was performed by adding 100µM of each compound over 
recombinant CypD immobilized on a CM5 sensor chip and CsA used as a 
positive control. Compound 6256 showed strong binding with CypD compared 
to other compounds (A). Concentration dependent binding of 6256 with CypD 
showed highest binding at 1 mM (B) and significant binding at 500 µM, 
therefore tested at lower dose (500 µM) in subsequent cell based assays.  
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Figure 5.11 - Pathologic PAC m responses to TLCS, in the presence or 
absence of 6256 
m changes in response to TLCS (500 µM) show significant depolarisation 
(red trace) with complete mitochondrial depolarisation on application of 
protonophore, CCCP. Pre-treatment with 6256 (500 µM) had partial protective 
effect on the level of depolarisation (green trace) and was therefore not tested 
in necrosis assays. Mean changes in TMRM fluorescence, from at least three 
biological replicates, over baseline are shown (F/Fo) + SEM, with respective 
number of recordings shown in the key.   
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5.3.5 Evaluation of small molecule CypD inhibitor - compound EA-4; 
effects on mitochondrial function and necrotic cell death 
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Figure 5.12 - Pathologic PAC m responses to TLCS, in the presence or 
absence of EA-4 
m changes in response to TLCS (500 µM) show significant depolarisation 
(red trace) with complete mitochondrial depolarisation on application of 
protonophore, CCCP. Pre-treatment with EA-4 (10 µM) decreased the level of 
depolarisation (green trace). Mean changes in TMRM fluorescence, from at 
least three biological replicates, over baseline are shown (F/Fo) + SEM, with 
respective number of recordings shown in the key (A). Compound EA-4 (10 
µM) partially protected murine cells from plasma membrane disruption and on 
its own did not increase PI uptake. Each bar is mean ± SEM of 16 fields of view 
from each of a minimum of three mice (B).  
A 
Control         TLCS    TLCS + EA-4    PAC + EA-4 
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5.3.6 Evaluation of small molecule CypD inhibitor - compound E6; 
effects on mitochondrial function and cell death 
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Figure 5.13 - Pathologic PAC m responses to TLCS, in the presence or 
absence of E6 
m changes in response to TLCS (500 µM) show significant depolarisation 
(red trace) with complete mitochondrial depolarisation on application of 
protonophore, CCCP. Pre-treatment with E6 (10 µM) had no effect on level of 
depolarisation (green trace). Mean changes in TMRM fluorescence, from at 
least three biological replicates, over baseline are shown (F/Fo) + SEM, with 
respective number of recordings shown in the key (A). Compound E6 (10 µM) 
failed to protect murine cells from plasma membrane disruption and on its own 
slightly increased PI uptake. Each bar is mean ± SEM of 16 fields of view from 
each of a minimum of three mice (B). The experiment was completed to 
demonstrate concordance between biological and biophysical assays in case a 
compound does not bind CypD on SPR.   
A 
Control         TLCS    TLCS + E6    PAC + E6 
B 
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5.3.7  Evaluation of small molecule CypD inhibitor - compound AP-1A02; 
binding with CypD, effects on mitochondrial function and cell death 
 
 
 
 
 
 
 
 
Figure 5.14 - Molecular docking and chemical structure of lead compound 
AP-1A02 
(A) Molecular modelling showing binding site of AP-1A02 on human CypD in 
same region as CsA (courtesy Neil Berry). (B) Chemical structure of AP-1A02.  
A 
B 
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Figure 5.15 - Dose dependent response of AP-1A02 on SPR 
Assay performed by passing AP-1A02 over recombinant CypD immobilized on 
a CM5 sensor chip. Inset, kinetics of AP-1A02 (10 µM). Kd of AP-1A02 was 
calculated by dividing the rate of association by the rate of association (A). AP-
1A02 inhibits PPIase activity of CypD. N-SUCCINYL-ALA-ALA-PRO-PHE-P-
NITROANILIDE was used as a substrate. A first order rate was fitted to the 
absorbance (330 nm) data to obtain a rate constant. The catalytic rate was 
calculated from the enzymatic rate minus the background rate (B).  
A 
B 
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Figure 5.16 - Pathologic PAC m and necrotic cell death responses to 
TLCS, in the presence or absence of AP-1A02 
m changes in response to TLCS (500 µM) show significant depolarisation 
(red trace) with complete mitochondrial depolarisation on application of 
protonophore, CCCP. Pre-treatment with AP-1A02 (100 µM) decreased the 
level of depolarisation (green trace). Mean changes in TMRM fluorescence, 
from at least three biological replicates, over baseline are shown (F/Fo) + SEM, 
with respective number of recordings shown in the key (A). Compound AP-
1A02 5µM (B) and 1 µM (C) protected murine cells from plasma membrane 
disruption and on its own had no effect on PI uptake. Each bar is mean ± SEM 
of 16 fields of view from each of a minimum of three mice (B and C). 
Compound AP-1A02 5µM tested in one human sample and protected human 
PACs from activation of necrotic cell death pathway. 
 
* 
Control           TLCS   TLCS + AP-1A02   PAC + AP-1A02 
 
C
  
D 
* 
Control               TLCS       TLCS + AP-1A02    
* 
* 
Murine sample: AP-1A02, 1 µM  
Human sample: AP-1A02, 5 µM  
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5.4 Discussion 
 
A drug discovery programme is initiated when there is unmet clinical need for a 
disease or clinical condition for which there is lack of availability of appropriate 
medical products. Given the dearth of targeted therapy for AP, a common and 
potentially life threating disease, it is but logical to invest in a robust drug 
discovery programme for identification of new targets and development of new 
compounds that could be used for the treatment of pancreatitis.  
There are two different approaches to drug discovery, target-based 
screening and phenotypic screening. With substantial experimental evidence to 
support that mitochondrial CypD is a promising molecular target for treatment 
of necrotizing pancreatitis (Mukherjee, Mareninova et al. 2015), the target- 
based methodology has been adopted to identify CypD inhibitors in this study. 
This strategy allows for the application of molecular and chemical knowledge to 
investigate specific molecular hypotheses and utilise small-molecule screening 
strategies, the advantages of which have previously been discussed.  
The lead compound, AP-1A02, identified as a result of this strategy is a 
novel, small molecule CypD inhibitor with a molecular weight of 246. The first 
compound that was identified as part of the screening process showed 
biological efficacy at 1mM dose whereas AP-1A02 has significantly reduced 
bile acid induced necrotic cell death not only in murine but also in human PACs 
at a dose of 5µM. Testing compounds selectively on freshly isolated human 
PACs reduces the chances of failure of a compound at a later stage in the drug 
discovery process. AP-1A02 also did not demonstrate any toxicity on its own, 
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unlike other compounds which showed an increase in necrotic cell death when 
incubated with PACs. This compound can form the basis of a lead optimization 
chemistry programme to increase potency of the chemical series. AP-1A02 
could not be tested in vivo, due to lack of solubility in the desired solvent. 
The next steps would involve collaboration with medicinal chemistry to 
improve the water solubility and efficacy in the nanomolar range and undertake 
assays such as; X-ray crystallography - to obtain high-resolution structures of 
the complexes, isothermal titration calorimetry - to derive the thermodynamic 
signature of the interactions and PPIase assay - to determine the cis/trans 
isomerisation kinetics and specificity. These assays can be crucial in optimizing 
lead molecules. Cyclophilin family members have high sequence homology, 
and therefore it is a challenge to develop an inhibitor specific to CypD (Davis, 
Walker et al. 2010). In order to set up a counter-screening programme, 
recombinant CypA and CypB will need to be produced to assess the binding 
affinity of these newly identified small molecular CypD inhibitors with CypA and 
CypB. Structural data would also be useful to optimize inhibitor(s) specific for 
CypD to prevent off target effects. Prior to submitting small molecules for 
evaluation in an in vivo model of AP, further medicinal chemistry modifications 
will have to be untaken to optimise solubility, metabolic stability, plasma protein 
binding and where appropriate permeability of drug leads. Pharmacokinetic 
studies in the mouse can then be performed to ensure lead molecules have 
acceptable exposure following oral doses of drug and these can be tested in 
experimental models of AP to evaluate their efficacy and safety profiles. 
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Other approaches for identification of new small molecular inhibitors of 
CypD would include the use of 2D quantitative structure activity relationship 
(QSAR) alongside 3D ligand-based pharmacophore models as described by 
Valasani et al (Valasani, Vangavaragu et al. 2014). Compounds screened and 
identified using this strategy can be used for molecular docking to interpret the 
efficacy of the novel molecules in inhibiting the enzymatic activity of CypD. 
Another strategy that can be employed to use compounds previously identified 
as potent inhibitors of cyclophilins (Guichou, Viaud et al. 2006, Li, Chen et al. 
2006, Ni, Yuan et al. 2009) as a backbone to synthesize a series of molecules 
and characterise their ability to inhibit CypD.  
It must also be highlighted that CypD inhibitors have a much wider 
clinical utility as preventing MPTP formation via CypD inhibition is also 
implicated in several other diseases such as ; cardiac and cerebral ischaemic-
reperfusion injury (Fakharnia, Khodagholi et al. 2017, Javadov, Jang et al. 
2017), neurodegeneration in multiple sclerosis (Warne, Pryce et al. 2016), 
Alzheimer’s disease (Du, Guo et al. 2008), counteracting skeletal muscle 
dysfunction in mitochondrial myopathy (Gineste, Hernandez et al. 2015), 
Duchenne muscular dystrophy (Reutenauer, Dorchies et al. 2008), 
development of acute lung injury following endotoxaemia (Fonai, Priber et al. 
2015), liver cancer (Chen, Feng et al. 2012), beta-cell survival (Fujimoto, Chen 
et al. 2010) and ischaemic renal injury (Devalaraja-Narashimha, Diener et al. 
2009) and hence this drug development programme has much wider 
implications. 
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6. Chapter 6 – Pharmacological inhibition of 
MPTP using TRO40303 - effects on 
pancreatic acinar cell function and 
experimental acute pancreatitis 
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6.1  Introduction  
 
TRO40303 (3, 5-Seco-4-nor-cholestan-5-one oxime-3-ol) is a cholesterol-oxime 
cytoprotective compound developed by Trophos (now acquired by Roche) that 
binds to the outer mitochondrial translocator protein (TSPO), delaying MPTP 
opening and cell death in rat cardiomyocytes and has been shown to 
significantly reduce the extent of myocardial infarction in a rat model (Schaller, 
Paradis et al. 2010). TRO40303 has  also been shown to protect HepG2 cells 
and primary mouse embryonic hepatocytes from palmitate intoxication and 
significantly reduce mortality in murine Fas-induced hepatotoxicity (Schaller, 
Michaud et al. 2015). Results from a randomized safety and tolerance phase 1 
trial showed that TRO40303 can be safely administered intravenously in 
humans at doses expected to be pharmacologically active (Le Lamer, Paradis 
et al. 2014). MPTP inhibition using TRO40303, a drug quite far in clinical 
development has not been investigated before in the setting of AP. This 
chapter describes experiments designed to test the protective effects of 
TRO40303 on acinar cell function, cell death in response to pancreatic toxins 
and severity of EAP. 
 
6.2 Methods 
 
Three doses of TRO40303 - 1 µM(T1), 3 µM(T3) and 10µM(T10) were initially 
tested in live murine PACs using confocal microscopy to measure m, 
cytosolic calcium and activation of necrotic cell death pathway. Typically cells 
were exposed to bile acid - tauro-lithocholate sulphate (TLCS), cholecystokinin 
(CCK) and palmitoleic acid ethyl ester (POAEE) in the presence and absence 
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of TRO40303 to evaluate protection against m loss and necrosis. All 
experiments were carried out with a constant concentration of DMSO (0.1%; 
Sigma, Gillingham, UK).T10 was also evaluated in protection against TLCS 
induced necrosis in human PACs. A liposomal preparation of TRO40303 
(Batch TRO-003J 20 mg/ml) was subsequently tested therapeutically in three 
different models of murine EAP: hyperstimulation - caerulein induced 
experimental model (CER-AP), bile acid-induced murine acute pancreatitis 
(TLCS-AP) and alcoholic (ethanol and palmitoleic acid) pancreatitis (FAEE-AP). 
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6.3 Results 
6.3.1 Acinar cell responses to TLCS in the presence of TRO40303 
6.3.1.1 Mitochondrial and Ca2+ responses in the presence of 10µM 
TRO40303 (T10) 
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Figure 6.1 - Pathologic PAC m responses to TLCS, in the presence or 
absence of 10 µM TRO40303 (T10) 
m changes in response to TLCS (500 µM) show significant depolarisation 
with complete depolarisation on application of protonophore CCCP, used as a 
positive control. Pre-treatment with T10 decreased the level of depolarisation, 
preserving m. Mean changes in TMRM fluorescence, from at least three 
biological replicates, over baseline are shown (F/Fo) + SEM, with respective 
number of recordings shown in the key.   
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Figure 6.2 - Pathologic PAC Ca2+ responses to TLCS, in the presence or 
absence of 10 µM TRO40303 (T10) 
Ca2+ changes in response to TLCS (500 µM) show typical large, rapid rise 
followed by a sustained plateau. Pre-treatment with T10 did not affect the initial 
rise in rise in but dampened the plateau phase. Mean changes in Fluo-4 
fluorescence, from at least three biological replicates, over baseline are shown 
(F/Fo) + SEM, with respective number of recordings shown in the key.  
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6.3.1.2 Mitochondrial and Ca2+ responses in the presence of 3 µM 
TRO40303 (T3) 
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Figure 6.3 - Pathologic PAC m responses to TLCS, in the presence or 
absence of 3 µM TRO40303 (T3) 
m changes in response to TLCS (500 µM) show significant depolarisation 
with complete depolarisation on application of protonophore CCCP, used as a 
positive control. Pre-treatment with T3 decreased the level of depolarisation, 
preserving m. Mean changes in TMRM fluorescence, from at least three 
biological replicates, over baseline are shown (F/Fo) + SEM, with respective 
number of recordings shown in the key.  
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Figure 6.4 - Pathologic PAC Ca2+ responses to TLCS, in the presence or 
absence of 3 µM TRO40303 (T3) 
Ca2+ changes in response to TLCS (500 µM) show typical large, rapid rise 
followed by a sustained plateau. Pre-treatment with T3 did not affect the initial 
rise in rise in but dampened the plateau phase. Mean changes in Fluo-4 
fluorescence, from at least three biological replicates, over baseline are shown 
(F/Fo) + SEM, with respective number of recordings shown in the key. 
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6.3.1.3 Mitochondrial and Ca2+ responses in the presence of 1 µM 
TRO40303 (T1) 
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Figure 6.5 - Pathologic PAC m responses to TLCS, in the presence or 
absence of 1 µM TRO40303 (T1) 
m changes in response to TLCS (500 µM) show significant depolarisation 
with complete depolarisation on application of protonophore CCCP, used as a 
positive control. Pre-treatment with T1 decreased the level of depolarisation, 
preserving m. Mean changes in TMRM fluorescence, from at least three 
biological replicates, over baseline are shown (F/Fo) + SEM, with respective 
number of recordings shown in the key.  
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Figure 6.6 - Pathologic PAC Ca2+ responses to TLCS, in the presence or 
absence of 1 µM TRO40303 (T1) 
Ca2+ changes in response to TLCS (500 µM) show typical large, rapid rise 
followed by a sustained plateau. Pre-treatment with T1 did not affect the initial 
rise in rise in but dampened the plateau phase. Mean changes in Fluo-4 
fluorescence, from at least three biological replicates, over baseline are shown 
(F/Fo) + SEM, with respective number of recordings shown in the key.  
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6.3.1.4 Effects of TRO40303 on necrotic cell death pathway activation in 
response to TLCS in murine pancreatic acinar cells 
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Figure 6.7 - PI uptake in response to TLCS in the presence or absence of 
TRO40303 in murine PACs 
Co-administration of T3 and T10 with TLCS (500 µM) protected cells from early 
plasma membrane rupture (PI uptake) compared to untreated cells. Dose 
dependent effects of TRO40303 on necrotic cell death pathway activation can 
also be seen, *P<0.05, unpaired t- test. 
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6.3.1.5 Effects of TRO40303 on necrotic cell death pathway activation in 
response to TLCS in human pancreatic acinar cells 
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Figure 6.8 - PI uptake in response to TLCS in the presence or absence of 
TRO40303 in human PACs 
Co- administration of T10 (A) and T3 (B) with TLCS (500 µM) protected cells 
from early plasma membrane rupture (PI uptake) compared to untreated cells. 
Dose dependent effects of TRO40303 on necrotic cell death pathway activation 
in human pancreatic acinar cells can also be seen, *P<0.05, unpaired t- test.  
 
Note: Results for human PACs are displayed in separate graphs; A) shows 
results using T10 tested in three human samples and B) shows results with 
T1& T3, which were tested in two separate human samples, hence the 
differences in control levels of cell death and response to TLCS in the two 
graphs.  
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6.3.2 Acinar cell responses to CCK in the presence of TRO40303 
6.3.2.1 Mitochondrial and Ca2+ responses in the presence of 10 µM 
TRO40303  
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Figure 6.9 - Pathologic PAC m responses to CCK, in the presence or 
absence of 10 µM TRO40303 (T10) 
m changes in response to CCK (10 nM) show significant depolarisation with 
complete depolarisation on application of protonophore CCCP, used as a 
positive control. Pre-treatment with T10 decreased the level of depolarisation, 
preserving m. Mean changes in TMRM fluorescence, from at least three 
biological replicates, over baseline are shown (F/Fo) + SEM, with respective 
number of recordings shown in the key.  
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Figure 6.10 - Pathologic PAC Ca2+ response to CCK, in the presence or 
absence of 10 µM TRO40303 (T10) 
Ca2+ changes in response to CCK (10 nM) show typical large, rapid rise 
followed by a plateau. Pre-treatment with T10 did not affect the initial rise in rise 
in but dampened the plateau phase. Mean changes in Fluo-4 fluorescence, 
from at least three biological replicates, over baseline are shown (F/Fo) + SEM, 
with respective number of recordings shown in the key.  
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6.3.2.2 Mitochondrial and Ca2+ responses in the presence of 1 µM 
TRO40303  
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Figure 6.11- Pathologic PAC m responses to CCK, in the presence or 
absence of 1 µM TRO40303 (T1) 
m changes in response to CCK (10 nM) show significant depolarisation with 
complete depolarisation on application of protonophore CCCP, used as a 
positive control. Pre-treatment with T1 decreased the level of depolarisation 
partially. Mean changes in TMRM fluorescence, from at least three biological 
replicates, over baseline are shown (F/Fo) + SEM, with respective number of 
recordings shown in the key.  
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Figure 6.12 - Pathologic PAC Ca2+ responses CCK, in the presence or 
absence of 1 µM TRO40303 (T1) 
Ca2+ changes in response to CCK (10 nM) show typical large, rapid rise 
followed by a plateau. Pre-treatment with T1 did not affect the initial rise in rise 
in but marginally reduced the plateau phase. Mean changes in Fluo-4 
fluorescence, from at least three biological replicates, over baseline are shown 
(F/Fo) + SEM, with respective number of recordings shown in the key.  
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6.3.3 Acinar cell responses to POAEE in the presence of TRO40303 
6.3.3.1 Mitochondrial and Ca2+ responses in the presence of 10 µM 
TRO40303  
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Figure 6.13 - Pathologic PAC m responses to POAEE, in the presence 
or absence of 10 µM TRO40303 (T10) 
m changes in response to POAEE (100 µM) show significant depolarisation 
with complete depolarisation on application of protonophore CCCP, used as a 
positive control. Pre-treatment with T10 partially decreased the level of 
depolarisation. Mean changes in TMRM fluorescence, from at least three 
biological replicates, over baseline are shown (F/Fo) + SEM, with respective 
number of recordings shown in the key.  
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Figure 6.14 - Pathologic PAC Ca2+ responses to POAEE, in the presence 
or absence of 10 µM TRO4O303 (T10) 
Ca2+ changes in response to POAEE (100 µM) show typical large, rapid rise 
followed by a plateau. Pre-treatment with T10 reduced the rise in cytosolic 
calcium. Mean changes in Fluo-4 fluorescence, from at least three biological 
replicates, over baseline are shown (F/Fo) + SEM, with respective number of 
recordings shown in the key.  
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6.3.3.2 Mitochondrial and Ca2+ responses in the presence of 1 µM 
TRO40303  
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Figure 6.15 - Pathologic PAC m responses to POAEE, in the presence 
or absence of 1 µM TRO40303 (T1) 
m changes in response to POAEE (100 µM) show significant depolarisation 
with complete depolarisation on application of protonophore CCCP, used as a 
positive control. Pre-treatment with T1 had no effect on the level of 
depolarisation. Mean changes in TMRM fluorescence, from at least three 
biological replicates, over baseline are shown (F/Fo) + SEM, with respective 
number of recordings shown in the key.  
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Figure 6.16 - Pathologic PAC Ca2+ responses to POAEE, in the presence 
or absence of 1 µM TRO40303 (T1) 
Ca2+ changes in response to POAEE (100 µM) show typical large, rapid rise 
followed by a plateau. Pre-treatment with T1 did not have a significant effect on 
the rise in cytosolic calcium. Mean changes in Fluo-4 fluorescence, from at 
least three biological replicates, over baseline are shown (F/Fo) + SEM, with 
respective number of recordings shown in the key.  
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6.3.4 Effects of TRO40303 on necrotic cell death pathway activation in 
response to POAEE in murine pancreatic acinar cells 
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Figure 6.17 - PI uptake in response to POAEE, in the presence or absence 
of TRO40303 
Co - administration of T10 and T30 with POAEE (100μM dissolved in 5 % 
ethanol) protected cells from early plasma membrane rupture (PI uptake) 
compared to untreated cells (n=2) *P<0.05, unpaired t- test.  
Control POAEE       POAEE+T10   POAEE + T30 
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6.3.5 Evaluation of binding of TRO40303 with CypD 
 
 
Figure 6.18 - SPR analysis of binding of TRO40303 to CypD 
Surface plasmon resonance demonstrated no binding affinity of TRO40303 
with CypD. Experiments were performed by the addition of 100µM TRO40303 
over recombinant CypD immobilized on a CM5 sensor chip. TRO40303 
resulted in the same response as buffer. CsA, which has a strong binding 
affinity for CypD, was used as a positive control. TRO40303 showed no binding 
with CypD. 
 
 
  
Chapter 6 - Results: TRO40303 in AP 
- 187 - 
 
 
6.3.6 Effect of TRO40303 treatment on severity of caerulein induced 
acute pancreatitis 
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Figure 6.19 - Serum amylase measurements in CER-AP 
Mean serum amylase is significantly elevated in acute pancreatitis induced by 
caerulein in untreated mice and reduced in animals treated with TRO40303 (T1 
= 1mg/kg, T3 = 3mg/kg, T10 = 10 mg/kg). P values for each group: CER = 2.43 
* 10-5, T1 = 0.007, T3 = 0.026, T10 = 0.007. 
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Figure 6.20 - Pancreatic trypsin measurements in CER-AP 
Pancreatic tryspin is significantly elevated in acute pancreatitis induced by 
caerulein in untreated mice and reduced in animals treated with TRO40303 (T1 
= 1mg/kg, T3 = 3mg/kg, T10 = 10 mg/kg). P values for each group: CER = 
0.005, T1 = 0.32, T3 = 0.014, T10 = 0.17.  
Control        CER           T1           T3            T10  
Control        CER           T1           T3            T10  
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Figure 6.21 - Pancreatic myeloperoxidase measurements mice in CER-AP 
Pancreatic myleoperoxidase activity as a measure of pancreatic neutrophil 
infiltration is significantly elevated in acute pancreatitis induced by caerulein in 
untreated mice and reduced in animals treated with TRO40303 (T1 = 1mg/kg, 
T3 = 3mg/kg, T10 = 10 mg/kg). P values for each group: CER = 1.58* 10-5, T1 
= 9.57* 10-5, T3 = 0.0047, T10 = 0.22. 
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Figure 6.22 - Lung myeloperoxidase measurements in CER-AP 
Lung myleoperoxidase activity as a measure of pancreatic neutrophil infiltration 
is significantly elevated in acute pancreatitis induced by caerulein in untreated 
mice and reduced in animals treated with TRO40303 (T1 = 1mg/kg, T3 = 
3mg/kg, T10 = 10 mg/kg). P values for each group: CER = 0.048, T1 = 0.06, T3 
= 0.10, T10 = 0.23.  
Control        CER           T1           T3            T10  
Control        CER           T1           T3            T10  
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Figure 6.23 - Serum IL-6 measurements in CER-AP 
IL-6 activity a pro-inflammatory cytokine is significantly elevated in acute 
pancreatitis induced by caerulein in untreated mice and reduced in animals 
treated with TRO40303 (T1 = 1mg/kg, T3 = 3mg/kg, T10 = 10 mg/kg). P values 
for each group: CER = 0.0026, T1 = 0.016, T3 = 0.006, T10 = 0.155. 
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Figure 6.24 - Oedema scores in CER-AP  
Oedema scores were significantly elevated in acute pancreatitis induced by 
caerulein in untreated mice and reduced in animals treated with TRO40303 (T1 
= 1mg/kg, T3 = 3mg/kg, T10 = 10 mg/kg). P values for each group: CER = 
1.01* 10-8, T1 = 0.0018, T3 = 0.0017, T10 = 0.0011. All values are mean + 
SEM from 10 fields scored per mouse with the average taken between two 
independent, blinded investigators.  
Control        CER           T1           T3            T10  
Control        CER           T1           T3            T10  
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Figure 6.25 - Inflammation scores in CER-AP  
Inflammation scores were significantly elevated in acute pancreatitis induced by 
caerulein in untreated mice and reduced in animals treated with TRO40303 (T1 
= 1mg/kg, T3 = 3mg/kg, T10 = 10 mg/kg). P values for each group: CER = 
3.83* 10-8, T1 = 1.2* 10-6, T3 = 0.00034, T10 = 0.001.All values are mean + 
SEM from 10 fields scored per mouse with the average taken between two 
independent, blinded investigators. 
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Figure 6.26 - Necrosis score scores in CER-AP  
Necrosis scores were significantly elevated in acute pancreatitis induced by 
caerulein in untreated mice and reduced in animals treated with TRO40303 (T1 
= 1mg/kg, T3 = 3mg/kg, T10 = 10 mg/kg). P values for each group: CER = 
6.25* 10-8, T1 = 6.05* 10-7, T3 = 0.003, T10 = 0.0046. All values are mean + 
SEM from 10 fields scored per mouse with the average taken between two 
independent, blinded investigators.  
Control        CER           T1           T3            T10  
Control        CER           T1           T3            T10  
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Figure 6.27 - Overall pancreatitis histopathology scores in CER-AP  
Overall pancreatitis histopathology scores were significantly elevated in acute 
pancreatitis induced by caerulein  in untreated mice and reduced in animals 
treated with TRO40303 (T1 = 1mg/kg, T3 = 3mg/kg, T10 = 10 mg/kg). P values 
for each group: CER = 6.39* 10-9, T1 = 1.05* 10-6, T3 = 0.00028, T10 = 
0.0009.All values are mean + SEM from 10 fields scored per mouse with the 
average taken between two independent, blinded investigators. 
 
            
 
Figure 6.28 - Representative histopathology for CER-AP with TRO40303  
Haematoxylin and Eosin stained X 200 magnification pancreatic sections 
showing significant histological features of acute pancreatitis characterized by ; 
oedema, neutrophil infiltration and necrosis produced by hyperstimulation 
model. Significant improvements in appearances were seen following 
TRO40303 treatment (3mg/kg) administered one hour after the induction of 
experimental acute pancreatitis.  
Control        CER           T1           T3            T10 
CER-AP  Control  CER-AP + TRO40303, 3 mg/kg  
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6.3.7 Effect of TRO40303 treatment on severity of TLCS induced acute 
pancreatitis 
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Figure 6.29 - Serum amylase measurements in TLCS-AP 
Mean serum amylase is significantly elevated in TLCS induced acute 
pancreatitis in untreated mice and reduced in animals treated with TRO40303 
(T3 = 3mg/kg). P values for each group: TLCS = 0.0078, T3 = 0.013 
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Figure 6.30 - Serum IL-6 measurements in TLCS-AP 
Serum IL-6, a pro-inflammatory cytokine, is significantly elevated in TLCS  
induced acute pancreatitis in untreated mice and reduced in animals treated 
with TRO40303 (T3 = 3mg/kg). P values for each group: TLCS = 0.012, T3 = 
0.08.  
Control          TLCS             T3  
     Control           TLCS          T3
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Figure 6.31 - Pancreas myeloperoxidase measurements TLCS-AP 
Pancreatic myleoperoxidase activity, a measure of pancreatic neutrophil 
infiltration, is significantly elevated in TLCS induced acute pancreatitis in 
untreated mice and reduced in animals treated with TRO40303 (T3 = 3mg/kg). 
P values for each group: TLCS = 0.00014, T3 = 0.048. 
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Figure 6.32 - Lung myeloperoxidase measurements in TLCS-AP 
Lung myleoperoxidase activity, a measure of neutrophil infiltration, is 
significantly elevated in TLCS induced acute pancreatitis in untreated mice and 
reduced in animals treated with TRO40303 (T3 = 3mg/kg). P values for each 
group: TLCS = 0.027, T3 = 0.041.  
         Control      TLCS             T3
  
Control                    TLCS                     T3
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Figure 6.33 - Oedema scores in TLCS-AP  
Oedema scores were significantly elevated in TLCS induced acute pancreatitis 
in untreated mice and reduced in animals treated with TRO40303 (T3 = 
3mg/kg). P values for each group: TLCS = 0.0001, T3 = 0.015. All values are 
mean + SEM from 10 fields scored per mouse with the average taken between 
two independent, blinded investigators. 
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Figure 6.34 - Inflammation scores in TLCS-AP  
Inflammation scores were significantly elevated in TLCS induced acute 
pancreatitis in untreated mice and reduced in animals treated with TRO40303 
(T3 = 3mg/kg). P values for each group: TLCS = 0.0014, T3 = 0.074. All values 
are mean + SEM from 10 fields scored per mouse with the average taken 
between two independent, blinded investigators.  
Control                TLCS        T3  
        Control              TLCS                 T3
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Figure 6.35 - Necrosis scores in TLCS-AP  
Necrosis scores were significantly elevated in TLCS induced acute pancreatitis 
in untreated mice and reduced in animals treated with TRO40303 (T3 = 
3mg/kg). P values for each group: TLCS = 0.0039, T3 = 0.045. All values are 
mean + SEM from 10 fields scored per mouse with the average taken between 
two independent, blinded investigators. 
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Figure 6.36 - Overall pancreatitis histopathology scores in TLCS-AP  
Overall pancreatitis histopathology scores were significantly elevated in TLCS 
induced acute pancreatitis in untreated mice and reduced in animals treated 
with TRO40303 (T3 = 3mg/kg). P values for each group: TLCS = 0.0012, T3 = 
0.035. All values are mean + SEM from 10 fields scored per mouse with the 
average taken between two independent, blinded investigators.  
Control                TLCS          T3 
Control                TLCS                   T3  
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Figure 6.37 - Representative histopathology for TLCS-AP with TRO40303  
Haematoxylin and Eosin stained X 200 magnification pancreatic sections 
showing significant histological features of acute pancreatitis characterized by ; 
oedema, neutrophil infiltration and necrosis produced by TLCS model. 
Significant improvements in appearances were seen following TRO40303 
treatment (3mg/kg) administered one hour after the induction of experimental 
acute pancreatitis.  
Control  TLCS-AP  TLCS-AP + TRO40303, 3 mg/kg 
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6.3.8 Effect of TRO40303 treatment on severity of alcoholic acute 
pancreatitis 
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Figure 6.38 - Serum amylase measurements in FAEE-AP 
Mean serum amylase is significantly elevated in FAEE acute pancreatitis in 
untreated mice and reduced in animals treated with TRO40303 (T3 = 3mg/kg). 
P values for each group: FAEE + Etoh = 0.013, T3 = 0.043. 
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Figure 6.39 - Pancreatic trypsin measurements in FAEE-AP 
Mean pancreatic trypsin is significantly elevated in FAEE acute pancreatitis in 
untreated mice and reduced in animals treated with TRO40303 (T3 = 3mg/kg). 
P values for each group: FAEE + Etoh = 0.00025, T3 = 0.018.  
Control                TLCS          T3
  
Control                 TLCS                 T3 
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Figure 6.40 - Pancreatic myeloperoxidase measurements in FAEE-AP 
Pancreatic myleoperoxidase activity as a measure of pancreatic neutrophil 
infiltration is significantly elevated in FAEE induced acute pancreatitis in 
untreated mice and reduced in animals treated with TRO40303 (T3 = 3mg/kg). 
P values for each group: FAEE + Etoh = 1.32* 10-5, T3 = 0.354. 
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Figure 6.41 - Lung myeloperoxidase measurements in FAEE-AP 
Lung myleoperoxidase activity as a measure of neutrophil infiltration is 
significantly elevated in FAEE induced acute pancreatitis in untreated mice and 
reduced in animals treated with TRO40303 (T3 = 3mg/kg). P values for each 
group: FAEE + Etoh = 0.0003, T3 = 0.0059.  
Control          TLCS             T3  
Control          TLCS             T3  
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Figure 6.42 - Oedema scores in FAEE-AP  
Oedema scores were significantly elevated in FAEE induced acute pancreatitis 
in untreated mice and reduced in mice treated with TRO40303 (T3 = 3mg/kg). 
P values for each group: FAEE + Etoh = 9.84*10-6, T3 = 0.0078. All values are 
mean + SEM from 10 fields scored per mouse with the average taken between 
two independent, blinded investigators. 
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Figure 6.43 - Inflammation scores in FAEE-AP  
Inflammation scores were significantly elevated in FAEE induced acute 
pancreatitis in untreated mice and reduced in mice treated with TRO40303 (T3 
= 3mg/kg). P values for each group: FAEE + Etoh = 0.00017, T3 = 0.0039. All 
values are mean + SEM from 10 fields scored per mouse with the average 
taken between two independent, blinded investigators.  
Control                    TLCS                T3  
Control                 TLCS            T3  
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Figure 6.44 - Necrosis scores in FAEE-AP 
Necrosis scores were significantly elevated in FAEE induced acute pancreatitis 
in untreated mice and reduced in animals treated with TRO40303 (T3 = 
3mg/kg). P values for each group: FAEE + Etoh = 0.0013, T3 = 0.00269. All 
values are mean + SEM from 10 fields scored per mouse with the average 
taken between two independent, blinded investigators. 
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Figure 6.45 - Overall pancreatitis histopathology scores in-FAEE-AP 
Overall pancreatitis histopathology scores were significantly elevated in FAEE 
induced acute pancreatitis in untreated mice and reduced in animals treated 
with TRO40303 (T3 = 3mg/kg). P values for each group: FAEE + Etoh = 0.001, 
T3 = 0.0059. All values are mean + SEM from 10 fields scored per mouse with 
the average taken between two independent, blinded investigators.  
   Control          TLCS             T3  
Control               TLCS          T3  
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Figure 6.46 - Representative histopathology for FAEE-AP with TRO40303 
Haematoxylin and Eosin stained X 200 magnification pancreatic sections 
showing significant histological features of acute pancreatitis characterized by ; 
oedema, neutrophil infiltration and necrosis produced by TLCS model. 
Significant improvements in appearances were seen following TRO40303 
treatment (3mg/kg) administered one hour after the induction of experimental 
acute pancreatitis.  
Control  FAEE-AP  FAEE-AP + TRO40303, 3 mg/kg 
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6.3.9 TRO40303 levels in plasma and pancreas 
 
 
 
Figure 6.47 - Pharmacokinetics of TRO40303 
(A) Plasma level of TRO40303 expressed in μg/ml during 24 hr after 
intraperitoneal administration to satellite mice (PK Trophos) of 3 and 10 mg/kg 
in liposomes compared to plasma level of TRO40303 15 min post 
administration in the caerulein model (satellite CER). (B) Pancreata level of 
TRO40303 expressed in μg/g tissue during 24 hr after administration to satellite 
mice (PK Trophos) of 3 mg/kg in liposomes compared to plasma level of 
TRO40303 15 min post administration in the caerulein model (satellite CER).  
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6.4 Discussion 
 
Mounting evidence places mitochondrial injury centre stage in the pathogenesis 
of AP (Maleth, Rakonczay et al. 2013). MPTP inhibition is therefore an 
attractive strategy for developing a treatment for AP. Since CypD - a 
mitochondrial matrix protein - is considered to be the key regulator of MPTP 
formation (Giorgio, Bisetto et al. 2009, Giorgio, von Stockum et al. 2013, 
Mukherjee, Mareninova et al. 2015) CypD inhibitors have been evaluated and 
shown to reduce pancreatic injury in vitro and in vivo in response to pancreatic 
toxins (Shalbueva, Mareninova et al. 2013, Mukherjee, Mareninova et al. 
2015). The experiments reported in this chapter demonstrate the protective 
effects of TRO40303 - a drug which inhibits MPTP formation by targeting 
mitochondrial translocator protein (TSPO) on the outer mitochondrial 
membrane (Schaller, Paradis et al. 2010) - on PAC injury developing in 
response to pancreatic toxins, which is a novel finding.  
FAEEs as well as TLCS induce toxic sustained calcium overload in 
PACs which leads to mitochondrial dysfunction and necrosis (Criddle, Raraty et 
al. 2004, Criddle, Murphy et al. 2006). Although not targeting calcium overload 
per se, TRO40303 inhibits the critical downstream effects on the mitochondria, 
confers mitochondrial protection and reduces cellular injury (Schaller, Paradis 
et al. 2010, Le Lamer, Paradis et al. 2014, Schaller, Michaud et al. 2015). Pre-
treatment with TRO40303 reduced mitochondrial dysfunction, cytosolic calcium 
overload and activation of necrotic cell death pathway in response to pancreatic 
toxins including TLCS, CCK and FAEEs in isolated murine PACs. The 
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protective effect of TRO40303 on TLCS induced necrosis in freshly isolated 
human PACs further supports the translational potential of this promising agent.  
Therapeutic administration of TRO40303 intraperitoneally (3 mg/kg in 
liposomes) ameliorated the severity of CER-AP, TLCS-AP as well as FAEE-AP 
in vivo. The cumulative data on the effects of TRO40303 contrasts with 
previous preclinical trials of drugs for AP, the majority of which have been 
conducted in a single model only (most often CER-AP) (Pandol, Saluja et al. 
2007) with treatment given prophylactically before disease induction. In the 
clinical setting, however, prophylactic administration of a drug is not possible in 
the majority of patients developing AP. The combination of ethanol with POA 
(Huang, Booth et al. 2014) as well as bile acid induced EAP (Laukkarinen, Van 
Acker et al. 2007) induce significant pancreatic damage with extensive acinar 
cell oedema, neutrophil infiltration and necrosis. The TLCS-AP model is 
considered to be representative of biliary acute pancreatitis in humans and has 
been extensively utilised in the past. The FAEE-AP model which has been 
reported recently is also considered to be clinically relevant. High levels of 
FAEEs accumulate in the pancreas following acute alcohol intoxication, in 
contrast to other organs commonly damaged by alcohol, (Laposata and Lange 
1986) and substantial evidence now implicates FAEEs in PAC (Criddle, Raraty 
et al. 2004, Criddle, Murphy et al. 2006, Gerasimenko, Gryshchenko et al. 
2013) as well as pancreatic ductal cell injury (Maleth, Balazs et al. 2015). 
Epidemiological studies have also shown a marked increase in the level of 
alcohol consumption in recent decades, which parallels a sustained rise in the 
incidence of AP (Yadav and Lowenfels 2013). The reduction in biochemical as 
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well as histological markers of severity in three different models of EAP on 
therapeutic administration therefore highlights the efficacy of TRO40303. 
The mitochondrion is the powerhouse of the cell. There is evidence 
indicating that sepsis-induced multiple organ failure depends on the 
development of mitochondrial dysfunction and consequent cellular energetic 
failure (Duran-Bedolla, Montes de Oca-Sandoval et al. 2014). Multiorgan failure 
is also the leading cause of death in patients with severe AP (Petrov, 
Shanbhag et al. 2010). TRO40303 is an MPTP modulator that has been shown 
to be protective in multiple cellular and animal models characterised by stress-
induced mitochondrial permeabilization,(Schaller, Paradis et al. 2010, Le 
Lamer, Paradis et al. 2014), (de Tassigny, Assaly et al. 2013, Richter, Gao et 
al. 2014) although whether TSPO binding is the primary mechanism of action 
remains to be confirmed (Sileikyte and Forte 2016). Pharmacokinetic profiles of 
TRO40303 have shown accumulation at substantial levels within the lungs, 
liver, heart and kidneys, (Schaller, Paradis et al. 2010) all organs contributing to 
organ failure in AP. Levels were higher in EAP than in naïve animals, possibly 
due to reduction in the speed of metabolism and/or excretion of the drug, a 
consideration in the design of any future human trials. Nevertheless the 
accumulation in vital organs suggests that TRO40303 might also usefully 
prevent or lessen systemic organ dysfunction in AP through direct effects on 
these organs, suggesting promise in this approach. 
These findings strengthen an established rationale for targeting the 
MPTP to treat a range of acute and chronic conditions in which necrotic cell 
death is a critical and/or prominent feature (Bernardi, Rasola et al. 2015, 
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Sileikyte and Forte 2016). CsA is the only licensed drug used experimentally to 
inhibit formation of the MPTP, the mechanism of action being inhibition of 
CypD, the most widely recognised regulator of the MPTP. Clinical trials testing 
the efficacy of CsA in this regard have been undertaken, with mixed results: a 
pilot study found reduction in the size and severity of myocardial infarction 
associated with CsA treatment prior to percutaneous coronary intervention 
(Piot, Croisille et al. 2008), not replicated in a larger study (Cung, Morel et al. 
2015). The immunosuppressive actions of CsA essential to its primary 
therapeutic use in controlling autoimmunity and allograft rejection, however, 
preclude widespread use in conditions where the MPTP is a target. For 
example AP predisposes to local and systemic infection, which contributes 
significantly to mortality (Petrov, Shanbhag et al. 2010, Afghani, Pandol et al. 
2015); the powerful immunosuppressive actions of CsA are likely to impact 
negatively on infective outcomes in AP. There are continuing major efforts to 
develop new, specific inhibitors of CypD although none is ready for first in man 
study. TRO40303, which does not have the immunosuppressive actions of CsA 
but which has been shown experimentally to have a significant impact on a 
number of forms of organ injury, has also been tested in a phase II trial of 
cardiac preservation following acute myocardial infarction, but was not found to 
have significant protective effects (Atar, Arheden et al. 2015). While the 
mechanism of action of TRO40303 remains to be confirmed (Sileikyte and 
Forte 2016), the experimental data shows that TRO40303 did not bind to CypD. 
Nevertheless since TRO40303 may have both pancreatic as well as systemic 
protective effects in AP and the therapeutic window is potentially longer than in 
myocardial infarction, there is perhaps a higher chance of efficacy in AP than in 
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myocardial infarction. While phenotypic screens have identified new MPTP 
inhibitors and a number of powerful compounds have been identified, all 
present challenges: cinnamic anilides were found to be no more effective than 
CsA in experimental myocardial infarction, isoxasoles are unstable in vivo and 
benzamides impair ATP generation (Sileikyte and Forte 2016). The small 
number of agents in development for the treatment of AP and the extensive 
work already undertaken to develop TRO40303 as a drug support the case to 
test TRO40303 in human AP. The previously conducted animal toxicology 
studies for TRO40303 have been based on the assumption that the drug would 
be administered as a single dose for its clinical application in cardiac 
ischaemic-reperfusion injury prior to performing percutaneous coronary 
intervention in patients with myocardial infarction. The pre-clinical toxicity profile 
of TRO40303 would therefore have to be re-evaluated if it is to be used for the 
treatment of human AP as it would require repeated doses.  
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There is an unmet clinical need for developing a treatment for AP as there is no 
licenced, targeted pharmacotherapy for this potentially life threating disease; 
the burden for which is increasing worldwide (Yadav and Lowenfels 2013). 
Positive findings from pre-clinical studies have not translated in human clinical 
trials with numerous negative RCTs (Pezzilli 2009). The main problems with 
translational drug discovery in AP have been; lack of clear consensus and 
elucidation of key pathological mechanisms implicated in the pathophysiology 
of disease and difficulty in designing clinical studies that can provide reliable, 
statistically significant answers. The PAC has long been established as the 
initial site of damage in AP (Pandol, Saluja et al. 2007), however the review of 
literature undertaken as part of this study reveals that this has not been the 
primary focus of strategies adopted for inhibition of EAP. Furthermore, the 
design of pre-clinical studies in EAP does not reflect the clinical picture in 
human AP, there is significant variability in the toxicity of models of EAP as well 
as the quality of reported studies. The poor translational power of animal 
models in stroke led to the establishment of the Stroke Therapy Academic 
Industry Roundtable, which issued recommendations to improve the quality of 
preclinical stroke research (Vaquero, Molero et al. 1999) and this initiative had 
a positive impact on the overall translational research strategy in ischaemic 
stroke. Perhaps a similar approach needs to be adopted by the pancreatic 
community. There is potentially a case for exploring and developing more 
clinically relevant experimental models of AP in higher mammals or non-human 
primates which would need to be closely monitored, regulated and restricted to 
highly specialised research facilities. 
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 This study builds on the present knowledge regarding mitochondrial 
function in AP and demonstrates that MPTP inhibition prevents mitochondrial 
dysfunction in PACs and ameliorates the severity of EAP. Findings in the 
current study show that both genetic deletion of CypD and pharmacological 
inhibition of MPTP using a variety of agents (CsA, Deb025, AP-1A02 and 
TRO40303) preserve mitochondrial function and reduce necrotic cell death, the 
aftermath of mitochondrial dysfunction. These results are in keeping with 
literature and support that MPTP opening in PACs is the key determinant of 
loss of MMP in response to pancreatic toxins, as well as subsequent 
impairment of mitochondrial metabolism with a decrease of ATP for energy 
dependant cellular functions (Mukherjee, Mareninova et al. 2015). Data from 
normal human PACs also confirms the potential of experiments on isolated 
acinar cells obtained from normal human pancreatic tissue to discover key 
mechanisms and concordance with in vitro murine findings. 
Although there has been considerable controversy with regards to the exact 
composition of MPTP, CypD has been the only protein that has consistently 
been considered to be the regulator of MPTP formation (Baines, Kaiser et al. 
2005, Giorgio, Bisetto et al. 2009) and has indeed been a key component of 
this study. Using the target-based approach for drug discovery; a novel, small 
molecule CypD inhibitor (AP-1A02) has been identified which prevents 
mitochondrial dysfunction and significantly reduces bile acid induced necrotic 
cell death not only in murine but also in human PACs. This compound can form 
the basis of a lead optimization chemistry programme to increase potency of 
the chemical series. The partnership between the University of Liverpool and 
Cypralis - a life sciences company focused on PPIase modulators - to identify 
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and develop novel CypD inhibitors is an encouraging development in the field. 
Given the high sequence homology of cyclophilin family members and 
biological significance of the other cyclophilins in humans, it would be prudent 
to have a counter-screening programme with other cyclophilins, especially 
CypA and CypB to identify inhibitors that are selective for CypD. Such an 
approach would reduce the potential off-target effects of non-selective 
cyclophilin inhibitors. The biological assays using confocal microscopy to 
evaluate m and activation of necrotic cell death pathway as part of this study, 
although extremely reliable, are time consuming. Other strategies can be 
adopted for high throughput screening of CypD inhibitors in the first instance 
and confocal microscopy can then be used at a later stage to evaluate and 
confirm the biological effects of MPTP inhibition on PACs. The mitochondrial 
calcium retention capacity (CRC) assay is one such method of evaluating 
MPTP opening (Fontaine, Eriksson et al. 1998) and further modifications of this 
technique (Yamaguchi, Andreyev et al. 2007) to isolate mitochondria and 
preserve function after freeze-thaw using the cryopreservative agent trehalose  
have been described which allow screening for novel MPTP inhibitors in a rapid 
and efficient manner. The use of rat AR42J cell line (Christophe 1994), the 
most commonly used cell line to study the exocrine pancreas, as opposed to 
freshly isolated murine PACs, for initial biological screening of MPTP inhibitors 
can also increase the throughput of identifying novel CypD inhibitors. The JC-
10 m assay (Kysenius, Brunello et al. 2014) can be performed in the format 
of a 96 microplate reader and provides an alternative, robust and efficient  
method for monitoring changes in m. JC-10 is a lipophilic, cationic dye which 
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concentrates in the mitochondrial matrix where it forms red fluorescent 
aggregates. However as the mitochondrial permeability increases, JC-10 
diffuses out of mitochondria, changes to monomeric form and stains cells in 
green fluorescence (Sakamuru, Attene-Ramos et al. 2016). The lactate 
dehydrogenase assay (LDH) for evaluating cell death can also be performed on 
the 96 well plate reader and is therefore an efficient and reliable means of 
evaluating cell death in PACs. LDH catalyses the interconversion of pyruvate to 
lactate and NADH to NAD+ (Madern 2002). Elevated levels of LDH are 
indicative of tissue injury and breakdown. LDH can be measured using 
colorimetric assays supplied by Promega (Orabi, Muili et al. 2013).  
 This study provides a comprehensive evaluation of TRO40303, a drug 
quite far in clinical development, examining its efficacy in preventing toxin 
induced pancreatic injury in vitro and in vivo. The protective effects of 
TRO40303 in isolated murine PAC experiments were observed to be mirrored 
in three different models of EAP and also in human PACs. Although the 
phenomenon of MPTP inhibition by TRO40303 has been observed, the exact 
mechanism by which the drug modulates MPTP remains unclear. We have 
shown that TRO40303 does not bind to CypD. The proposed mechanism of 
action of TRO40303 that it inhibits MPTP formation as it binds with the TSPO 
located on the OMM has also been challenged. There is evidence from 
conditional knockout mice in which the TSPO gene has been eliminated in the 
liver and heart (Sileikyte, Blachly-Dyson et al. 2014) that the role of TSPO in 
the regulation of the MPTP in hepatocytes and cardiomyocytes is dispensable. 
There are however data indicating that ‘TSPO ligands’  bind to and inhibit the 
mitochondrial FOF1-ATP synthase (Stelzer, Frazee et al. 2010) which forms the 
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MPTP. It would therefore appear logical to utilise structural biological assays 
such as NMR to evaluate the binding between TRO40303 and OSCP binding 
site of the FOF1-ATP synthase as well as other components of the FOF1-ATP 
synthase to see whether TRO40303 directly inhibits the formation of MPTP.  
Binding of TRO40303 with TSPO may indirectly modulate MPTP 
opening as TSPO could act on well-known activators of the pore such as 
reactive oxygen species, calcium and/or other proteins that have been involved 
in MPTP opening (Morin, Musman et al. 2016). TRO40303 could favour the 
VDAC - hexokinase interaction thereby facilitating a metabolic switch from 
oxidative phosphorylation to glycolysis and maintain ATP levels within the cell 
(Schaller, Paradis et al. 2010). Cardioprotection from TSPO ligands such as 4'-
chlorodiazepam is associated with inhibition of mitochondrial accumulation of 
cholesterol at reperfusion (Paradis, Leoni et al. 2013). Rapid accumulation of 
cholesterol within the mitochondrial matrix, in the presence of reactive oxygen 
species can lead to the formation of a complex mixture of oxysterols which can 
induce MPTP opening. The effects of TRO40303 on VDAC - hexokinase 
interaction and mitochondrial accumulation of cholesterol within the PAC can 
be evaluated in future experiments to investigate the mechanism by which 
TRO40303 prevents MPTP inhibition. 
Loss of m leads to depletion of intracellular ATP levels and 
subsequent necrosis. Having demonstrated the preservation of mitochondrial 
function in response to pancreatic toxins, the effects of TRO40303 in 
maintaining ATP levels in PACs can be evaluated using a luciferin/luciferase 
luminescence-based assay. In order to examine the effects of the drug on 
mitochondrial calcium and intracellular levels of reactive oxygen species, the 
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dyes Rhod-2 and 2’,7’ – dichlorofluorescin diacetate  (DCFDA) can be used 
and confocal microscopy experiments undertaken using the protocols 
described for m and cytosolic calcium. NF-κB activation is thought to be an 
early and critical component of the inflammatory response during acute 
pancreatitis (Rakonczay, Hegyi et al. 2008). Traditional methods for examining 
NF-κB activity in vitro including protein determination of NF-κB pathway 
markers (phosphorylated IκB; p65 nuclear translocation; IKK upregulation), 
electromobility shift assay (EMSA) and immunohistochemistry for 
phosphorylated p65 (Algul, Tando et al. 2002) can also be used to study the 
effects of TRO40303 on the NF-κB pathway. 
The two most important determinants of outcome in patients with AP are 
pancreatic necrosis and organ failure. TRO40303 has been shown to reduce 
activation of necrotic cell death pathway in vitro and ameliorate the severity of 
EAP; however its impact on organ failure can be investigated in further detail. 
There is increasing evidence that the intestine has a central role, both as culprit 
and victim, in severe AP (Flint and Windsor 2003) contributing to multi organ 
dysfunction syndrome (MODS). Pancreatic inflammation causes reflex 
splanchnic vasoconstriction which leads to ischaemia / reperfusion injury. This 
cascade of events results in gut mucosal injury, intestinal barrier failure, 
endotoxemia, and bacterial translocation which contribute to the SIRS 
response in AP. Bacterial translocation increases the risk of infected pancreatic 
necrosis (Windsor, Fearon et al. 1993) in cases of sterile pancreatic necrosis. 
There is also evidence to suggest that there is early organ-selective 
mitochondrial dysfunction in the lung and jejunum followed by the heart, liver 
and kidney (Mittal, Hickey et al. 2011) in EAP. Since TRO40303 is known to 
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prevent ischaemia/reperfusion injury in the heart, future experiments could 
evaluate the effect of therapeutic administration of the drug on mitochondrial 
dysfunction in different organs using mitochondrial spirometry. The ex vivo 
working heart model (Vidavalur, Swarnakar et al. 2008) and intra-vital 
microscopy for measuring microcirculation can also be used to study the effects 
of TRO40303 on cardiovascular system.  
All in all the findings reported in this thesis confirm the role of MPTP 
formation in the pathogenesis of AP and pave the way for further development 
of TRO40303 and novel, small molecular  CypD inhibitors, as potential drug 
candidates for the treatment of patients with acute pancreatitis.
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